drug1_db
stringlengths 7
7
| drug2_db
stringlengths 7
7
| drug1_id
int64 0
1.69k
| drug2_id
int64 0
1.69k
| drug_pair
sequencelengths 2
2
| drug1_name
stringlengths 4
85
| drug2_name
stringlengths 4
85
| drug1_desc
stringlengths 27
1.09k
| drug2_desc
stringlengths 27
6.14k
| label
stringclasses 3
values | label_idx
int64 0
2
| all_paths
sequencelengths 1
10
| all_paths_str
sequencelengths 1
10
| path_str
stringlengths 0
3.57k
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00321 | DB01001 | 21 | 688 | [
"DDInter78",
"DDInter1632"
] | Amitriptyline | Salbutamol | Amitriptyline is a tricyclic antidepressant that has been used to treat depression for decades. ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961. Amitriptyline has been investigated in the treatment of pain-related conditions, attributed to its analgesic properties. | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formulated as a racemic mixture of the R- and S-isomers. The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity. This lead to the development of levalbuterol, the single R-isomer of salbutamol. However, the high cost of levalbuterol compared to salbutamol has deterred wide-spread use of this enantiomerically pure version of the drug. Salbutamol is generally used for acute episodes of bronchospasm caused by bronchial asthma, chronic bronchitis and other chronic bronchopulmonary disorders such as chronic obstructive pulmonary disorder (COPD). It is also used prophylactically for exercise-induced asthma.[Label,A174379,A174400] | Moderate | 1 | [
[
[
21,
24,
688
]
],
[
[
21,
25,
874
],
[
874,
24,
688
]
],
[
[
21,
24,
455
],
[
455,
24,
688
]
],
[
[
21,
24,
1148
],
[
1148,
63,
688
]
],
[
[
21,
6,
8374
],
[
8374,
45,
688
]
],
[
[
21,
21,
28714
],
[
28714,
60,
688
]
],
[
[
21,
23,
112
],
[
112,
23,
688
]
],
[
[
21,
25,
22
],
[
22,
63,
688
]
],
[
[
21,
1,
1237
],
[
1237,
63,
688
]
],
[
[
21,
35,
401
],
[
401,
63,
688
]
]
] | [
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
]
],
[
[
"Amitriptyline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epinephrine"
],
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
]
],
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
]
],
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
]
],
[
[
"Amitriptyline",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Salbutamol"
]
],
[
[
"Amitriptyline",
"{u} (Compound) causes {v} (Side Effect)",
"Asthenia"
],
[
"Asthenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Salbutamol"
]
],
[
[
"Amitriptyline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Salbutamol"
]
],
[
[
"Amitriptyline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ephedrine"
],
[
"Ephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
]
],
[
[
"Amitriptyline",
"{u} (Compound) resembles {v} (Compound)",
"Clomipramine"
],
[
"Clomipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
]
],
[
[
"Amitriptyline",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
]
]
] | Amitriptyline may lead to a major life threatening interaction when taken with Epinephrine and Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Amitriptyline (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Salbutamol (Compound)
Amitriptyline (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Salbutamol (Compound)
Amitriptyline may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Salbutamol
Amitriptyline may lead to a major life threatening interaction when taken with Ephedrine and Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Amitriptyline (Compound) resembles Clomipramine (Compound) and Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Amitriptyline (Compound) resembles Promethazine (Compound) and Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol |
DB00580 | DB00586 | 311 | 1,512 | [
"DDInter1910",
"DDInter537"
] | Valdecoxib | Diclofenac | Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke. | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first line therapy for acute and chronic pain and inflammation from a variety of causes. Diclofenac was the product of rational drug design based on the structures of [phenylbutazone], [mefenamic acid], and [indomethacin]. The addition of two chlorine groups in the ortho position of the phenyl ring locks the ring in maximal torsion which appears to be related to increased potency. It is often used in combination with [misoprostol] to prevent NSAID-induced gastric ulcers. Diclofenac was first approved by the FDA in July 1988 under the trade name Voltaren, marketed by Novartis (previously Ciba-Geigy). | Moderate | 1 | [
[
[
311,
24,
1512
]
],
[
[
311,
63,
752
],
[
752,
23,
1512
]
],
[
[
311,
24,
885
],
[
885,
63,
1512
]
],
[
[
311,
63,
1271
],
[
1271,
24,
1512
]
],
[
[
311,
25,
1510
],
[
1510,
64,
1512
]
],
[
[
311,
24,
365
],
[
365,
64,
1512
]
],
[
[
311,
63,
553
],
[
553,
25,
1512
]
],
[
[
311,
63,
752
],
[
752,
23,
1263
],
[
1263,
63,
1512
]
],
[
[
311,
24,
885
],
[
885,
63,
1020
],
[
1020,
1,
1512
]
],
[
[
311,
24,
129
],
[
129,
64,
1364
],
[
1364,
40,
1512
]
]
] | [
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
]
],
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Diclofenac"
]
],
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
]
],
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alteplase"
],
[
"Alteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
]
],
[
[
"Valdecoxib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diclofenac"
]
],
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dalteparin"
],
[
"Dalteparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diclofenac"
]
],
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fondaparinux"
],
[
"Fondaparinux",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diclofenac"
]
],
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bromfenac"
],
[
"Bromfenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
]
],
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clonidine"
],
[
"Clonidine",
"{u} (Compound) resembles {v} (Compound)",
"Diclofenac"
]
],
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Guanfacine"
],
[
"Guanfacine",
"{u} (Compound) resembles {v} (Compound)",
"Diclofenac"
]
]
] | Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Diclofenac
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Alteplase and Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac
Valdecoxib may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Diclofenac
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Dalteparin and Dalteparin may lead to a major life threatening interaction when taken with Diclofenac
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Fondaparinux and Fondaparinux may lead to a major life threatening interaction when taken with Diclofenac
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Bromfenac and Bromfenac may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Clonidine and Clonidine (Compound) resembles Diclofenac (Compound)
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Guanfacine and Guanfacine (Compound) resembles Diclofenac (Compound) |
DB00322 | DB06372 | 141 | 259 | [
"DDInter742",
"DDInter1594"
] | Floxuridine | Rilonacept | An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection. Floxuridine is available as a sterile, nonpyrogenic, lyophilized powder for reconstitution. When administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract. | Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome (FCAS) and Muckle-Wells Syndrome (MWS), in adults and children greater than 12 years old. | Moderate | 1 | [
[
[
141,
24,
259
]
],
[
[
141,
63,
1461
],
[
1461,
23,
259
]
],
[
[
141,
24,
0
],
[
0,
24,
259
]
],
[
[
141,
24,
1330
],
[
1330,
63,
259
]
],
[
[
141,
63,
377
],
[
377,
24,
259
]
],
[
[
141,
35,
139
],
[
139,
24,
259
]
],
[
[
141,
25,
770
],
[
770,
24,
259
]
],
[
[
141,
1,
1083
],
[
1083,
24,
259
]
],
[
[
141,
25,
1011
],
[
1011,
64,
259
]
],
[
[
141,
25,
1377
],
[
1377,
25,
259
]
]
] | [
[
[
"Floxuridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
]
],
[
[
"Floxuridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rilonacept"
]
],
[
[
"Floxuridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dactinomycin"
],
[
"Dactinomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
]
],
[
[
"Floxuridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naxitamab"
],
[
"Naxitamab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
]
],
[
[
"Floxuridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mitomycin"
],
[
"Mitomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
]
],
[
[
"Floxuridine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zidovudine"
],
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
]
],
[
[
"Floxuridine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
]
],
[
[
"Floxuridine",
"{u} (Compound) resembles {v} (Compound)",
"Trifluridine"
],
[
"Trifluridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
]
],
[
[
"Floxuridine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rilonacept"
]
],
[
[
"Floxuridine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rilonacept"
]
]
] | Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Rilonacept
Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Dactinomycin and Dactinomycin may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab and Naxitamab may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Mitomycin and Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Floxuridine (Compound) resembles Zidovudine (Compound) and Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Floxuridine may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Floxuridine (Compound) resembles Trifluridine (Compound) and Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Floxuridine may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Rilonacept
Floxuridine may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Rilonacept |
DB00960 | DB13142 | 887 | 841 | [
"DDInter1471",
"DDInter274"
] | Pindolol | Calcium glubionate anhydrous | Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension. Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia. Research into pindolol's use in the treatment of hypertension began in the early 1970s. Pindolol was granted FDA approval on 3 September 1982. | Calcium glubionate (or glubionate calcium) is a mineral supplement to prevent or treat low blood calcium levels in people who do not get enough calcium from their diets. | Moderate | 1 | [
[
[
887,
24,
841
]
],
[
[
887,
1,
88
],
[
88,
24,
841
]
],
[
[
887,
62,
1152
],
[
1152,
24,
841
]
],
[
[
887,
40,
1121
],
[
1121,
24,
841
]
],
[
[
887,
1,
88
],
[
88,
23,
1152
],
[
1152,
24,
841
]
],
[
[
887,
62,
1152
],
[
1152,
24,
1436
],
[
1436,
24,
841
]
],
[
[
887,
1,
819
],
[
819,
40,
88
],
[
88,
24,
841
]
],
[
[
887,
40,
1121
],
[
1121,
1,
88
],
[
88,
24,
841
]
],
[
[
887,
24,
1053
],
[
1053,
23,
255
],
[
255,
24,
841
]
],
[
[
887,
1,
88
],
[
88,
1,
819
],
[
819,
24,
841
]
]
] | [
[
[
"Pindolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium glubionate anhydrous"
]
],
[
[
"Pindolol",
"{u} (Compound) resembles {v} (Compound)",
"Metoprolol"
],
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium glubionate anhydrous"
]
],
[
[
"Pindolol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Liothyronine"
],
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium glubionate anhydrous"
]
],
[
[
"Pindolol",
"{u} (Compound) resembles {v} (Compound)",
"Bisoprolol"
],
[
"Bisoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium glubionate anhydrous"
]
],
[
[
"Pindolol",
"{u} (Compound) resembles {v} (Compound)",
"Metoprolol"
],
[
"Metoprolol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Liothyronine"
],
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium glubionate anhydrous"
]
],
[
[
"Pindolol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Liothyronine"
],
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Patiromer"
],
[
"Patiromer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium glubionate anhydrous"
]
],
[
[
"Pindolol",
"{u} (Compound) resembles {v} (Compound)",
"Acebutolol"
],
[
"Acebutolol",
"{u} (Compound) resembles {v} (Compound)",
"Metoprolol"
],
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium glubionate anhydrous"
]
],
[
[
"Pindolol",
"{u} (Compound) resembles {v} (Compound)",
"Bisoprolol"
],
[
"Bisoprolol",
"{u} (Compound) resembles {v} (Compound)",
"Metoprolol"
],
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium glubionate anhydrous"
]
],
[
[
"Pindolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Delafloxacin"
],
[
"Delafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium glubionate anhydrous"
]
],
[
[
"Pindolol",
"{u} (Compound) resembles {v} (Compound)",
"Metoprolol"
],
[
"Metoprolol",
"{u} (Compound) resembles {v} (Compound)",
"Acebutolol"
],
[
"Acebutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium glubionate anhydrous"
]
]
] | Pindolol (Compound) resembles Metoprolol (Compound) and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Calcium glubionate anhydrous
Pindolol may cause a minor interaction that can limit clinical effects when taken with Liothyronine and Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Calcium glubionate anhydrous
Pindolol (Compound) resembles Bisoprolol (Compound) and Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Calcium glubionate anhydrous
Pindolol (Compound) resembles Metoprolol (Compound) and Metoprolol may cause a minor interaction that can limit clinical effects when taken with Liothyronine and Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Calcium glubionate anhydrous
Pindolol may cause a minor interaction that can limit clinical effects when taken with Liothyronine and Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Patiromer and Patiromer may cause a moderate interaction that could exacerbate diseases when taken with Calcium glubionate anhydrous
Pindolol (Compound) resembles Acebutolol (Compound) and Acebutolol (Compound) resembles Metoprolol (Compound) and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Calcium glubionate anhydrous
Pindolol (Compound) resembles Bisoprolol (Compound) and Bisoprolol (Compound) resembles Metoprolol (Compound) and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Calcium glubionate anhydrous
Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine may cause a minor interaction that can limit clinical effects when taken with Delafloxacin and Delafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Calcium glubionate anhydrous
Pindolol (Compound) resembles Metoprolol (Compound) and Metoprolol (Compound) resembles Acebutolol (Compound) and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Calcium glubionate anhydrous |
DB00055 | DB06605 | 834 | 1,409 | [
"DDInter605",
"DDInter108"
] | Drotrecogin alfa | Apixaban | Drotrecogin alfa is activated human protein C that is synthesized by recombinant DNA technology. It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond. Drotrecogin alfa was withdrawn from the market after a major study indicated that it was not effective in improving outcomes in patients with sepsis. | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012. | Major | 2 | [
[
[
834,
25,
1409
]
],
[
[
834,
23,
539
],
[
539,
62,
1409
]
],
[
[
834,
24,
109
],
[
109,
24,
1409
]
],
[
[
834,
24,
41
],
[
41,
63,
1409
]
],
[
[
834,
25,
1496
],
[
1496,
63,
1409
]
],
[
[
834,
25,
235
],
[
235,
64,
1409
]
],
[
[
834,
25,
1047
],
[
1047,
25,
1409
]
],
[
[
834,
64,
1271
],
[
1271,
25,
1409
]
],
[
[
834,
23,
539
],
[
539,
62,
802
],
[
802,
64,
1409
]
],
[
[
834,
24,
109
],
[
109,
6,
7950
],
[
7950,
45,
1409
]
]
] | [
[
[
"Drotrecogin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
]
],
[
[
"Drotrecogin alfa",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
],
[
"Capsicum",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Apixaban"
]
],
[
[
"Drotrecogin alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
]
],
[
[
"Drotrecogin alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
],
[
"Levomilnacipran",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
]
],
[
[
"Drotrecogin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nintedanib"
],
[
"Nintedanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
]
],
[
[
"Drotrecogin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
],
[
"Desirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
]
],
[
[
"Drotrecogin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trastuzumab emtansine"
],
[
"Trastuzumab emtansine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
]
],
[
[
"Drotrecogin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alteplase"
],
[
"Alteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
]
],
[
[
"Drotrecogin alfa",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
],
[
"Capsicum",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tinzaparin"
],
[
"Tinzaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
]
],
[
[
"Drotrecogin alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Apixaban"
]
]
] | Drotrecogin alfa may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Apixaban
Drotrecogin alfa may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Apixaban
Drotrecogin alfa may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Apixaban
Drotrecogin alfa may lead to a major life threatening interaction when taken with Nintedanib and Nintedanib may cause a moderate interaction that could exacerbate diseases when taken with Apixaban
Drotrecogin alfa may lead to a major life threatening interaction when taken with Desirudin and Desirudin may lead to a major life threatening interaction when taken with Apixaban
Drotrecogin alfa may lead to a major life threatening interaction when taken with Trastuzumab emtansine and Trastuzumab emtansine may lead to a major life threatening interaction when taken with Apixaban
Drotrecogin alfa may lead to a major life threatening interaction when taken with Alteplase and Alteplase may lead to a major life threatening interaction when taken with Apixaban
Drotrecogin alfa may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Tinzaparin and Tinzaparin may lead to a major life threatening interaction when taken with Apixaban
Drotrecogin alfa may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine and Duloxetine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Apixaban (Compound) |
DB00960 | DB01143 | 887 | 923 | [
"DDInter1471",
"DDInter65"
] | Pindolol | Amifostine | Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension. Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia. Research into pindolol's use in the treatment of hypertension began in the early 1970s. Pindolol was granted FDA approval on 3 September 1982. | A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia. | Moderate | 1 | [
[
[
887,
24,
923
]
],
[
[
887,
21,
28642
],
[
28642,
60,
923
]
],
[
[
887,
1,
819
],
[
819,
63,
923
]
],
[
[
887,
40,
1121
],
[
1121,
24,
923
]
],
[
[
887,
24,
714
],
[
714,
24,
923
]
],
[
[
887,
1,
88
],
[
88,
24,
923
]
],
[
[
887,
24,
885
],
[
885,
63,
923
]
],
[
[
887,
63,
1061
],
[
1061,
24,
923
]
],
[
[
887,
21,
28642
],
[
28642,
60,
336
],
[
336,
24,
923
]
],
[
[
887,
1,
819
],
[
819,
21,
28642
],
[
28642,
60,
923
]
]
] | [
[
[
"Pindolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amifostine"
]
],
[
[
"Pindolol",
"{u} (Compound) causes {v} (Side Effect)",
"Shock"
],
[
"Shock",
"{u} (Side Effect) is caused by {v} (Compound)",
"Amifostine"
]
],
[
[
"Pindolol",
"{u} (Compound) resembles {v} (Compound)",
"Acebutolol"
],
[
"Acebutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amifostine"
]
],
[
[
"Pindolol",
"{u} (Compound) resembles {v} (Compound)",
"Bisoprolol"
],
[
"Bisoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amifostine"
]
],
[
[
"Pindolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
],
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amifostine"
]
],
[
[
"Pindolol",
"{u} (Compound) resembles {v} (Compound)",
"Metoprolol"
],
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amifostine"
]
],
[
[
"Pindolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amifostine"
]
],
[
[
"Pindolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amifostine"
]
],
[
[
"Pindolol",
"{u} (Compound) causes {v} (Side Effect)",
"Shock"
],
[
"Shock",
"{u} (Side Effect) is caused by {v} (Compound)",
"Nifedipine"
],
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amifostine"
]
],
[
[
"Pindolol",
"{u} (Compound) resembles {v} (Compound)",
"Acebutolol"
],
[
"Acebutolol",
"{u} (Compound) causes {v} (Side Effect)",
"Shock"
],
[
"Shock",
"{u} (Side Effect) is caused by {v} (Compound)",
"Amifostine"
]
]
] | Pindolol (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Amifostine (Compound)
Pindolol (Compound) resembles Acebutolol (Compound) and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Amifostine
Pindolol (Compound) resembles Bisoprolol (Compound) and Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Amifostine
Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Amifostine
Pindolol (Compound) resembles Metoprolol (Compound) and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Amifostine
Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Amifostine
Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Amifostine
Pindolol (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Nifedipine (Compound) and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Amifostine
Pindolol (Compound) resembles Acebutolol (Compound) and Acebutolol (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Amifostine (Compound) |
DB00454 | DB09272 | 1,349 | 412 | [
"DDInter1150",
"DDInter632"
] | Meperidine | Eluxadoline | A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration. | Eluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). The mu-, kappa-, and delta-opioid receptors mediate endogenous and exogenous opioid response in the central nervous system and peripherally in the gastrointestinal system. Agonism of peripheral mu-opioid receptors results in reduced colonic motility, while antagonism of central delta-opioid receptors results in improved analgesia, making eluxadoline usable for the symptoms of both pain and diarrhea characteristic of IBS-D. Marketed under the tradename Viberzi (FDA), eluxadoline is an antimotility agent that decreases bowel contractions, inhibits colonic transit, and reduces fluid/ion secretion resulting in improved symptoms of abdominal pain and reductions in the Bristol Stool Scale. | Moderate | 1 | [
[
[
1349,
24,
412
]
],
[
[
1349,
63,
1594
],
[
1594,
24,
412
]
],
[
[
1349,
24,
543
],
[
543,
24,
412
]
],
[
[
1349,
64,
475
],
[
475,
24,
412
]
],
[
[
1349,
24,
407
],
[
407,
63,
412
]
],
[
[
1349,
25,
593
],
[
593,
24,
412
]
],
[
[
1349,
40,
411
],
[
411,
24,
412
]
],
[
[
1349,
63,
1594
],
[
1594,
24,
1105
],
[
1105,
24,
412
]
],
[
[
1349,
24,
543
],
[
543,
63,
1594
],
[
1594,
24,
412
]
],
[
[
1349,
64,
475
],
[
475,
24,
1594
],
[
1594,
24,
412
]
]
] | [
[
[
"Meperidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Meperidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Meperidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
],
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Meperidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Meperidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Meperidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Meperidine",
"{u} (Compound) resembles {v} (Compound)",
"Remifentanil"
],
[
"Remifentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Meperidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trihexyphenidyl"
],
[
"Trihexyphenidyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Meperidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
],
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Meperidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
]
] | Meperidine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Meperidine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Meperidine may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Meperidine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Meperidine may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Meperidine (Compound) resembles Remifentanil (Compound) and Remifentanil may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Meperidine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Trihexyphenidyl and Trihexyphenidyl may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Meperidine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Meperidine may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline |
DB01320 | DB11967 | 651 | 710 | [
"DDInter783",
"DDInter210"
] | Fosphenytoin | Binimetinib | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials. | Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with the BRAF V600E or V600K mutations, as detected by an FDA-approved test. | Moderate | 1 | [
[
[
651,
24,
710
]
],
[
[
651,
25,
1593
],
[
1593,
24,
710
]
],
[
[
651,
63,
883
],
[
883,
24,
710
]
],
[
[
651,
24,
1619
],
[
1619,
63,
710
]
],
[
[
651,
24,
129
],
[
129,
24,
710
]
],
[
[
651,
25,
466
],
[
466,
63,
710
]
],
[
[
651,
40,
362
],
[
362,
24,
710
]
],
[
[
651,
25,
405
],
[
405,
25,
710
]
],
[
[
651,
63,
770
],
[
770,
25,
710
]
],
[
[
651,
64,
1213
],
[
1213,
25,
710
]
]
] | [
[
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Fosphenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
],
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Fosphenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Fosphenytoin",
"{u} (Compound) resembles {v} (Compound)",
"Phenytoin"
],
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Fosphenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
],
[
"Acalabrutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Binimetinib"
]
],
[
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Binimetinib"
]
],
[
[
"Fosphenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Binimetinib"
]
]
] | Fosphenytoin may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Fosphenytoin may lead to a major life threatening interaction when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Fosphenytoin (Compound) resembles Phenytoin (Compound) and Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Fosphenytoin may lead to a major life threatening interaction when taken with Acalabrutinib and Acalabrutinib may lead to a major life threatening interaction when taken with Binimetinib
Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Binimetinib
Fosphenytoin may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may lead to a major life threatening interaction when taken with Binimetinib |
DB00531 | DB08880 | 450 | 1,510 | [
"DDInter456",
"DDInter1771"
] | Cyclophosphamide | Teriflunomide | Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of hepatoxicity and teratogenicity for patients using teriflunomide. | Major | 2 | [
[
[
450,
25,
1510
]
],
[
[
450,
63,
1461
],
[
1461,
23,
1510
]
],
[
[
450,
24,
129
],
[
129,
63,
1510
]
],
[
[
450,
24,
1136
],
[
1136,
24,
1510
]
],
[
[
450,
23,
697
],
[
697,
24,
1510
]
],
[
[
450,
62,
597
],
[
597,
24,
1510
]
],
[
[
450,
24,
535
],
[
535,
25,
1510
]
],
[
[
450,
24,
713
],
[
713,
64,
1510
]
],
[
[
450,
62,
1451
],
[
1451,
25,
1510
]
],
[
[
450,
63,
1648
],
[
1648,
25,
1510
]
]
] | [
[
[
"Cyclophosphamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Teriflunomide"
]
],
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teriflunomide"
]
],
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
],
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teriflunomide"
]
],
[
[
"Cyclophosphamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teriflunomide"
]
],
[
[
"Cyclophosphamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teriflunomide"
]
],
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenofibrate"
],
[
"Fenofibrate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
],
[
"Dimethyl fumarate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Cyclophosphamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Interferon alfa-n1"
],
[
"Interferon alfa-n1",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
]
] | Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Teriflunomide
Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Denosumab and Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Cyclophosphamide may cause a minor interaction that can limit clinical effects when taken with Phenobarbital and Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Cyclophosphamide may cause a minor interaction that can limit clinical effects when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Fenofibrate and Fenofibrate may lead to a major life threatening interaction when taken with Teriflunomide
Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarate may lead to a major life threatening interaction when taken with Teriflunomide
Cyclophosphamide may cause a minor interaction that can limit clinical effects when taken with Interferon alfa-n1 and Interferon alfa-n1 may lead to a major life threatening interaction when taken with Teriflunomide
Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may lead to a major life threatening interaction when taken with Teriflunomide |
DB00381 | DB11126 | 376 | 900 | [
"DDInter79",
"DDInter276"
] | Amlodipine | Calcium gluconate | Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called _dihydropyridine calcium channel blockers_. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial depression and cardiac conduction abnormalities than other calcium channel blockers. Amlodipine is commonly used in the treatment of high blood pressure and angina. Amlodipine has antioxidant properties and an ability to enhance the production of nitric oxide (NO), an important vasodilator that decreases blood pressure. The option for single daily dosing of amlodipine is an attractive feature of this drug [FDA label]. | Calcium gluconate is used as mineral supplement and medication when there is insufficient calcium in the diet. Supplementation may be done to treat or prevent osteoporosis or rickets, consequences of hypocalcemia. It can also be taken by mouth but is not recommended by injection into a muscle. Calcium Gluconate Injection, USP is a sterile, nonpyrogenic supersaturated solution of calcium gluconate for intravenous use only. Each mL contains: Calcium gluconate 94 mg; calcium saccharate (tetrahydrate) 4.5 mg; water for injection q.s. Hydrochloric acid and/or sodium hydroxide may have been added for pH adjustment (6.0 to 8.2). Calcium saccharate provides 6% of the total calcium and stabilizes the supersaturated solution of calcium gluconate. Each 10 mL of the injection provides 93 mg elemental calcium (Ca++) equivalent to 1 g of calcium gluconate. | Moderate | 1 | [
[
[
376,
24,
900
]
],
[
[
376,
1,
336
],
[
336,
24,
900
]
],
[
[
376,
40,
84
],
[
84,
24,
900
]
],
[
[
376,
1,
336
],
[
336,
40,
84
],
[
84,
24,
900
]
],
[
[
376,
40,
84
],
[
84,
1,
336
],
[
336,
24,
900
]
],
[
[
376,
5,
11590
],
[
11590,
44,
729
],
[
729,
24,
900
]
],
[
[
376,
1,
336
],
[
336,
1,
1081
],
[
1081,
24,
900
]
],
[
[
376,
40,
409
],
[
409,
40,
84
],
[
84,
24,
900
]
],
[
[
376,
10,
11576
],
[
11576,
44,
729
],
[
729,
24,
900
]
],
[
[
376,
21,
28698
],
[
28698,
60,
729
],
[
729,
24,
900
]
]
] | [
[
[
"Amlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium gluconate"
]
],
[
[
"Amlodipine",
"{u} (Compound) resembles {v} (Compound)",
"Nifedipine"
],
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium gluconate"
]
],
[
[
"Amlodipine",
"{u} (Compound) resembles {v} (Compound)",
"Nisoldipine"
],
[
"Nisoldipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium gluconate"
]
],
[
[
"Amlodipine",
"{u} (Compound) resembles {v} (Compound)",
"Nifedipine"
],
[
"Nifedipine",
"{u} (Compound) resembles {v} (Compound)",
"Nisoldipine"
],
[
"Nisoldipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium gluconate"
]
],
[
[
"Amlodipine",
"{u} (Compound) resembles {v} (Compound)",
"Nisoldipine"
],
[
"Nisoldipine",
"{u} (Compound) resembles {v} (Compound)",
"Nifedipine"
],
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium gluconate"
]
],
[
[
"Amlodipine",
"{u} (Compound) treats {v} (Disease)",
"hypertension"
],
[
"hypertension",
"{u} (Disease) is treated by {v} (Compound)",
"Penbutolol"
],
[
"Penbutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium gluconate"
]
],
[
[
"Amlodipine",
"{u} (Compound) resembles {v} (Compound)",
"Nifedipine"
],
[
"Nifedipine",
"{u} (Compound) resembles {v} (Compound)",
"Nicardipine"
],
[
"Nicardipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium gluconate"
]
],
[
[
"Amlodipine",
"{u} (Compound) resembles {v} (Compound)",
"Felodipine"
],
[
"Felodipine",
"{u} (Compound) resembles {v} (Compound)",
"Nisoldipine"
],
[
"Nisoldipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium gluconate"
]
],
[
[
"Amlodipine",
"{u} (Compound) palliates {v} (Disease)",
"coronary artery disease"
],
[
"coronary artery disease",
"{u} (Disease) is treated by {v} (Compound)",
"Penbutolol"
],
[
"Penbutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium gluconate"
]
],
[
[
"Amlodipine",
"{u} (Compound) causes {v} (Side Effect)",
"Insomnia"
],
[
"Insomnia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Penbutolol"
],
[
"Penbutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium gluconate"
]
]
] | Amlodipine (Compound) resembles Nifedipine (Compound) and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Calcium gluconate
Amlodipine (Compound) resembles Nisoldipine (Compound) and Nisoldipine may cause a moderate interaction that could exacerbate diseases when taken with Calcium gluconate
Amlodipine (Compound) resembles Nifedipine (Compound) and Nifedipine (Compound) resembles Nisoldipine (Compound) and Nisoldipine may cause a moderate interaction that could exacerbate diseases when taken with Calcium gluconate
Amlodipine (Compound) resembles Nisoldipine (Compound) and Nisoldipine (Compound) resembles Nifedipine (Compound) and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Calcium gluconate
Amlodipine (Compound) treats hypertension (Disease) and hypertension (Disease) is treated by Penbutolol (Compound) and Penbutolol may cause a moderate interaction that could exacerbate diseases when taken with Calcium gluconate
Amlodipine (Compound) resembles Nifedipine (Compound) and Nifedipine (Compound) resembles Nicardipine (Compound) and Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Calcium gluconate
Amlodipine (Compound) resembles Felodipine (Compound) and Felodipine (Compound) resembles Nisoldipine (Compound) and Nisoldipine may cause a moderate interaction that could exacerbate diseases when taken with Calcium gluconate
Amlodipine (Compound) palliates coronary artery disease (Disease) and coronary artery disease (Disease) is treated by Penbutolol (Compound) and Penbutolol may cause a moderate interaction that could exacerbate diseases when taken with Calcium gluconate
Amlodipine (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Penbutolol (Compound) and Penbutolol may cause a moderate interaction that could exacerbate diseases when taken with Calcium gluconate |
DB00242 | DB10795 | 1,064 | 221 | [
"DDInter392",
"DDInter1486"
] | Cladribine | Poliovirus type 1 antigen (formaldehyde inactivated) | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Poliovirus type 1 antigen is a suspension of poliovirus Type 1 (Mahoney) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus Type 1. The vaccine contains purified and inactivated poliovirus type 1 that were grown from a continuous line of monkey kidney cells. | Moderate | 1 | [
[
[
1064,
24,
221
]
],
[
[
1064,
25,
36
],
[
36,
24,
221
]
],
[
[
1064,
64,
581
],
[
581,
24,
221
]
],
[
[
1064,
25,
351
],
[
351,
63,
221
]
],
[
[
1064,
36,
1488
],
[
1488,
24,
221
]
],
[
[
1064,
24,
869
],
[
869,
24,
221
]
],
[
[
1064,
37,
1224
],
[
1224,
24,
221
]
],
[
[
1064,
25,
36
],
[
36,
64,
581
],
[
581,
24,
221
]
],
[
[
1064,
64,
581
],
[
581,
25,
36
],
[
36,
24,
221
]
],
[
[
1064,
25,
350
],
[
350,
63,
36
],
[
36,
24,
221
]
]
] | [
[
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eribulin"
],
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Cladribine",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Fludarabine"
],
[
"Fludarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Cytarabine"
],
[
"Cytarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eribulin"
],
[
"Eribulin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eribulin"
],
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carfilzomib"
],
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
],
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
]
] | Cladribine may lead to a major life threatening interaction when taken with Eribulin and Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Cladribine may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Cladribine may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Cladribine (Compound) resembles Fludarabine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Fludarabine and Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Cytarabine and Cladribine may lead to a major life threatening interaction when taken with Cytarabine and Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Cladribine may lead to a major life threatening interaction when taken with Eribulin and Eribulin may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Cladribine may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Eribulin and Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Cladribine may lead to a major life threatening interaction when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Eribulin and Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated) |
DB00480 | DB09122 | 1,668 | 1,613 | [
"DDInter1035",
"DDInter1409"
] | Lenalidomide | Peginterferon beta-1a | Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties. It is a 4-amino-glutamyl analogue of [thalidomide] and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms. However, lenalidomide is much safer and potent than thalidomide, with fewer adverse effects and toxicities.[A714, A228543] Thalidomide and its analogues, including lenalidomide, are referred to as immunomodulatory imide drugs (also known as cereblon modulators), which are a class of immunomodulatory drugs that contain an imide group. Lenalidomide works through various mechanisms of actions that promote malignant cell death and enhance host immunity | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792] Peginterferon beta-1a is an interferon therapy used for the management of relapsing forms of MS. It was originally approved by the FDA in 2014 for subcutaneous use, and was approved for intramuscular use in January 2021. Currently, it is the only approved pegylated interferon for the management of MS with an proven ability to reduce relapses and delay the progression of disability resulting from MS. | Moderate | 1 | [
[
[
1668,
24,
1613
]
],
[
[
1668,
25,
671
],
[
671,
24,
1613
]
],
[
[
1668,
24,
1627
],
[
1627,
24,
1613
]
],
[
[
1668,
24,
1155
],
[
1155,
63,
1613
]
],
[
[
1668,
64,
1463
],
[
1463,
24,
1613
]
],
[
[
1668,
63,
1560
],
[
1560,
24,
1613
]
],
[
[
1668,
25,
1377
],
[
1377,
25,
1613
]
],
[
[
1668,
24,
139
],
[
139,
25,
1613
]
],
[
[
1668,
64,
1066
],
[
1066,
25,
1613
]
],
[
[
1668,
25,
671
],
[
671,
63,
600
],
[
600,
24,
1613
]
]
] | [
[
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Lenalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluvastatin"
],
[
"Fluvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
],
[
"Cannabidiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
],
[
"Tucatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Lenalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lovastatin"
],
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
],
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Lenalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zidovudine"
],
[
"Zidovudine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Lenalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Lenalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluvastatin"
],
[
"Fluvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
]
] | Lenalidomide may lead to a major life threatening interaction when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib and Tucatinib may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Lenalidomide may lead to a major life threatening interaction when taken with Lovastatin and Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Lenalidomide may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Peginterferon beta-1a
Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine may lead to a major life threatening interaction when taken with Peginterferon beta-1a
Lenalidomide may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Peginterferon beta-1a
Lenalidomide may lead to a major life threatening interaction when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a |
DB00067 | DB11718 | 317 | 927 | [
"DDInter1921",
"DDInter640"
] | Vasopressin | Encorafenib | Vasopressin (arginine-vasopressin or antidiuretic hormone) is a nonapeptide primarily produced in the hypothalamus that exhibits diverse physiological functions related to diuresis, hemodynamic modulation, and behaviour.[A110, A111, A112, A113, A228008] Vasopressin is very similar to oxytocin, differing in the third and eighth amino acids. Despite a wide variety of functions, exogenous vasopressin is primarily used to control blood pressure during systemic shock by increasing vasoconstriction and renal fluid reuptake by acting through V<sub>1</sub> and V<sub>2</sub> cellular receptors.[A228008, A228013, A228018, L31413] The vasopressive effect of posterior pituitary gland extracts was noted in 1895, while vasopressin itself was not purified until 1951. It has been used for | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and secretion. Mutations in this gene, most frequently the V600E mutation, are the most commonly identified cancer-causing mutations in melanoma, and have been isolated in various other cancers as well, including non-Hodgkin lymphoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukemia and adenocarcinoma of the lung. On June 27, 2018, the Food and Drug Administration approved encorafenib and [binimetinib] (BRAFTOVI and MEKTOVI, Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. | Moderate | 1 | [
[
[
317,
24,
927
]
],
[
[
317,
23,
112
],
[
112,
23,
927
]
],
[
[
317,
24,
659
],
[
659,
24,
927
]
],
[
[
317,
24,
484
],
[
484,
63,
927
]
],
[
[
317,
63,
521
],
[
521,
24,
927
]
],
[
[
317,
25,
39
],
[
39,
25,
927
]
],
[
[
317,
24,
129
],
[
129,
25,
927
]
],
[
[
317,
24,
913
],
[
913,
64,
927
]
],
[
[
317,
25,
351
],
[
351,
64,
927
]
],
[
[
317,
23,
112
],
[
112,
23,
1247
],
[
1247,
23,
927
]
]
] | [
[
[
"Vasopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Vasopressin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Encorafenib"
]
],
[
[
"Vasopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Vasopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Vasopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Vasopressin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
],
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
],
[
[
"Vasopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
],
[
[
"Vasopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
],
[
[
"Vasopressin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
],
[
[
"Vasopressin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Encorafenib"
]
]
] | Vasopressin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Vasopressin may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Encorafenib
Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Encorafenib
Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Encorafenib
Vasopressin may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Encorafenib
Vasopressin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib |
DB00938 | DB11730 | 455 | 351 | [
"DDInter1635",
"DDInter1588"
] | Salmeterol | Ribociclib | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salmeterol was first described in the literature in 1988. Salmeterol's structure is similar to salbutamol's with an aralkyloxy-alkyl substitution on the amine. Salmeterol was granted FDA approval on 4 February 1994. | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. Ribociclib was approved by the U.S. FDA in March, 2017 as Kisqali. | Major | 2 | [
[
[
455,
25,
351
]
],
[
[
455,
24,
222
],
[
222,
23,
351
]
],
[
[
455,
24,
1654
],
[
1654,
63,
351
]
],
[
[
455,
63,
867
],
[
867,
24,
351
]
],
[
[
455,
23,
1486
],
[
1486,
24,
351
]
],
[
[
455,
24,
98
],
[
98,
24,
351
]
],
[
[
455,
62,
175
],
[
175,
24,
351
]
],
[
[
455,
24,
129
],
[
129,
25,
351
]
],
[
[
455,
63,
876
],
[
876,
25,
351
]
],
[
[
455,
25,
1155
],
[
1155,
25,
351
]
]
] | [
[
[
"Salmeterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ribociclib"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
],
[
"Somapacitan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olanzapine"
],
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Salmeterol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
],
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Salmeterol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tizanidine"
],
[
"Tizanidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Salmeterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tucatinib"
],
[
"Tucatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
]
] | Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan and Somapacitan may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Olanzapine and Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Salmeterol may cause a minor interaction that can limit clinical effects when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Salmeterol may cause a minor interaction that can limit clinical effects when taken with Triamcinolone and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Ribociclib
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Tizanidine and Tizanidine may lead to a major life threatening interaction when taken with Ribociclib
Salmeterol may lead to a major life threatening interaction when taken with Tucatinib and Tucatinib may lead to a major life threatening interaction when taken with Ribociclib |
DB00539 | DB09280 | 11 | 1,604 | [
"DDInter1837",
"DDInter1101"
] | Toremifene | Lumacaftor | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has estrogenic (agonist) activity on the cardiovascular system and on bone tissue and it has weak estrogenic effects on uterine tissue, however, it also has antiestrogenic (estrogen-antagonist) activity on breast tissue. | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, a transmembrane ion channel involved in the transport of chloride and sodium ions across cell membranes of the lungs, pancreas, and other organs. Mutations in the CFTR gene result in altered production, misfolding, or function of the CFTR protein and consequently abnormal fluid and ion transport across cell membranes.[A20298, A20299] As a result, CF patients produce thick, sticky mucus that clogs the ducts of organs where it is produced making patients more susceptible to infections, lung damage, pancreatic insufficiency, and malnutrition. Lumacaftor improves CF symptoms and underlying disease pathology by aiding the conformational stability of F508del-mutated CFTR proteins, preventing misfolding and resulting in increased processing and trafficking of mature protein to the cell surface. Results from clinical trials indicated that treatment with Orkambi (lumacaftor/ivacaftor) results in improved lung function, reduced chance of experiencing a pulmonary exacerbation, increased weight gain, and improvements in CF symptoms.[FDA Label] This data has been heavily scrutinized, however, with clinical trials showing only modest improvements despite a hefty yearly cost of $259,000 for Orkambi. Improvements in lung function (ppFEV1) were found to be statistically significant, but minimal, with only a 2.6-3.0% change from baseline with more than 70% of patients failing to achieve an absolute improvement of at least 5%.[A20343, L936] A wide variety of CFTR mutations correlate to the Cystic Fibrosis phenotype and are associated with differing levels of disease severity. The most common mutation, affecting approximately 70% of patients with CF worldwide, is known as F508del-CFTR, or delta-F508 (ΔF508), in which a deletion in the amino acid phenylalanine at position 508 results in impaired production of the CFTR protein, thereby causing a significant reduction in the amount of ion transporter present on cell membranes. When used in combination with as the fixed dose combination product Orkambi, lumacaftor is specific for the management of CF in patients with delta-F508 mutations as it acts as a protein-folding chaperone, aiding the conformational stability of the mutated CFTR protein. Consequently, lumacaftor increases successful production of CFTR ion channels and the total number of receptors available for use at the cell membrane for fluid and ion transport. The next most common mutation, G551D, affecting 4-5% of CF patients worldwide, is characterized as a missense mutation, whereby there is sufficient amount of protein at the cell surface, but opening and closing mechanisms of the channel are altered. Treatment of patients with G551D and other rarer missense mutations is usually managed with (Kalydeco), as it aids with altered gating mechanisms by potentiating channel opening probability of CFTR protein. Prior to the development of lumacaftor and (Kalydeco), management of CF primarily involved therapies for the control of infections, nutritional support, clearance of mucus, and management of symptoms rather than improvements in the underlying disease process. Approved for use by the Food and Drug Administration in July 2015 and by Health Canada in January 2016, Orkambi was the first combination product approved for the management of Cystic Fibrosis with delta-F508 mutations. Ivacaftor is manufactured and distributed by Vertex Pharmaceuticals. | Major | 2 | [
[
[
11,
25,
1604
]
],
[
[
11,
24,
671
],
[
671,
24,
1604
]
],
[
[
11,
64,
1251
],
[
1251,
24,
1604
]
],
[
[
11,
25,
1005
],
[
1005,
24,
1604
]
],
[
[
11,
63,
201
],
[
201,
24,
1604
]
],
[
[
11,
35,
1423
],
[
1423,
24,
1604
]
],
[
[
11,
25,
877
],
[
877,
63,
1604
]
],
[
[
11,
25,
786
],
[
786,
25,
1604
]
],
[
[
11,
25,
985
],
[
985,
64,
1604
]
],
[
[
11,
24,
629
],
[
629,
25,
1604
]
]
] | [
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumacaftor"
]
],
[
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
],
[
"Fluvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumacaftor"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mirtazapine"
],
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumacaftor"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vardenafil"
],
[
"Vardenafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumacaftor"
]
],
[
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Montelukast"
],
[
"Montelukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumacaftor"
]
],
[
[
"Toremifene",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ospemifene"
],
[
"Ospemifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumacaftor"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumacaftor"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rilpivirine"
],
[
"Rilpivirine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumacaftor"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
],
[
"Osimertinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumacaftor"
]
],
[
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumacaftor"
]
]
] | Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor
Toremifene may lead to a major life threatening interaction when taken with Mirtazapine and Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor
Toremifene may lead to a major life threatening interaction when taken with Vardenafil and Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor
Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Montelukast and Montelukast may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor
Toremifene (Compound) resembles Ospemifene (Compound) and Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Ospemifene and Ospemifene may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor
Toremifene may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor
Toremifene may lead to a major life threatening interaction when taken with Rilpivirine and Rilpivirine may lead to a major life threatening interaction when taken with Lumacaftor
Toremifene may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may lead to a major life threatening interaction when taken with Lumacaftor
Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may lead to a major life threatening interaction when taken with Lumacaftor |
DB09133 | DB09293 | 1,527 | 116 | [
"DDInter965",
"DDInter954"
] | Iothalamic acid | Iodide I-131 | Iothalamic acid is an iodine containing organic anion used as a diagnostic contrast agent. | Iodide I-131 (as Sodium iodide I-131) is a radioisotopic drug used for the treatment and palliation of thyroid malignancy. Iodine-131 is notable for causing mutation and death in cells that it penetrates, which is due to its mode of beta decay. As a result of beta decay, approximately 10% of its energy and radiation dose is via gamma radiation, while the other 90% (beta radiation) causes tissue damage without contributing to any ability to see or image the isotope. Low levels of beta radiation are also known for causing cancer as this dose is highly mutagenic. For this reason, less toxic iodine isotopes such as I-123 are more frequently used in nuclear imaging, while I-131 is reserved for its tissue destroying effects. Because the thyroid gland naturally takes up iodine from the body, therapeutic methods using radioisotopes can take advantage of this mechanism for localization of drug to the site of malignancy. Therapeutic solutions of Sodium Iodide-131 are indicated for the treatment of hyperthyroidism and thyroid carcinomas that take up iodine. Palliative effects may be observed in patients with advanced thyroid malignancy if the metastatic lesions take up iodine. It is also indicated for use in performance of the radioactive iodide (RAI) uptake test to evaluate thyroid function. | Moderate | 1 | [
[
[
1527,
24,
116
]
],
[
[
1527,
24,
278
],
[
278,
63,
116
]
],
[
[
1527,
64,
485
],
[
485,
24,
116
]
],
[
[
1527,
25,
1399
],
[
1399,
63,
116
]
],
[
[
1527,
63,
33
],
[
33,
25,
116
]
],
[
[
1527,
24,
278
],
[
278,
63,
1211
],
[
1211,
24,
116
]
],
[
[
1527,
64,
485
],
[
485,
25,
1487
],
[
1487,
24,
116
]
],
[
[
1527,
25,
1399
],
[
1399,
63,
701
],
[
701,
24,
116
]
],
[
[
1527,
64,
50
],
[
50,
62,
682
],
[
682,
24,
116
]
],
[
[
1527,
64,
914
],
[
914,
24,
1486
],
[
1486,
24,
116
]
]
] | [
[
[
"Iothalamic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-131"
]
],
[
[
"Iothalamic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopodic acid"
],
[
"Iopodic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-131"
]
],
[
[
"Iothalamic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pentamidine"
],
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-131"
]
],
[
[
"Iothalamic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lithium carbonate"
],
[
"Lithium carbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-131"
]
],
[
[
"Iothalamic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiodarone"
],
[
"Amiodarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iodide I-131"
]
],
[
[
"Iothalamic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopodic acid"
],
[
"Iopodic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioxilan"
],
[
"Ioxilan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-131"
]
],
[
[
"Iothalamic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pentamidine"
],
[
"Pentamidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-131"
]
],
[
[
"Iothalamic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lithium carbonate"
],
[
"Lithium carbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-131"
]
],
[
[
"Iothalamic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sulfasalazine"
],
[
"Sulfasalazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Thiopental"
],
[
"Thiopental",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-131"
]
],
[
[
"Iothalamic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diflunisal"
],
[
"Diflunisal",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-131"
]
]
] | Iothalamic acid may cause a moderate interaction that could exacerbate diseases when taken with Iopodic acid and Iopodic acid may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131
Iothalamic acid may lead to a major life threatening interaction when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131
Iothalamic acid may lead to a major life threatening interaction when taken with Lithium carbonate and Lithium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131
Iothalamic acid may cause a moderate interaction that could exacerbate diseases when taken with Amiodarone and Amiodarone may lead to a major life threatening interaction when taken with Iodide I-131
Iothalamic acid may cause a moderate interaction that could exacerbate diseases when taken with Iopodic acid and Iopodic acid may cause a moderate interaction that could exacerbate diseases when taken with Ioxilan and Ioxilan may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131
Iothalamic acid may lead to a major life threatening interaction when taken with Pentamidine and Pentamidine may lead to a major life threatening interaction when taken with Hydroxychloroquine and Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131
Iothalamic acid may lead to a major life threatening interaction when taken with Lithium carbonate and Lithium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131
Iothalamic acid may lead to a major life threatening interaction when taken with Sulfasalazine and Sulfasalazine may cause a minor interaction that can limit clinical effects when taken with Thiopental and Thiopental may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131
Iothalamic acid may lead to a major life threatening interaction when taken with Diflunisal and Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131 |
DB00635 | DB09037 | 1,573 | 920 | [
"DDInter1515",
"DDInter1413"
] | Prednisone | Pembrolizumab | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Pembrolizumab is a highly selective IgG4-kappa humanized monoclonal antibody against PD-1 receptors. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype containing a stabilizing S228P Fc mutation. It contains 32 cysteine residues and the complete folded molecule includes 4 disulfide linkages as interchain bonds and 23 interchain bonds. It was developed by Merck & Co and first approved for the treatment of metastatic malignant melanoma by the FDA on September 4, 2014, becoming the first approved therapy against PD-1. In the time since its initial approval, pembrolizumab has been granted approval in the treatment of a wide variety of cancers.[L38934,L43257] | Moderate | 1 | [
[
[
1573,
24,
920
]
],
[
[
1573,
1,
891
],
[
891,
24,
920
]
],
[
[
1573,
40,
251
],
[
251,
24,
920
]
],
[
[
1573,
25,
770
],
[
770,
25,
920
]
],
[
[
1573,
1,
891
],
[
891,
1,
175
],
[
175,
24,
920
]
],
[
[
1573,
1,
175
],
[
175,
40,
891
],
[
891,
24,
920
]
],
[
[
1573,
40,
251
],
[
251,
1,
891
],
[
891,
24,
920
]
],
[
[
1573,
25,
770
],
[
770,
64,
891
],
[
891,
24,
920
]
],
[
[
1573,
1,
1220
],
[
1220,
25,
1019
],
[
1019,
63,
920
]
],
[
[
1573,
25,
770
],
[
770,
25,
1019
],
[
1019,
63,
920
]
]
] | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pembrolizumab"
]
],
[
[
"Prednisone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pembrolizumab"
]
],
[
[
"Prednisone",
"{u} (Compound) resembles {v} (Compound)",
"Betamethasone"
],
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pembrolizumab"
]
],
[
[
"Prednisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pembrolizumab"
]
],
[
[
"Prednisone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisolone"
],
[
"Prednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pembrolizumab"
]
],
[
[
"Prednisone",
"{u} (Compound) resembles {v} (Compound)",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pembrolizumab"
]
],
[
[
"Prednisone",
"{u} (Compound) resembles {v} (Compound)",
"Betamethasone"
],
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pembrolizumab"
]
],
[
[
"Prednisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pembrolizumab"
]
],
[
[
"Prednisone",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
],
[
"Deflazacort",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pembrolizumab"
]
],
[
[
"Prednisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
],
[
"Deflazacort",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pembrolizumab"
]
]
] | Prednisone (Compound) resembles Prednisolone (Compound) and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Pembrolizumab
Prednisone (Compound) resembles Betamethasone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Pembrolizumab
Prednisone may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Pembrolizumab
Prednisone (Compound) resembles Prednisolone (Compound) and Prednisolone (Compound) resembles Triamcinolone (Compound) and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Pembrolizumab
Prednisone (Compound) resembles Triamcinolone (Compound) and Triamcinolone (Compound) resembles Prednisolone (Compound) and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Pembrolizumab
Prednisone (Compound) resembles Betamethasone (Compound) and Betamethasone (Compound) resembles Prednisolone (Compound) and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Pembrolizumab
Prednisone may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Pembrolizumab
Prednisone (Compound) resembles Dexamethasone (Compound) and Dexamethasone may lead to a major life threatening interaction when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Pembrolizumab
Prednisone may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Pembrolizumab |
DB00414 | DB00930 | 590 | 166 | [
"DDInter16",
"DDInter432"
] | Acetohexamide | Colesevelam | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Colesevelam is a bile acid sequestrant. Colesevelam is used with exercise and diet changes (restriction of cholesterol and fat intake) to reduce the amount of cholesterol and certain fatty substances in the blood. It works by binding bile acids in the intestine. Bile acids are made when cholesterol is broken down in the body. Removing these bile acids helps to lower blood cholesterol. | Moderate | 1 | [
[
[
590,
24,
166
]
],
[
[
590,
24,
1019
],
[
1019,
63,
166
]
],
[
[
590,
63,
1645
],
[
1645,
24,
166
]
],
[
[
590,
24,
175
],
[
175,
24,
166
]
],
[
[
590,
63,
1101
],
[
1101,
25,
166
]
],
[
[
590,
24,
1019
],
[
1019,
63,
959
],
[
959,
63,
166
]
],
[
[
590,
63,
1645
],
[
1645,
24,
959
],
[
959,
63,
166
]
],
[
[
590,
24,
175
],
[
175,
24,
959
],
[
959,
63,
166
]
],
[
[
590,
23,
1400
],
[
1400,
62,
959
],
[
959,
63,
166
]
],
[
[
590,
24,
1019
],
[
1019,
63,
1645
],
[
1645,
24,
166
]
]
] | [
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Colesevelam"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
],
[
"Deflazacort",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Colesevelam"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metformin"
],
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Colesevelam"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Colesevelam"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Colesevelam"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
],
[
"Deflazacort",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Colesevelam"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metformin"
],
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Colesevelam"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Colesevelam"
]
],
[
[
"Acetohexamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tromethamine"
],
[
"Tromethamine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Colesevelam"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
],
[
"Deflazacort",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metformin"
],
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Colesevelam"
]
]
] | Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Colesevelam
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Colesevelam
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Colesevelam
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Colesevelam
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Colesevelam
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Colesevelam
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Colesevelam
Acetohexamide may cause a minor interaction that can limit clinical effects when taken with Tromethamine and Tromethamine may cause a minor interaction that can limit clinical effects when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Colesevelam
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Colesevelam |
DB01211 | DB11978 | 609 | 124 | [
"DDInter393",
"DDInter822"
] | Clarithromycin | Glasdegib | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration. | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionality. The great lipophilicity of this group of compounds brought interest to further modification. This analysis concluded that the presence of p-cyano ureas presented good physicochemical and pharmacokinetic properties from which glasdegib was developed. Glasdegib was developed by Pfizer Inc and approved on November 21, 2018 by the FDA for the treatment of Acute Myeloid Leukemia (AML). Glasdegib targets cancerous cells by inhibiting the sonic hedgehog receptor smoothened (SMO), a transmembrane protein involved in the Hedgehog (Hh) signaling cascade. Aberrant of Hh signaling is one of the main pathophysiologies of AML, with observed overexpression or constitutive activation of SMO.[A258498,A258503] Although the efficacy of glasdegib monotherapy is limited, the landmark Phase 2 Bright AML 1003 trial showed a superior overall survival and complete response when glasdegib is combined with low dose cytarabine. Currently, the current gold standard of AML in older patients is still venetoclax with hypomethylation agents, new clinical combinations of glasdegib are being tested in hope of replacing venetoclax due to glasdegib's more favorable side effects profile. | Major | 2 | [
[
[
609,
25,
124
]
],
[
[
609,
25,
1135
],
[
1135,
23,
124
]
],
[
[
609,
62,
1247
],
[
1247,
23,
124
]
],
[
[
609,
24,
466
],
[
466,
62,
124
]
],
[
[
609,
24,
1079
],
[
1079,
24,
124
]
],
[
[
609,
24,
1032
],
[
1032,
63,
124
]
],
[
[
609,
63,
79
],
[
79,
24,
124
]
],
[
[
609,
25,
180
],
[
180,
63,
124
]
],
[
[
609,
23,
1204
],
[
1204,
24,
124
]
],
[
[
609,
62,
752
],
[
752,
24,
124
]
]
] | [
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glasdegib"
]
],
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Glasdegib"
]
],
[
[
"Clarithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Glasdegib"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Glasdegib"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telavancin"
],
[
"Telavancin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levosalbutamol"
],
[
"Levosalbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oliceridine"
],
[
"Oliceridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Clarithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ambrisentan"
],
[
"Ambrisentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Clarithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
]
] | Clarithromycin may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Telavancin and Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol and Levosalbutamol may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Clarithromycin may lead to a major life threatening interaction when taken with Oliceridine and Oliceridine may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Ambrisentan and Ambrisentan may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib |
DB00365 | DB01211 | 839 | 609 | [
"DDInter842",
"DDInter393"
] | Grepafloxacin | Clarithromycin | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration. | Major | 2 | [
[
[
839,
25,
609
]
],
[
[
839,
24,
1601
],
[
1601,
23,
609
]
],
[
[
839,
64,
600
],
[
600,
23,
609
]
],
[
[
839,
62,
1101
],
[
1101,
23,
609
]
],
[
[
839,
23,
222
],
[
222,
23,
609
]
],
[
[
839,
24,
770
],
[
770,
24,
609
]
],
[
[
839,
25,
1383
],
[
1383,
63,
609
]
],
[
[
839,
24,
52
],
[
52,
63,
609
]
],
[
[
839,
25,
1144
],
[
1144,
24,
609
]
],
[
[
839,
64,
1010
],
[
1010,
24,
609
]
]
] | [
[
[
"Grepafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
]
],
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loratadine"
],
[
"Loratadine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clarithromycin"
]
],
[
[
"Grepafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clarithromycin"
]
],
[
[
"Grepafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clarithromycin"
]
],
[
[
"Grepafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clarithromycin"
]
],
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Grepafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sodium sulfate"
],
[
"Sodium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
],
[
"Dulaglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Grepafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nateglinide"
],
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Grepafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mefloquine"
],
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
]
] | Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Loratadine and Loratadine may cause a minor interaction that can limit clinical effects when taken with Clarithromycin
Grepafloxacin may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Clarithromycin
Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Clarithromycin
Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Clarithromycin
Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin
Grepafloxacin may lead to a major life threatening interaction when taken with Sodium sulfate and Sodium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin
Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide and Dulaglutide may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin
Grepafloxacin may lead to a major life threatening interaction when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin
Grepafloxacin may lead to a major life threatening interaction when taken with Mefloquine and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin |
DB00366 | DB00802 | 1,594 | 1,322 | [
"DDInter600",
"DDInter43"
] | Doxylamine | Alfentanil | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | A short-acting opioid anesthetic and analgesic derivative of fentanyl. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients. | Moderate | 1 | [
[
[
1594,
24,
1322
]
],
[
[
1594,
24,
411
],
[
411,
1,
1322
]
],
[
[
1594,
21,
29118
],
[
29118,
60,
1322
]
],
[
[
1594,
24,
1219
],
[
1219,
24,
1322
]
],
[
[
1594,
24,
401
],
[
401,
63,
1322
]
],
[
[
1594,
74,
701
],
[
701,
24,
1322
]
],
[
[
1594,
63,
1648
],
[
1648,
24,
1322
]
],
[
[
1594,
40,
888
],
[
888,
24,
1322
]
],
[
[
1594,
35,
272
],
[
272,
63,
1322
]
],
[
[
1594,
35,
128
],
[
128,
24,
1322
]
]
] | [
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alfentanil"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remifentanil"
],
[
"Remifentanil",
"{u} (Compound) resembles {v} (Compound)",
"Alfentanil"
]
],
[
[
"Doxylamine",
"{u} (Compound) causes {v} (Side Effect)",
"Tachycardia"
],
[
"Tachycardia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Alfentanil"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azatadine"
],
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alfentanil"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alfentanil"
]
],
[
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alfentanil"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alfentanil"
]
],
[
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound)",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alfentanil"
]
],
[
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alfentanil"
]
],
[
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
],
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alfentanil"
]
]
] | Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Remifentanil and Remifentanil (Compound) resembles Alfentanil (Compound)
Doxylamine (Compound) causes Tachycardia (Side Effect) and Tachycardia (Side Effect) is caused by Alfentanil (Compound)
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Azatadine and Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Alfentanil
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Alfentanil
Doxylamine (Compound) resembles Clemastine (Compound) and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Alfentanil
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Alfentanil
Doxylamine (Compound) resembles Tamoxifen (Compound) and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Alfentanil
Doxylamine (Compound) resembles Chlorpheniramine (Compound) and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Alfentanil
Doxylamine (Compound) resembles Dexbrompheniramine (Compound) and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Alfentanil |
DB00877 | DB01261 | 629 | 170 | [
"DDInter1678",
"DDInter1679"
] | Sirolimus | Sitagliptin | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive activities were later discovered, it was extensively investigated as an immunosuppressive and antitumour agent. Its primary mechanism of action is the inhibition of the mammalian target of rapamycin (mTOR), which is a serine/threonine-specific protein kinase that regulates cell growth, proliferation, and survival. mTOR is an important therapeutic target for various diseases, as it was shown to regulate longevity and maintain normal glucose homeostasis. Targeting mTOR received more attention especially in cancer, as mTOR signalling pathways are constitutively activated in | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar[FDA label,A2255]. Sitagliptin was granted FDA approval on October 16, 2006. | Moderate | 1 | [
[
[
629,
24,
170
]
],
[
[
629,
6,
8374
],
[
8374,
45,
170
]
],
[
[
629,
18,
7885
],
[
7885,
46,
170
]
],
[
[
629,
7,
6448
],
[
6448,
57,
170
]
],
[
[
629,
21,
28850
],
[
28850,
60,
170
]
],
[
[
629,
24,
52
],
[
52,
62,
170
]
],
[
[
629,
24,
623
],
[
623,
24,
170
]
],
[
[
629,
63,
989
],
[
989,
24,
170
]
],
[
[
629,
24,
241
],
[
241,
63,
170
]
],
[
[
629,
25,
129
],
[
129,
63,
170
]
]
] | [
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Sirolimus",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Sitagliptin"
]
],
[
[
"Sirolimus",
"{u} (Compound) downregulates {v} (Gene)",
"MELK"
],
[
"MELK",
"{u} (Gene) is upregulated by {v} (Compound)",
"Sitagliptin"
]
],
[
[
"Sirolimus",
"{u} (Compound) upregulates {v} (Gene)",
"CTSD"
],
[
"CTSD",
"{u} (Gene) is downregulated by {v} (Compound)",
"Sitagliptin"
]
],
[
[
"Sirolimus",
"{u} (Compound) causes {v} (Side Effect)",
"Back pain"
],
[
"Back pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Sitagliptin"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
],
[
"Dulaglutide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sitagliptin"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quetiapine"
],
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Progesterone"
],
[
"Progesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erdafitinib"
],
[
"Erdafitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
]
] | Sirolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sitagliptin (Compound)
Sirolimus (Compound) downregulates MELK (Gene) and MELK (Gene) is upregulated by Sitagliptin (Compound)
Sirolimus (Compound) upregulates CTSD (Gene) and CTSD (Gene) is downregulated by Sitagliptin (Compound)
Sirolimus (Compound) causes Back pain (Side Effect) and Back pain (Side Effect) is caused by Sitagliptin (Compound)
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide and Dulaglutide may cause a minor interaction that can limit clinical effects when taken with Sitagliptin
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine and Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Progesterone and Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib and Erdafitinib may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin
Sirolimus may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin |
DB00635 | DB11988 | 1,573 | 270 | [
"DDInter1515",
"DDInter1321"
] | Prednisone | Ocrelizumab | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-humanized CD20 antibodies such as [rituximab], ocrelizumab is expected to be less immunogenic with repeated infusions, improving the benefit-to-risk profile for patients with MS.[A18875,A251745] MS is a chronic, inflammatory, autoimmune disease of the central nervous system that leads to neurological disabilities and a significantly reduced quality of life. Most patients with MS experience episodes of relapses with worsening function, followed by recovery periods or remissions. Primary progressive multiple sclerosis (PPMS) accounts for 10-15% of the overall population of patients with MS, and leads to the gradual worsening of neurologic disability from symptom onset, often without early relapses or remissions . Developed by Genentech/Roche, ocrelizumab was approved by the FDA in March 2017 under the market name Ocrevus for intravenous injection. It was later approved by Health Canada in August 2017, making the drug the first available treatment for PPMS in both the US and Canada. In clinical trials of patients with relapsing forms of MS, treatment with ocrelizumab resulted in reduced relapse rates and reduced worsening of disability compared to [interferon beta-1a]. In phase 3 clinical trials of patients with PPMS, treatment with ocrelizumab led to lower clinical and MRI progression rates compared to placebo. | Moderate | 1 | [
[
[
1573,
24,
270
]
],
[
[
1573,
23,
1193
],
[
1193,
23,
270
]
],
[
[
1573,
62,
1461
],
[
1461,
23,
270
]
],
[
[
1573,
24,
713
],
[
713,
24,
270
]
],
[
[
1573,
1,
175
],
[
175,
24,
270
]
],
[
[
1573,
24,
287
],
[
287,
63,
270
]
],
[
[
1573,
63,
66
],
[
66,
24,
270
]
],
[
[
1573,
25,
652
],
[
652,
63,
270
]
],
[
[
1573,
25,
770
],
[
770,
24,
270
]
],
[
[
1573,
40,
251
],
[
251,
24,
270
]
]
] | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Prednisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Prednisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
],
[
"Dimethyl fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Prednisone",
"{u} (Compound) resembles {v} (Compound)",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
],
[
"Diroximel fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Prednisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brexucabtagene autoleucel"
],
[
"Brexucabtagene autoleucel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Prednisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Prednisone",
"{u} (Compound) resembles {v} (Compound)",
"Betamethasone"
],
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
]
] | Prednisone may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Ocrelizumab
Prednisone may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ocrelizumab
Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Prednisone (Compound) resembles Triamcinolone (Compound) and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate and Diroximel fumarate may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Prednisone may lead to a major life threatening interaction when taken with Brexucabtagene autoleucel and Brexucabtagene autoleucel may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Prednisone may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Prednisone (Compound) resembles Betamethasone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab |
DB01172 | DB01362 | 416 | 497 | [
"DDInter1004",
"DDInter960"
] | Kanamycin | Iohexol | Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate. | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Major | 2 | [
[
[
416,
25,
497
]
],
[
[
416,
25,
258
],
[
258,
40,
497
]
],
[
[
416,
21,
28787
],
[
28787,
60,
497
]
],
[
[
416,
64,
1680
],
[
1680,
24,
497
]
],
[
[
416,
24,
242
],
[
242,
63,
497
]
],
[
[
416,
23,
699
],
[
699,
24,
497
]
],
[
[
416,
63,
1416
],
[
1416,
25,
497
]
],
[
[
416,
25,
1329
],
[
1329,
64,
497
]
],
[
[
416,
24,
1372
],
[
1372,
64,
497
]
],
[
[
416,
64,
789
],
[
789,
25,
497
]
]
] | [
[
[
"Kanamycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Kanamycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iodixanol"
],
[
"Iodixanol",
"{u} (Compound) resembles {v} (Compound)",
"Iohexol"
]
],
[
[
"Kanamycin",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Iohexol"
]
],
[
[
"Kanamycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etacrynic acid"
],
[
"Etacrynic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iohexol"
]
],
[
[
"Kanamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
],
[
"Remdesivir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iohexol"
]
],
[
[
"Kanamycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nadolol"
],
[
"Nadolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iohexol"
]
],
[
[
"Kanamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rofecoxib"
],
[
"Rofecoxib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Kanamycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gallium nitrate"
],
[
"Gallium nitrate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Kanamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neostigmine"
],
[
"Neostigmine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Kanamycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Foscarnet"
],
[
"Foscarnet",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
]
] | Kanamycin may lead to a major life threatening interaction when taken with Iodixanol and Iodixanol (Compound) resembles Iohexol (Compound)
Kanamycin (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Iohexol (Compound)
Kanamycin may lead to a major life threatening interaction when taken with Etacrynic acid and Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Iohexol
Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir and Remdesivir may cause a moderate interaction that could exacerbate diseases when taken with Iohexol
Kanamycin may cause a minor interaction that can limit clinical effects when taken with Nadolol and Nadolol may cause a moderate interaction that could exacerbate diseases when taken with Iohexol
Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Rofecoxib and Rofecoxib may lead to a major life threatening interaction when taken with Iohexol
Kanamycin may lead to a major life threatening interaction when taken with Gallium nitrate and Gallium nitrate may lead to a major life threatening interaction when taken with Iohexol
Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Neostigmine and Neostigmine may lead to a major life threatening interaction when taken with Iohexol
Kanamycin may lead to a major life threatening interaction when taken with Foscarnet and Foscarnet may lead to a major life threatening interaction when taken with Iohexol |
DB01263 | DB06772 | 859 | 310 | [
"DDInter1494",
"DDInter259"
] | Posaconazole | Cabazitaxel | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more readily penetrate the blood–brain barrier compared to other taxanes like [paclitaxel] and [docetaxel].[A7056, A260421, A260621] Cabazitaxel is used to treat metastatic castration-resistant prostate cancer. It was first approved by the FDA on June 17, 2010. It was also approved by the EMA on March 17, 2011 and Health Canada on December 17, 2019. | Moderate | 1 | [
[
[
859,
24,
310
]
],
[
[
859,
63,
973
],
[
973,
24,
310
]
],
[
[
859,
6,
4973
],
[
4973,
45,
310
]
],
[
[
859,
21,
28894
],
[
28894,
60,
310
]
],
[
[
859,
25,
868
],
[
868,
63,
310
]
],
[
[
859,
24,
1047
],
[
1047,
24,
310
]
],
[
[
859,
24,
913
],
[
913,
63,
310
]
],
[
[
859,
64,
1213
],
[
1213,
24,
310
]
],
[
[
859,
62,
1101
],
[
1101,
24,
310
]
],
[
[
859,
25,
1491
],
[
1491,
24,
310
]
]
] | [
[
[
"Posaconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Posaconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Posaconazole",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Cabazitaxel"
]
],
[
[
"Posaconazole",
"{u} (Compound) causes {v} (Side Effect)",
"Cardiac failure"
],
[
"Cardiac failure",
"{u} (Side Effect) is caused by {v} (Compound)",
"Cabazitaxel"
]
],
[
[
"Posaconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Posaconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
],
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Posaconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Posaconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Posaconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Posaconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Midostaurin"
],
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
]
] | Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Posaconazole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Cabazitaxel (Compound)
Posaconazole (Compound) causes Cardiac failure (Side Effect) and Cardiac failure (Side Effect) is caused by Cabazitaxel (Compound)
Posaconazole may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine and Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Posaconazole may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Posaconazole may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Posaconazole may lead to a major life threatening interaction when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel |
DB00603 | DB05541 | 303 | 801 | [
"DDInter1137",
"DDInter239"
] | Medroxyprogesterone acetate | Brivaracetam | Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prevent pregnancy, manage pain in endometriosis, prevent pregnancy, and is also used in palliative care for endometrial and renal carcinoma.[L8657,L8660,L8663,L8666,L8669] Medroxyprogesterone acetate was granted FDA approval on 18 June 1959. | Brivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam . It is available under the brand name Briviact made by UCB. Briviact received FDA approval on February 19, 2016 . | Minor | 0 | [
[
[
303,
23,
801
]
],
[
[
303,
24,
1411
],
[
1411,
23,
801
]
],
[
[
303,
63,
600
],
[
600,
23,
801
]
],
[
[
303,
24,
1411
],
[
1411,
62,
660
],
[
660,
23,
801
]
],
[
[
303,
6,
8374
],
[
8374,
45,
477
],
[
477,
23,
801
]
],
[
[
303,
63,
600
],
[
600,
25,
477
],
[
477,
23,
801
]
],
[
[
303,
24,
1411
],
[
1411,
63,
168
],
[
168,
23,
801
]
],
[
[
303,
21,
28688
],
[
28688,
60,
477
],
[
477,
23,
801
]
],
[
[
303,
63,
600
],
[
600,
24,
101
],
[
101,
23,
801
]
],
[
[
303,
24,
1411
],
[
1411,
64,
600
],
[
600,
23,
801
]
]
] | [
[
[
"Medroxyprogesterone acetate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Brivaracetam"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Brivaracetam"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Brivaracetam"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Esomeprazole"
],
[
"Esomeprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Brivaracetam"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Cilostazol"
],
[
"Cilostazol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Brivaracetam"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cilostazol"
],
[
"Cilostazol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Brivaracetam"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Brivaracetam"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} (Compound) causes {v} (Side Effect)",
"Epistaxis"
],
[
"Epistaxis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Cilostazol"
],
[
"Cilostazol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Brivaracetam"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexlansoprazole"
],
[
"Dexlansoprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Brivaracetam"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Brivaracetam"
]
]
] | Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a minor interaction that can limit clinical effects when taken with Brivaracetam
Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Brivaracetam
Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a minor interaction that can limit clinical effects when taken with Esomeprazole and Esomeprazole may cause a minor interaction that can limit clinical effects when taken with Brivaracetam
Medroxyprogesterone acetate (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cilostazol (Compound) and Cilostazol may cause a minor interaction that can limit clinical effects when taken with Brivaracetam
Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Cilostazol and Cilostazol may cause a minor interaction that can limit clinical effects when taken with Brivaracetam
Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Brivaracetam
Medroxyprogesterone acetate (Compound) causes Epistaxis (Side Effect) and Epistaxis (Side Effect) is caused by Cilostazol (Compound) and Cilostazol may cause a minor interaction that can limit clinical effects when taken with Brivaracetam
Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole and Dexlansoprazole may cause a minor interaction that can limit clinical effects when taken with Brivaracetam
Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Brivaracetam |
DB00400 | DB12015 | 353 | 1,033 | [
"DDInter843",
"DDInter53"
] | Griseofulvin | Alpelisib | An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections. | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metabolism. Alpelisib was designed to target this enzyme that appears to be mutated at a rate of nearly 30% in human cancers, leading to hyperactivation. There are several isoform-specific PI3K inhibitors that are under clinical development or currently approved, such as [idelalisib] used for chronic lymphocytic leukemia (CLL). Approved by the FDA in May 2019, alpelisib is the first approved PI3K inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer in combination with [fulvestrant] for postmenopausal women and male patients. To initiate alpelisib therapy, it is required that the presence of a PIK3CA mutation in the tissue and/or liquid biopsy sample collection should be confirmed via FDA-approved diagnostic tests. Alpelisib is marketed under the trade name Piqray and is available as oral tablets. Studies evaluating the therapeutic effectiveness of alpelisib in other cancers, such as ovarian cancer and colorectal cancer , are under ongoing investigations. Alpelisib was granted FDA approval on 24 May 2019. In April 2022, the FDA granted the use of alpelisib in the treatment of PIK3CA-Related Overgrowth Spectrum (PROS) in adults and children who require systemic therapy. | Moderate | 1 | [
[
[
353,
24,
1033
]
],
[
[
353,
24,
1135
],
[
1135,
23,
1033
]
],
[
[
353,
24,
154
],
[
154,
24,
1033
]
],
[
[
353,
63,
576
],
[
576,
24,
1033
]
],
[
[
353,
23,
1612
],
[
1612,
24,
1033
]
],
[
[
353,
24,
861
],
[
861,
63,
1033
]
],
[
[
353,
62,
1101
],
[
1101,
24,
1033
]
],
[
[
353,
24,
697
],
[
697,
25,
1033
]
],
[
[
353,
24,
1135
],
[
1135,
63,
1335
],
[
1335,
24,
1033
]
],
[
[
353,
63,
576
],
[
576,
25,
322
],
[
322,
24,
1033
]
]
] | [
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Alpelisib"
]
],
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurasidone"
],
[
"Lurasidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methadone"
],
[
"Methadone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Griseofulvin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fostemsavir"
],
[
"Fostemsavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ripretinib"
],
[
"Ripretinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Griseofulvin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alpelisib"
]
],
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxcarbazepine"
],
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methadone"
],
[
"Methadone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
]
] | Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Alpelisib
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Lurasidone and Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Methadone and Methadone may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Griseofulvin may cause a minor interaction that can limit clinical effects when taken with Fostemsavir and Fostemsavir may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib and Ripretinib may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Griseofulvin may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Phenobarbital may lead to a major life threatening interaction when taken with Alpelisib
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine and Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Methadone and Methadone may lead to a major life threatening interaction when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib |
DB00564 | DB04845 | 1,236 | 309 | [
"DDInter293",
"DDInter1001"
] | Carbamazepine | Ixabepilone | Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbamazepine was the first anticonvulsant used to treat individuals with bipolar disorder. | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. Ixabepilone is a semisynthetic analogue of epothilone B. It has a lactone–lactam modification that minimizes susceptibility to esterase degradation. | Moderate | 1 | [
[
[
1236,
24,
309
]
],
[
[
1236,
6,
8374
],
[
8374,
45,
309
]
],
[
[
1236,
21,
28987
],
[
28987,
60,
309
]
],
[
[
1236,
40,
307
],
[
307,
23,
309
]
],
[
[
1236,
25,
1419
],
[
1419,
24,
309
]
],
[
[
1236,
24,
1619
],
[
1619,
63,
309
]
],
[
[
1236,
25,
1593
],
[
1593,
63,
309
]
],
[
[
1236,
24,
1487
],
[
1487,
24,
309
]
],
[
[
1236,
63,
1051
],
[
1051,
24,
309
]
],
[
[
1236,
1,
1335
],
[
1335,
24,
309
]
]
] | [
[
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
],
[
[
"Carbamazepine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Ixabepilone"
]
],
[
[
"Carbamazepine",
"{u} (Compound) causes {v} (Side Effect)",
"Chills"
],
[
"Chills",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ixabepilone"
]
],
[
[
"Carbamazepine",
"{u} (Compound) resembles {v} (Compound)",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ixabepilone"
]
],
[
[
"Carbamazepine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
],
[
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
],
[
[
"Carbamazepine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
],
[
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
],
[
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aminoglutethimide"
],
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
],
[
[
"Carbamazepine",
"{u} (Compound) resembles {v} (Compound)",
"Oxcarbazepine"
],
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
]
] | Carbamazepine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ixabepilone (Compound)
Carbamazepine (Compound) causes Chills (Side Effect) and Chills (Side Effect) is caused by Ixabepilone (Compound)
Carbamazepine (Compound) resembles Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Ixabepilone
Carbamazepine may lead to a major life threatening interaction when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone
Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone
Carbamazepine may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone
Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine and Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone
Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide and Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone
Carbamazepine (Compound) resembles Oxcarbazepine (Compound) and Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone |
DB00762 | DB11601 | 613 | 1,270 | [
"DDInter973",
"DDInter1889"
] | Irinotecan | Tuberculin purified protein derivative | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde). | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycobacterium tuberculosis* through early diagnosis and appropriate therapeutic intervention. The purified protein fraction is isolated from culture media filtrates of a human strain of Mycobacterium tuberculosis. It is included in the World Health Organization's List of Essential Medicines. | Moderate | 1 | [
[
[
613,
24,
1270
]
],
[
[
613,
24,
1531
],
[
1531,
24,
1270
]
],
[
[
613,
64,
1064
],
[
1064,
24,
1270
]
],
[
[
613,
63,
1555
],
[
1555,
24,
1270
]
],
[
[
613,
25,
1259
],
[
1259,
63,
1270
]
],
[
[
613,
25,
976
],
[
976,
24,
1270
]
],
[
[
613,
24,
738
],
[
738,
63,
1270
]
],
[
[
613,
24,
1531
],
[
1531,
24,
350
],
[
350,
24,
1270
]
],
[
[
613,
64,
1064
],
[
1064,
25,
350
],
[
350,
24,
1270
]
],
[
[
613,
63,
1555
],
[
1555,
24,
350
],
[
350,
24,
1270
]
]
] | [
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
],
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Irinotecan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Irinotecan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Irinotecan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
],
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
],
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Irinotecan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carfilzomib"
],
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
],
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
]
] | Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Irinotecan may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Irinotecan may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Irinotecan may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Irinotecan may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative |
DB00619 | DB11689 | 1,419 | 321 | [
"DDInter909",
"DDInter1659"
] | Imatinib | Selumetinib | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy".. The discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient. Imatinib was approved on February 1st,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751] | Activation of the Raf-MEK-ERK signalling pathway is known to be implemented in several types of malignancies; thus, mitogen-activated protein kinase kinase (MEK) inhibitors such as selumetinib are important tools that can target the problematic overactivity of this pathway. Results from clinical trials investigating earlier developed MEK inhibitors were underwhelming. However, selumetinib demonstrated impressive efficacy and tolerability in Phase I trials, leading to its continued investigation for the treatment of various types of tumours in Phase II trials. Currently, the novel MEK 1 / 2 inhibitor, selumetinib, is approved solely for the treatment of Neurofibromatosis type 1 (NF-1) in a limited age group. NF-1 is considered rare, with an estimated incidence of 1/3000 individuals. It is a genetic, autosomal dominant condition resulting from mutations of the NF1 gene, which can lead to various complications, including the development of multiple tumours in the nervous system.[A193533,A193608] Some patients with this disorder develop plexiform neurofibromas (PN); however, this is considered relatively uncommon compared to other variants of NF-1. Luckily, the use of selumetinib in patients with NF-1 have shown efficacy in shrinking associated tumours and is linked to other positive clinical outcomes. Selumetinib was approved by the FDA on April 10, 2020. It was later approved by Health Canada on August 23, 2022. | Major | 2 | [
[
[
1419,
25,
321
]
],
[
[
1419,
25,
982
],
[
982,
63,
321
]
],
[
[
1419,
24,
392
],
[
392,
24,
321
]
],
[
[
1419,
63,
752
],
[
752,
24,
321
]
],
[
[
1419,
24,
1297
],
[
1297,
63,
321
]
],
[
[
1419,
25,
126
],
[
126,
24,
321
]
],
[
[
1419,
62,
1101
],
[
1101,
24,
321
]
],
[
[
1419,
35,
478
],
[
478,
24,
321
]
],
[
[
1419,
63,
600
],
[
600,
25,
321
]
],
[
[
1419,
25,
913
],
[
913,
64,
321
]
]
] | [
[
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Selumetinib"
]
],
[
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selumetinib"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selumetinib"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selumetinib"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
],
[
"Osilodrostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selumetinib"
]
],
[
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selumetinib"
]
],
[
[
"Imatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selumetinib"
]
],
[
[
"Imatinib",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selumetinib"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Selumetinib"
]
],
[
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Selumetinib"
]
]
] | Imatinib may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Selumetinib
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Selumetinib
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Selumetinib
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Selumetinib
Imatinib may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Selumetinib
Imatinib may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Selumetinib
Imatinib (Compound) resembles Nilotinib (Compound) and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Selumetinib
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Selumetinib
Imatinib may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Selumetinib |
DB01166 | DB06595 | 477 | 1,491 | [
"DDInter379",
"DDInter1214"
] | Cilostazol | Midostaurin | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions. | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hematopoietic tumors . It was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents. | Moderate | 1 | [
[
[
477,
24,
1491
]
],
[
[
477,
62,
112
],
[
112,
23,
1491
]
],
[
[
477,
63,
888
],
[
888,
24,
1491
]
],
[
[
477,
24,
1017
],
[
1017,
63,
1491
]
],
[
[
477,
24,
1342
],
[
1342,
24,
1491
]
],
[
[
477,
64,
1091
],
[
1091,
24,
1491
]
],
[
[
477,
25,
1250
],
[
1250,
24,
1491
]
],
[
[
477,
25,
351
],
[
351,
63,
1491
]
],
[
[
477,
35,
673
],
[
673,
24,
1491
]
],
[
[
477,
64,
441
],
[
441,
25,
1491
]
]
] | [
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Cilostazol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Midostaurin"
]
],
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
],
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amprenavir"
],
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Cilostazol",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
],
[
"Aripiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Delavirdine"
],
[
"Delavirdine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Midostaurin"
]
]
] | Cilostazol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin and Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Cilostazol may lead to a major life threatening interaction when taken with Amprenavir and Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Cilostazol may lead to a major life threatening interaction when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Cilostazol may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Cilostazol (Compound) resembles Aripiprazole (Compound) and Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole and Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Cilostazol may lead to a major life threatening interaction when taken with Delavirdine and Delavirdine may lead to a major life threatening interaction when taken with Midostaurin |
DB00712 | DB12364 | 1,274 | 1,421 | [
"DDInter763",
"DDInter200"
] | Flurbiprofen | Betrixaban | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically prior to ocular surgery to prevent or reduce intraoperative miosis. Flurbiprofen is structurally and pharmacologically related to fenoprofen, ibuprofen, and ketoprofen. | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals Inc., is prescribed as a venous thromboembolism (VTE) prophylactic for adult patients with moderate to severe restricted motility or with other risks for VTE . VTE can be manifested as deep vein thrombosis or pulmonary embolism and it is a leading cause of preventable death in hospitalized patients . | Major | 2 | [
[
[
1274,
25,
1421
]
],
[
[
1274,
23,
297
],
[
297,
23,
1421
]
],
[
[
1274,
24,
1017
],
[
1017,
24,
1421
]
],
[
[
1274,
63,
529
],
[
529,
24,
1421
]
],
[
[
1274,
25,
990
],
[
990,
24,
1421
]
],
[
[
1274,
24,
1412
],
[
1412,
63,
1421
]
],
[
[
1274,
24,
714
],
[
714,
25,
1421
]
],
[
[
1274,
63,
1027
],
[
1027,
25,
1421
]
],
[
[
1274,
25,
235
],
[
235,
25,
1421
]
],
[
[
1274,
37,
1650
],
[
1650,
64,
1421
]
]
] | [
[
[
"Flurbiprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Flurbiprofen",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
],
[
"Clove",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Betrixaban"
]
],
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvoxamine"
],
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Flurbiprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
],
[
"Lomitapide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
],
[
"Calaspargase pegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
],
[
"Iloprost",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Piroxicam"
],
[
"Piroxicam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Flurbiprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
],
[
"Desirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
],
[
"Avapritinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
]
] | Flurbiprofen may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Betrixaban
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine and Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Flurbiprofen may lead to a major life threatening interaction when taken with Lomitapide and Lomitapide may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol and Calaspargase pegol may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may lead to a major life threatening interaction when taken with Betrixaban
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Piroxicam and Piroxicam may lead to a major life threatening interaction when taken with Betrixaban
Flurbiprofen may lead to a major life threatening interaction when taken with Desirudin and Desirudin may lead to a major life threatening interaction when taken with Betrixaban
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib and Flurbiprofen may lead to a major life threatening interaction when taken with Avapritinib and Avapritinib may lead to a major life threatening interaction when taken with Betrixaban |
DB00046 | DB00783 | 1,179 | 1,438 | [
"DDInter940",
"DDInter679"
] | Insulin lispro | Estradiol | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions. Insulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to | Estradiol is a naturally occurring hormone circulating endogenously in females. It is commercially available in several hormone therapy products for managing conditions associated with reduced estrogen, such as vulvovaginal atrophy and hot flashes. Some available forms of estradiol include oral tablets, injections, vaginal rings, transdermal patches, sprays, gels, and creams.[L11485,L11488,L11491, L11494,L11497,L11500,L11503] When used for oral or IM administration, estradiol is commonly synthesized as a pro-drug ester (such as , , , , and ). Because it has a low oral bioavailability on its own, estradiol is commonly formulated with an ester side-chain. (EE) is a synthetic form of estradiol commonly used as the estrogenic component of most combination oral contraceptive pills (OCPs). Ethinyl estradiol is different from estradiol due to its higher biovailability and increased resistance to metabolism, rendering it more suitable for oral administration. | Moderate | 1 | [
[
[
1179,
24,
1438
]
],
[
[
1179,
24,
1561
],
[
1561,
40,
1438
]
],
[
[
1179,
24,
629
],
[
629,
63,
1438
]
],
[
[
1179,
24,
245
],
[
245,
24,
1438
]
],
[
[
1179,
24,
1561
],
[
1561,
1,
1417
],
[
1417,
40,
1438
]
],
[
[
1179,
24,
629
],
[
629,
63,
1561
],
[
1561,
40,
1438
]
],
[
[
1179,
24,
245
],
[
245,
24,
1561
],
[
1561,
40,
1438
]
],
[
[
1179,
23,
1203
],
[
1203,
62,
1685
],
[
1685,
24,
1438
]
],
[
[
1179,
24,
1561
],
[
1561,
40,
11409
],
[
11409,
40,
1438
]
],
[
[
1179,
24,
50
],
[
50,
6,
15333
],
[
15333,
45,
1438
]
]
] | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estradiol"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Testosterone"
],
[
"Testosterone",
"{u} (Compound) resembles {v} (Compound)",
"Estradiol"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estradiol"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estradiol"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Testosterone"
],
[
"Testosterone",
"{u} (Compound) resembles {v} (Compound)",
"Estramustine"
],
[
"Estramustine",
"{u} (Compound) resembles {v} (Compound)",
"Estradiol"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Testosterone"
],
[
"Testosterone",
"{u} (Compound) resembles {v} (Compound)",
"Estradiol"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Testosterone"
],
[
"Testosterone",
"{u} (Compound) resembles {v} (Compound)",
"Estradiol"
]
],
[
[
"Insulin lispro",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Monopotassium phosphate"
],
[
"Monopotassium phosphate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Insulin human"
],
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estradiol"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Testosterone"
],
[
"Testosterone",
"{u} (Compound) resembles {v} (Compound)",
"Trilostane"
],
[
"Trilostane",
"{u} (Compound) resembles {v} (Compound)",
"Estradiol"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfasalazine"
],
[
"Sulfasalazine",
"{u} (Compound) binds {v} (Gene)",
"SLCO1B1"
],
[
"SLCO1B1",
"{u} (Gene) is bound by {v} (Compound)",
"Estradiol"
]
]
] | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Testosterone and Testosterone (Compound) resembles Estradiol (Compound)
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Estradiol
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Estradiol
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Testosterone and Testosterone (Compound) resembles Estramustine (Compound) and Estramustine (Compound) resembles Estradiol (Compound)
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Testosterone and Testosterone (Compound) resembles Estradiol (Compound)
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Testosterone and Testosterone (Compound) resembles Estradiol (Compound)
Insulin lispro may cause a minor interaction that can limit clinical effects when taken with Monopotassium phosphate and Monopotassium phosphate may cause a minor interaction that can limit clinical effects when taken with Insulin human and Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Estradiol
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Testosterone and Testosterone (Compound) resembles Trilostane (Compound) and Trilostane (Compound) resembles Estradiol (Compound)
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine and Sulfasalazine (Compound) binds SLCO1B1 (Gene) and SLCO1B1 (Gene) is bound by Estradiol (Compound) |
DB06605 | DB08918 | 1,409 | 41 | [
"DDInter108",
"DDInter1059"
] | Apixaban | Levomilnacipran | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012. | Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is a more potent inhibitor of norepinephrine reuptake than serotonin reuptake.[A261181, A38560] Levomilnacipran is the more active 1S,2R-enantiomer in the racemate [milnacipran].[A261181, L47956] Once administered, interconversion between levomilnacipran and its stereoisomer does not occur in humans. First approved by the FDA on July 25, 2013, levomilnacipran is used to treat major depressive disorder in adults. While levomilnacipran was previously investigated and proposed as a potential treatment for stroke in Europe, the EMA decided against this use. | Moderate | 1 | [
[
[
1409,
24,
41
]
],
[
[
1409,
63,
901
],
[
901,
40,
41
]
],
[
[
1409,
6,
10215
],
[
10215,
45,
41
]
],
[
[
1409,
21,
28847
],
[
28847,
60,
41
]
],
[
[
1409,
25,
498
],
[
498,
63,
41
]
],
[
[
1409,
64,
330
],
[
330,
24,
41
]
],
[
[
1409,
25,
707
],
[
707,
24,
41
]
],
[
[
1409,
24,
283
],
[
283,
63,
41
]
],
[
[
1409,
63,
121
],
[
121,
25,
41
]
],
[
[
1409,
25,
760
],
[
760,
64,
41
]
]
] | [
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
]
],
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Milnacipran"
],
[
"Milnacipran",
"{u} (Compound) resembles {v} (Compound)",
"Levomilnacipran"
]
],
[
[
"Apixaban",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",
"Levomilnacipran"
]
],
[
[
"Apixaban",
"{u} (Compound) causes {v} (Side Effect)",
"Eye disorder"
],
[
"Eye disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Levomilnacipran"
]
],
[
[
"Apixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Edoxaban"
],
[
"Edoxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
]
],
[
[
"Apixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ramucirumab"
],
[
"Ramucirumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
]
],
[
[
"Apixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Danaparoid"
],
[
"Danaparoid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
]
],
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
]
],
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenfluramine"
],
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levomilnacipran"
]
],
[
[
"Apixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levomilnacipran"
]
]
] | Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran and Milnacipran (Compound) resembles Levomilnacipran (Compound)
Apixaban (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Levomilnacipran (Compound)
Apixaban (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Levomilnacipran (Compound)
Apixaban may lead to a major life threatening interaction when taken with Edoxaban and Edoxaban may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran
Apixaban may lead to a major life threatening interaction when taken with Ramucirumab and Ramucirumab may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran
Apixaban may lead to a major life threatening interaction when taken with Danaparoid and Danaparoid may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine and Fenfluramine may lead to a major life threatening interaction when taken with Levomilnacipran
Apixaban may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may lead to a major life threatening interaction when taken with Levomilnacipran |
DB00983 | DB01284 | 480 | 1,042 | [
"DDInter776",
"DDInter1782"
] | Formoterol | Tetracosactide | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major clinical advantage of formoterol over other inhaled beta-agonists is its rapid onset of action (2-3 minutes), which is at least as fast as [salbutamol], combined with a long duration of action (12 hours) - for this reason, treatment guidelines for asthma recommend its use as both a reliever and maintenance medication. It is available as a single-entity product [L10986,L11223] and in several formulations in combination with both inhaled corticosteroids [L10995,L10619] and long-acting | Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticosteroids in the adrenal cortex. Tetracosactide exhibits the same activity as natural ACTH with regard to all its biological activities. The complex results in a product whose absorption in man is effected over a longer period of time as compared to corticotropin. Therefore, therapy may be maintained with less frequent administration. | Minor | 0 | [
[
[
480,
23,
1042
]
],
[
[
480,
24,
209
],
[
209,
62,
1042
]
],
[
[
480,
63,
455
],
[
455,
23,
1042
]
],
[
[
480,
24,
688
],
[
688,
23,
1042
]
],
[
[
480,
74,
1052
],
[
1052,
23,
1042
]
],
[
[
480,
64,
461
],
[
461,
24,
1042
]
],
[
[
480,
63,
811
],
[
811,
24,
1042
]
],
[
[
480,
24,
761
],
[
761,
63,
1042
]
],
[
[
480,
24,
1130
],
[
1130,
24,
1042
]
],
[
[
480,
25,
772
],
[
772,
24,
1042
]
]
] | [
[
[
"Formoterol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetracosactide"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Racepinephrine"
],
[
"Racepinephrine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetracosactide"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
[
"Salmeterol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetracosactide"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
[
"Salbutamol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetracosactide"
]
],
[
[
"Formoterol",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ritodrine"
],
[
"Ritodrine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetracosactide"
]
],
[
[
"Formoterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Timolol"
],
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metolazone"
],
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
],
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pioglitazone"
],
[
"Pioglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Formoterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carvedilol"
],
[
"Carvedilol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
]
] | Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Racepinephrine and Racepinephrine may cause a minor interaction that can limit clinical effects when taken with Tetracosactide
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a minor interaction that can limit clinical effects when taken with Tetracosactide
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a minor interaction that can limit clinical effects when taken with Tetracosactide
Formoterol (Compound) resembles Ritodrine (Compound) and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Ritodrine and Ritodrine may cause a minor interaction that can limit clinical effects when taken with Tetracosactide
Formoterol may lead to a major life threatening interaction when taken with Timolol and Timolol may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Metolazone and Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone and Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Formoterol may lead to a major life threatening interaction when taken with Carvedilol and Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide |
DB00682 | DB12159 | 126 | 12 | [
"DDInter1951",
"DDInter609"
] | Warfarin | Dupilumab | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors. | Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways. As an interleukin-4 receptor alpha antagonist, dupilumab inhibits the signaling of pro-inflammatory cytokines, called interleukins (IL), that induce inflammatory and immunological reactions in several atopic or allergic conditions, such as eczema, allergic reaction, and rhinosinusitis. Dupilumab was generated by recombinant DNA technology in Chinese Hamster Ovary cell suspension culture. Dupilumab is commonly marketed as Dupixent, which is available as a formulation for subcutaneous injection. It was first approved by the FDA in 2017. It is currently used to treat atopic dermatitis, asthma as an add-on maintenance treatment, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis. It is used as monotherapy or in combination with other drugs, such as corticosteroids.[L7186,L7192,L41439] Dupilumab is currently under investigations for potential therapeutic use in diseases driven by allergic reactions or type 2 inflammation, such as pediatric atopic dermatitis, and chronic obstructive pulmonary disease. It is also being studied in combination with another antibody that which targets IL-33. | Moderate | 1 | [
[
[
126,
24,
12
]
],
[
[
126,
63,
1461
],
[
1461,
23,
12
]
],
[
[
126,
25,
4
],
[
4,
24,
12
]
],
[
[
126,
63,
58
],
[
58,
24,
12
]
],
[
[
126,
24,
1683
],
[
1683,
24,
12
]
],
[
[
126,
63,
581
],
[
581,
25,
12
]
],
[
[
126,
24,
908
],
[
908,
25,
12
]
],
[
[
126,
63,
1461
],
[
1461,
62,
58
],
[
58,
24,
12
]
],
[
[
126,
25,
4
],
[
4,
63,
599
],
[
599,
24,
12
]
],
[
[
126,
63,
58
],
[
58,
23,
1461
],
[
1461,
23,
12
]
]
] | [
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dupilumab"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dupilumab"
]
],
[
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dupilumab"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
],
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dupilumab"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dupilumab"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dupilumab"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Golimumab"
],
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dupilumab"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Alefacept"
],
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dupilumab"
]
],
[
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dupilumab"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
],
[
"Alefacept",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dupilumab"
]
]
] | Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Dupilumab
Warfarin may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Dupilumab
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Dupilumab
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Dupilumab
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Dupilumab
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Golimumab and Golimumab may lead to a major life threatening interaction when taken with Dupilumab
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Dupilumab
Warfarin may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Dupilumab
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Dupilumab |
DB00226 | DB00443 | 1,000 | 251 | [
"DDInter845",
"DDInter195"
] | Guanadrel | Betamethasone | Guanadrel is an antihypertensive agent and postganglionic adrenergic blocking agent. | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and negligible mineralocorticoid activity. | Moderate | 1 | [
[
[
1000,
24,
251
]
],
[
[
1000,
24,
617
],
[
617,
40,
251
]
],
[
[
1000,
24,
870
],
[
870,
1,
251
]
],
[
[
1000,
24,
1148
],
[
1148,
62,
251
]
],
[
[
1000,
25,
1214
],
[
1214,
24,
251
]
],
[
[
1000,
24,
433
],
[
433,
63,
251
]
],
[
[
1000,
63,
245
],
[
245,
24,
251
]
],
[
[
1000,
24,
593
],
[
593,
64,
251
]
],
[
[
1000,
24,
617
],
[
617,
40,
11456
],
[
11456,
40,
251
]
],
[
[
1000,
24,
870
],
[
870,
1,
11456
],
[
11456,
40,
251
]
]
] | [
[
[
"Guanadrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
]
],
[
[
"Guanadrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
],
[
"Budesonide",
"{u} (Compound) resembles {v} (Compound)",
"Betamethasone"
]
],
[
[
"Guanadrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Betamethasone"
]
],
[
[
"Guanadrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Betamethasone"
]
],
[
[
"Guanadrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Minoxidil"
],
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
]
],
[
[
"Guanadrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
],
[
"Ertugliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
]
],
[
[
"Guanadrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
]
],
[
[
"Guanadrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betamethasone"
]
],
[
[
"Guanadrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
],
[
"Budesonide",
"{u} (Compound) resembles {v} (Compound)",
"Mometasone"
],
[
"Mometasone",
"{u} (Compound) resembles {v} (Compound)",
"Betamethasone"
]
],
[
[
"Guanadrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Mometasone"
],
[
"Mometasone",
"{u} (Compound) resembles {v} (Compound)",
"Betamethasone"
]
]
] | Guanadrel may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide (Compound) resembles Betamethasone (Compound)
Guanadrel may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Betamethasone (Compound)
Guanadrel may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a minor interaction that can limit clinical effects when taken with Betamethasone
Guanadrel may lead to a major life threatening interaction when taken with Minoxidil and Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone
Guanadrel may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin and Ertugliflozin may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone
Guanadrel may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone
Guanadrel may cause a moderate interaction that could exacerbate diseases when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Betamethasone
Guanadrel may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide (Compound) resembles Mometasone (Compound) and Mometasone (Compound) resembles Betamethasone (Compound)
Guanadrel may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Mometasone (Compound) and Mometasone (Compound) resembles Betamethasone (Compound) |
DB04865 | DB06228 | 4 | 792 | [
"DDInter1335",
"DDInter1609"
] | Omacetaxine mepesuccinate | Rivaroxaban | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the plant, Cephalotaxus species. In October 2005, omacetaxine mepesuccinate received Orphan Drug designation from the EMEA for the treatment of chronic myeloid leukemia (CML). Then in March 2006, it received Orphan Drug status from the FDA for the treatment of CML. In November 2006, omacetaxine mepesuccinate, for the treatment of CML, was granted Fast Track designation by the FDA. Most recently, in October 2012, omacetaxine mepesuccinate was | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, 2011. | Major | 2 | [
[
[
4,
25,
792
]
],
[
[
4,
63,
453
],
[
453,
40,
792
]
],
[
[
4,
7,
2384
],
[
2384,
46,
792
]
],
[
[
4,
24,
1303
],
[
1303,
63,
792
]
],
[
[
4,
63,
79
],
[
79,
24,
792
]
],
[
[
4,
24,
1683
],
[
1683,
24,
792
]
],
[
[
4,
25,
375
],
[
375,
63,
792
]
],
[
[
4,
64,
581
],
[
581,
24,
792
]
],
[
[
4,
25,
292
],
[
292,
64,
792
]
],
[
[
4,
64,
885
],
[
885,
25,
792
]
]
] | [
[
[
"Omacetaxine mepesuccinate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linezolid"
],
[
"Linezolid",
"{u} (Compound) resembles {v} (Compound)",
"Rivaroxaban"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} (Compound) upregulates {v} (Gene)",
"CDK6"
],
[
"CDK6",
"{u} (Gene) is upregulated by {v} (Compound)",
"Rivaroxaban"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guselkumab"
],
[
"Guselkumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Regorafenib"
],
[
"Regorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rivaroxaban"
]
]
] | Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Linezolid and Linezolid (Compound) resembles Rivaroxaban (Compound)
Omacetaxine mepesuccinate (Compound) upregulates CDK6 (Gene) and CDK6 (Gene) is upregulated by Rivaroxaban (Compound)
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Guselkumab and Guselkumab may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban
Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban
Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban
Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Regorafenib and Regorafenib may lead to a major life threatening interaction when taken with Rivaroxaban
Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Epoprostenol and Epoprostenol may lead to a major life threatening interaction when taken with Rivaroxaban |
DB13179 | DB15091 | 68 | 676 | [
"DDInter1882",
"DDInter1901"
] | Troleandomycin | Upadacitinib | A macrolide antibiotic that is similar to erythromycin. | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage damage and bone destruction, leading to co-morbidities. Despite a variety of therapeutic agents available for treatment, up to 40% of the patients do not respond to current therapies, including biological therapies. The etiology of the disease is mostly unknown; however, the role of JAK as a driver of immune-mediated conditions was discovered, leading to the use of JAK as therapeutic targets for rheumatoid arthritis. To reduce dose-related toxicity (as seen with some pan-JAK inhibitors) without significantly affecting efficacy, more selective JAK1 inhibitors, upadacitinib and [filgotinib], were developed. The FDA approved upadacitinib in August 2019 and it is used for the treatment of active rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and ankylosing spondylitis. In December 2019, it was additionally approved by the European Commission and Health Canada.[L10899,L42540] Upadacitinib is marketed under the brand name RINVOQ for oral administration. | Major | 2 | [
[
[
68,
25,
676
]
],
[
[
68,
64,
283
],
[
283,
24,
676
]
],
[
[
68,
63,
600
],
[
600,
24,
676
]
],
[
[
68,
62,
1374
],
[
1374,
24,
676
]
],
[
[
68,
25,
159
],
[
159,
24,
676
]
],
[
[
68,
63,
891
],
[
891,
25,
676
]
],
[
[
68,
64,
629
],
[
629,
25,
676
]
],
[
[
68,
62,
1101
],
[
1101,
25,
676
]
],
[
[
68,
64,
283
],
[
283,
64,
1249
],
[
1249,
24,
676
]
],
[
[
68,
64,
1593
],
[
1593,
63,
1249
],
[
1249,
24,
676
]
]
] | [
[
[
"Troleandomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Troleandomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
],
[
[
"Troleandomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
],
[
[
"Troleandomycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Abiraterone"
],
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
],
[
[
"Troleandomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
],
[
[
"Troleandomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
],
[
"Prednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Troleandomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Troleandomycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Troleandomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nafcillin"
],
[
"Nafcillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
],
[
[
"Troleandomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nafcillin"
],
[
"Nafcillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
]
] | Troleandomycin may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Troleandomycin may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Troleandomycin may cause a minor interaction that can limit clinical effects when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Troleandomycin may lead to a major life threatening interaction when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Troleandomycin may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may lead to a major life threatening interaction when taken with Upadacitinib
Troleandomycin may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may lead to a major life threatening interaction when taken with Upadacitinib
Troleandomycin may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Upadacitinib
Troleandomycin may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may lead to a major life threatening interaction when taken with Nafcillin and Nafcillin may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Troleandomycin may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Nafcillin and Nafcillin may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib |
DB01197 | DB06822 | 1,603 | 802 | [
"DDInter292",
"DDInter1812"
] | Captopril | Tinzaparin | Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment of hypertension. | Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. Tinzaparin is composed of molecules with and without a special site for high affinity binding to antithrombin III (ATIII). This complex greatly accelerates the inhibition of factor Xa. It is an anticoagulant and considered an antithrombotic. Tinzaparin must be given either subcutaneously or parenterally. LMWHs are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin. | Moderate | 1 | [
[
[
1603,
24,
802
]
],
[
[
1603,
63,
305
],
[
305,
24,
802
]
],
[
[
1603,
40,
610
],
[
610,
24,
802
]
],
[
[
1603,
63,
582
],
[
582,
25,
802
]
],
[
[
1603,
24,
885
],
[
885,
25,
802
]
],
[
[
1603,
24,
1421
],
[
1421,
64,
802
]
],
[
[
1603,
63,
305
],
[
305,
24,
1496
],
[
1496,
63,
802
]
],
[
[
1603,
40,
610
],
[
610,
1,
1058
],
[
1058,
24,
802
]
],
[
[
1603,
63,
582
],
[
582,
23,
944
],
[
944,
62,
802
]
],
[
[
1603,
24,
885
],
[
885,
23,
944
],
[
944,
62,
802
]
]
] | [
[
[
"Captopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tinzaparin"
]
],
[
[
"Captopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tinzaparin"
]
],
[
[
"Captopril",
"{u} (Compound) resembles {v} (Compound)",
"Enalapril"
],
[
"Enalapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tinzaparin"
]
],
[
[
"Captopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Reteplase"
],
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tinzaparin"
]
],
[
[
"Captopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tinzaparin"
]
],
[
[
"Captopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
],
[
"Betrixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tinzaparin"
]
],
[
[
"Captopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
],
[
"Nintedanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tinzaparin"
]
],
[
[
"Captopril",
"{u} (Compound) resembles {v} (Compound)",
"Enalapril"
],
[
"Enalapril",
"{u} (Compound) resembles {v} (Compound)",
"Moexipril"
],
[
"Moexipril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tinzaparin"
]
],
[
[
"Captopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Reteplase"
],
[
"Reteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tinzaparin"
]
],
[
[
"Captopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tinzaparin"
]
]
] | Captopril may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Tinzaparin
Captopril (Compound) resembles Enalapril (Compound) and Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Tinzaparin
Captopril may cause a moderate interaction that could exacerbate diseases when taken with Reteplase and Reteplase may lead to a major life threatening interaction when taken with Tinzaparin
Captopril may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may lead to a major life threatening interaction when taken with Tinzaparin
Captopril may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban and Betrixaban may lead to a major life threatening interaction when taken with Tinzaparin
Captopril may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib and Nintedanib may cause a moderate interaction that could exacerbate diseases when taken with Tinzaparin
Captopril (Compound) resembles Enalapril (Compound) and Enalapril (Compound) resembles Moexipril (Compound) and Moexipril may cause a moderate interaction that could exacerbate diseases when taken with Tinzaparin
Captopril may cause a moderate interaction that could exacerbate diseases when taken with Reteplase and Reteplase may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Tinzaparin
Captopril may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Tinzaparin |
DB00692 | DB00820 | 274 | 402 | [
"DDInter1448",
"DDInter1736"
] | Phentolamine | Tadalafil | Phentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointestinal adverse effects with the prolonged use of large oral doses of phentolamine.[A261781, A261786] It has several therapeutic uses, including the treatment of hypertensive episodes, prevention of norepinephrine-induced extravasation, diagnosis of pheochromocytoma, reversal of soft-tissue anesthesia, and treatment of pharmacologically-induced mydriasis.[L48420, L48415, L48390] Phentolamine is administered intravenously, intramuscularly, submucosally, and topically. | Tadalafil is a selective phosphodiesterase-5 inhibitor that is used in the treatment of erectile dysfunction (ED), pulmonary arterial hypertension (PAH), and benign prostatic hypertrophy.[L39100, L39105] It was first approved in 2003 by the FDA for use in ED and later in 2009 for PAH. In contrast to other PDE5 inhibitors like [sildenafil], tadalafil has greater selectivity for PDE5 and a longer half-life which has made it a more suitable option for chronic once-daily dosing in the treatment of PAH. | Moderate | 1 | [
[
[
274,
24,
402
]
],
[
[
274,
21,
29122
],
[
29122,
60,
402
]
],
[
[
274,
63,
1061
],
[
1061,
23,
402
]
],
[
[
274,
24,
885
],
[
885,
62,
402
]
],
[
[
274,
24,
1450
],
[
1450,
63,
402
]
],
[
[
274,
21,
29122
],
[
29122,
60,
885
],
[
885,
62,
402
]
],
[
[
274,
21,
29196
],
[
29196,
60,
1061
],
[
1061,
23,
402
]
],
[
[
274,
21,
29024
],
[
29024,
60,
1250
],
[
1250,
63,
402
]
],
[
[
274,
21,
29434
],
[
29434,
60,
1419
],
[
1419,
24,
402
]
],
[
[
274,
63,
1061
],
[
1061,
21,
29106
],
[
29106,
60,
402
]
]
] | [
[
[
"Phentolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tadalafil"
]
],
[
[
"Phentolamine",
"{u} (Compound) causes {v} (Side Effect)",
"Mediastinal disorder"
],
[
"Mediastinal disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Tadalafil"
]
],
[
[
"Phentolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
"Treprostinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tadalafil"
]
],
[
[
"Phentolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tadalafil"
]
],
[
[
"Phentolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
],
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tadalafil"
]
],
[
[
"Phentolamine",
"{u} (Compound) causes {v} (Side Effect)",
"Mediastinal disorder"
],
[
"Mediastinal disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tadalafil"
]
],
[
[
"Phentolamine",
"{u} (Compound) causes {v} (Side Effect)",
"Paraesthesia"
],
[
"Paraesthesia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Treprostinil"
],
[
"Treprostinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tadalafil"
]
],
[
[
"Phentolamine",
"{u} (Compound) causes {v} (Side Effect)",
"Hypertension"
],
[
"Hypertension",
"{u} (Side Effect) is caused by {v} (Compound)",
"Pazopanib"
],
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tadalafil"
]
],
[
[
"Phentolamine",
"{u} (Compound) causes {v} (Side Effect)",
"Angina pectoris"
],
[
"Angina pectoris",
"{u} (Side Effect) is caused by {v} (Compound)",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tadalafil"
]
],
[
[
"Phentolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
"Treprostinil",
"{u} (Compound) causes {v} (Side Effect)",
"Myalgia"
],
[
"Myalgia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Tadalafil"
]
]
] | Phentolamine (Compound) causes Mediastinal disorder (Side Effect) and Mediastinal disorder (Side Effect) is caused by Tadalafil (Compound)
Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a minor interaction that can limit clinical effects when taken with Tadalafil
Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a minor interaction that can limit clinical effects when taken with Tadalafil
Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Tadalafil
Phentolamine (Compound) causes Mediastinal disorder (Side Effect) and Mediastinal disorder (Side Effect) is caused by Epoprostenol (Compound) and Epoprostenol may cause a minor interaction that can limit clinical effects when taken with Tadalafil
Phentolamine (Compound) causes Paraesthesia (Side Effect) and Paraesthesia (Side Effect) is caused by Treprostinil (Compound) and Treprostinil may cause a minor interaction that can limit clinical effects when taken with Tadalafil
Phentolamine (Compound) causes Hypertension (Side Effect) and Hypertension (Side Effect) is caused by Pazopanib (Compound) and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Tadalafil
Phentolamine (Compound) causes Angina pectoris (Side Effect) and Angina pectoris (Side Effect) is caused by Imatinib (Compound) and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Tadalafil
Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) causes Myalgia (Side Effect) and Myalgia (Side Effect) is caused by Tadalafil (Compound) |
DB00624 | DB12500 | 1,561 | 283 | [
"DDInter1775",
"DDInter714"
] | Testosterone | Fedratinib | Testosterone is a steroid sex hormone indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.[L8983,L8935,L8938,L8986,L8989,L8992,L8995] Testosterone antagonizes the androgen receptor to induce gene expression that causes the growth and development of masculine sex organs and secondary sexual characteristics.[A187114,L8983,L8935,L8938,L8986,L8989,L8992,L8995] Testosterone was isolated from samples and also synthesized in 1935. | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
1561,
24,
283
]
],
[
[
1561,
24,
351
],
[
351,
23,
283
]
],
[
[
1561,
63,
1419
],
[
1419,
24,
283
]
],
[
[
1561,
24,
891
],
[
891,
24,
283
]
],
[
[
1561,
40,
559
],
[
559,
24,
283
]
],
[
[
1561,
1,
1374
],
[
1374,
24,
283
]
],
[
[
1561,
24,
159
],
[
159,
63,
283
]
],
[
[
1561,
25,
1250
],
[
1250,
24,
283
]
],
[
[
1561,
24,
1017
],
[
1017,
25,
283
]
],
[
[
1561,
25,
1510
],
[
1510,
25,
283
]
]
] | [
[
[
"Testosterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Testosterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fedratinib"
]
],
[
[
"Testosterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Testosterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Testosterone",
"{u} (Compound) resembles {v} (Compound)",
"Estrone"
],
[
"Estrone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Testosterone",
"{u} (Compound) resembles {v} (Compound)",
"Abiraterone"
],
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Testosterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Testosterone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Testosterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
],
[
[
"Testosterone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
]
] | Testosterone may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Testosterone may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Testosterone may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Testosterone (Compound) resembles Estrone (Compound) and Estrone may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Testosterone (Compound) resembles Abiraterone (Compound) and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Testosterone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Testosterone may lead to a major life threatening interaction when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Testosterone may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may lead to a major life threatening interaction when taken with Fedratinib
Testosterone may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Fedratinib |
DB00586 | DB15035 | 1,512 | 503 | [
"DDInter537",
"DDInter1959"
] | Diclofenac | Zanubrutinib | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first line therapy for acute and chronic pain and inflammation from a variety of causes. Diclofenac was the product of rational drug design based on the structures of [phenylbutazone], [mefenamic acid], and [indomethacin]. The addition of two chlorine groups in the ortho position of the phenyl ring locks the ring in maximal torsion which appears to be related to increased potency. It is often used in combination with [misoprostol] to prevent NSAID-induced gastric ulcers. Diclofenac was first approved by the | Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long-term survival. BTK is an enzyme that plays a role in oncogenic signalling pathways, promoting the survival and proliferation of malignant B cells. Compared to the first-generation BTK inhibitor [ibrutinib], zanubrutinib displays higher potency and selectivity for BTK with fewer off-target effects. Due to this enhanced selectivity towards BTK, zanubrutinib belongs to the second-generation BTK inhibitor drug group that also includes [acalabrutinib], which was approved by the FDA in 2017. Zanubrutinib was granted accelerated approval by the FDA in November 2019 based on clinical trial results that demonstrated an 84% overall response rate from zanubrutinib therapy in patients with MCL, which measures the proportion of patients in a trial whose tumour is entirely or partially destroyed by a drug. It is currently marketed under the trade name BRUKINSA™ and is available as oral capsules. In August 2021, the FDA granted accelerated approval to zanubrutinib for the treatment of adults with Waldenström’s macroglobulinemia. This indication is valid in the US, Europe, and Canada. In September 2021, zanubrutinib was granted another accelerated approval for the treatment of relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20-based regimen. In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended zanubrutinib be granted marketing authorization for the treatment of chronic lymphocytic leukemia. | Major | 2 | [
[
[
1512,
25,
503
]
],
[
[
1512,
24,
222
],
[
222,
24,
503
]
],
[
[
1512,
63,
121
],
[
121,
24,
503
]
],
[
[
1512,
62,
752
],
[
752,
24,
503
]
],
[
[
1512,
25,
39
],
[
39,
25,
503
]
],
[
[
1512,
63,
1018
],
[
1018,
25,
503
]
],
[
[
1512,
24,
885
],
[
885,
25,
503
]
],
[
[
1512,
64,
834
],
[
834,
25,
503
]
],
[
[
1512,
24,
1274
],
[
1274,
37,
503
]
],
[
[
1512,
24,
222
],
[
222,
63,
1324
],
[
1324,
24,
503
]
]
] | [
[
[
"Diclofenac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenfluramine"
],
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Diclofenac",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Diclofenac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
],
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Diclofenac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Drotrecogin alfa"
],
[
"Drotrecogin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zanubrutinib"
]
]
] | Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine and Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Diclofenac may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Diclofenac may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Zanubrutinib
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine may lead to a major life threatening interaction when taken with Zanubrutinib
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may lead to a major life threatening interaction when taken with Zanubrutinib
Diclofenac may lead to a major life threatening interaction when taken with Drotrecogin alfa and Drotrecogin alfa may lead to a major life threatening interaction when taken with Zanubrutinib
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib and Flurbiprofen may lead to a major life threatening interaction when taken with Zanubrutinib
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib |
DB00214 | DB11901 | 1,028 | 913 | [
"DDInter1836",
"DDInter107"
] | Torasemide | Apalutamide | Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993. | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Resistant Prostate Cancer, and Prostatic Neoplasms, Castration-Resistant, among others. Exerting an antitumor action, apalutamide blocking the effect of androgens that promote tumor growth. It targets the AR ligand-binding domain and prevents AR nuclear translocation, DNA binding, and transcription of AR gene targets in prostate tumors . In mice bearing human CRPC xenograft models, apalutamide treatment produced tumor regressions in a dose-dependent manner that was more effective than that of or . Unlike bicalutamide, apalutamide antagonized AR-mediated signaling in AR overexpressing human CRPC cell lines . Androgen-deprivation therapy, or hormone therapy, can be used as part of maintenance therapy for patients with non-metastatic prostate cancer. Although most patients achieve therapeutic responses at the initial hormone therapy, many patients progress to non-metastatic castration-resistant (resistance to hormone therapy) prostate cancer which is the second-most common cause of cancer-related deaths in American males . Castration-resistant prostate cancer is often incurable, which poses significant clinical challenges for patients. Approximately 10 to 20 % of prostate cancer cases are castration-resistant, and up to 16% of these patients show no evidence of cancer metastasis at the time of castration-resistant diagnosis . Higher prostate-specific antigen (PSA) and shorter PSA doubling time (PSA DT) are associated with a higher risk for metastases and death . In a phase-2 multicenter open-label study, 89% of patients with non-metastatic, castration-resistant prostate cancer had ≥50% PSA decline at week 12 of apalutamide treatment . In a randomized trial, the median metastasis-free survival for patients taking apalutamide was 40.5 months compared to 16.2 months for patients taking a placebo . Apalutamide displayed good tolerability and safety profile in clinical studies. Apalutamide was approved in February 2018 by the FDA as Erleada for the treatment of patients with non-metastatic prostate cancer that is resistant to treatment with hormone therapy (castration-resistant). It is available as oral tablets. Apalutamide is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer . | Moderate | 1 | [
[
[
1028,
24,
913
]
],
[
[
1028,
24,
112
],
[
112,
23,
913
]
],
[
[
1028,
63,
600
],
[
600,
24,
913
]
],
[
[
1028,
24,
28
],
[
28,
24,
913
]
],
[
[
1028,
24,
1619
],
[
1619,
63,
913
]
],
[
[
1028,
24,
593
],
[
593,
25,
913
]
],
[
[
1028,
25,
1166
],
[
1166,
25,
913
]
],
[
[
1028,
24,
1019
],
[
1019,
64,
913
]
],
[
[
1028,
24,
112
],
[
112,
24,
110
],
[
110,
62,
913
]
],
[
[
1028,
63,
600
],
[
600,
25,
312
],
[
312,
23,
913
]
]
] | [
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Apalutamide"
]
],
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
],
[
"Bisacodyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
],
[
[
"Torasemide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolasetron"
],
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
],
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
],
[
"Deflazacort",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
],
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polatuzumab vedotin"
],
[
"Polatuzumab vedotin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Apalutamide"
]
],
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eplerenone"
],
[
"Eplerenone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Apalutamide"
]
]
] | Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl and Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Apalutamide
Torasemide may lead to a major life threatening interaction when taken with Dolasetron and Dolasetron may lead to a major life threatening interaction when taken with Apalutamide
Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and Deflazacort may lead to a major life threatening interaction when taken with Apalutamide
Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab vedotin and Polatuzumab vedotin may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Eplerenone and Eplerenone may cause a minor interaction that can limit clinical effects when taken with Apalutamide |
DB08895 | DB09330 | 976 | 985 | [
"DDInter1825",
"DDInter1352"
] | Tofacitinib | Osimertinib | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate. Besides rheumatoid arthritis, tofacitinib has also been studied in clinical trials for the prevention of organ transplant rejection, and is currently under investigation for the treatment of psoriasis. Known adverse effects include nausea and headache as well as more serious immunologic and hematological adverse effects. Tofacitinib is marketed under the brand name Xeljanz by Pfizer. | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and which has progressed following therapy with a first-generation EGFR tyrosine kinase inhibitor. Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs due to the presence of specific activating EGFR mutations within the tumour cells. More specifically, deletions around the LREA motif in exon 19 and exon 21 L858R point mutations are correlated with response to therapy. Development of third-generation EGFR-TKIs, such as osimertinib, has been in response to altered tumour resistance patterns following treatment and toxic side effects that impact patient quality of life. Treatment with first-generation EGFR-TKIs (gefitinib and erlotinib) has been associated with the development of resistance through activating mutations in the EGFR gene. Second-generation EGFR-TKIs (afatinib and dacomitinib) were then developed to be more potent inhibitors, although their use is associated with increased toxicity through nonspecific targeting of wild-type EGFR. In contrast, third-generation inhibitors are specific for the gate-keeper T790M mutations which increases ATP binding activity to EGFR and result in poor prognosis for late-stage disease. Furthermore, osimertinib has been shown to spare wild-type EGFR during therapy, thereby reducing non-specific binding and limiting toxicity.[A7926,A7927,A7931] | Major | 2 | [
[
[
976,
25,
985
]
],
[
[
976,
64,
168
],
[
168,
23,
985
]
],
[
[
976,
63,
608
],
[
608,
23,
985
]
],
[
[
976,
64,
134
],
[
134,
24,
985
]
],
[
[
976,
25,
119
],
[
119,
63,
985
]
],
[
[
976,
24,
1040
],
[
1040,
24,
985
]
],
[
[
976,
24,
988
],
[
988,
63,
985
]
],
[
[
976,
63,
62
],
[
62,
24,
985
]
],
[
[
976,
25,
1362
],
[
1362,
24,
985
]
],
[
[
976,
62,
307
],
[
307,
24,
985
]
]
] | [
[
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Osimertinib"
]
],
[
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Osimertinib"
]
],
[
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Talazoparib"
],
[
"Talazoparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voxelotor"
],
[
"Voxelotor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tacrine"
],
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Tofacitinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
]
] | Tofacitinib may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Tofacitinib may lead to a major life threatening interaction when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Tofacitinib may lead to a major life threatening interaction when taken with Talazoparib and Talazoparib may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Voxelotor and Voxelotor may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Tacrine and Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Tofacitinib may lead to a major life threatening interaction when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Tofacitinib may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib |
DB00445 | DB01197 | 322 | 1,603 | [
"DDInter655",
"DDInter292"
] | Epirubicin | Captopril | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment of hypertension. | Moderate | 1 | [
[
[
322,
24,
1603
]
],
[
[
322,
24,
610
],
[
610,
1,
1603
]
],
[
[
322,
7,
1720
],
[
1720,
46,
1603
]
],
[
[
322,
7,
4893
],
[
4893,
57,
1603
]
],
[
[
322,
18,
2801
],
[
2801,
57,
1603
]
],
[
[
322,
21,
28725
],
[
28725,
60,
1603
]
],
[
[
322,
24,
663
],
[
663,
24,
1603
]
],
[
[
322,
24,
1662
],
[
1662,
63,
1603
]
],
[
[
322,
63,
1560
],
[
1560,
24,
1603
]
],
[
[
322,
25,
1377
],
[
1377,
25,
1603
]
]
] | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Captopril"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enalapril"
],
[
"Enalapril",
"{u} (Compound) resembles {v} (Compound)",
"Captopril"
]
],
[
[
"Epirubicin",
"{u} (Compound) upregulates {v} (Gene)",
"RELB"
],
[
"RELB",
"{u} (Gene) is upregulated by {v} (Compound)",
"Captopril"
]
],
[
[
"Epirubicin",
"{u} (Compound) upregulates {v} (Gene)",
"S100A13"
],
[
"S100A13",
"{u} (Gene) is downregulated by {v} (Compound)",
"Captopril"
]
],
[
[
"Epirubicin",
"{u} (Compound) downregulates {v} (Gene)",
"PUF60"
],
[
"PUF60",
"{u} (Gene) is downregulated by {v} (Compound)",
"Captopril"
]
],
[
[
"Epirubicin",
"{u} (Compound) causes {v} (Side Effect)",
"Pancytopenia"
],
[
"Pancytopenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Captopril"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Captopril"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
],
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Captopril"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
],
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Captopril"
]
],
[
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Captopril"
]
]
] | Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Enalapril and Enalapril (Compound) resembles Captopril (Compound)
Epirubicin (Compound) upregulates RELB (Gene) and RELB (Gene) is upregulated by Captopril (Compound)
Epirubicin (Compound) upregulates S100A13 (Gene) and S100A13 (Gene) is downregulated by Captopril (Compound)
Epirubicin (Compound) downregulates PUF60 (Gene) and PUF60 (Gene) is downregulated by Captopril (Compound)
Epirubicin (Compound) causes Pancytopenia (Side Effect) and Pancytopenia (Side Effect) is caused by Captopril (Compound)
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Captopril
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Captopril
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Captopril
Epirubicin may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Captopril |
DB00283 | DB00382 | 701 | 62 | [
"DDInter395",
"DDInter1734"
] | Clemastine | Tacrine | An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness. | A centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders. Tacrine has been discontinued for the United States market. | Moderate | 1 | [
[
[
701,
24,
62
]
],
[
[
701,
24,
1507
],
[
1507,
63,
62
]
],
[
[
701,
35,
1594
],
[
1594,
24,
62
]
],
[
[
701,
63,
352
],
[
352,
24,
62
]
],
[
[
701,
35,
1511
],
[
1511,
63,
62
]
],
[
[
701,
24,
1507
],
[
1507,
63,
19
],
[
19,
63,
62
]
],
[
[
701,
24,
19
],
[
19,
24,
1507
],
[
1507,
63,
62
]
],
[
[
701,
35,
1594
],
[
1594,
24,
1507
],
[
1507,
63,
62
]
],
[
[
701,
24,
770
],
[
770,
64,
1001
],
[
1001,
62,
62
]
],
[
[
701,
63,
352
],
[
352,
24,
1507
],
[
1507,
63,
62
]
]
] | [
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tacrine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dicyclomine"
],
[
"Dicyclomine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tacrine"
]
],
[
[
"Clemastine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tacrine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trospium"
],
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tacrine"
]
],
[
[
"Clemastine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
[
"Mepenzolate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tacrine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dicyclomine"
],
[
"Dicyclomine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hyoscyamine"
],
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tacrine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hyoscyamine"
],
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dicyclomine"
],
[
"Dicyclomine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tacrine"
]
],
[
[
"Clemastine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dicyclomine"
],
[
"Dicyclomine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tacrine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mechlorethamine"
],
[
"Mechlorethamine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tacrine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trospium"
],
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dicyclomine"
],
[
"Dicyclomine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tacrine"
]
]
] | Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Dicyclomine and Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Tacrine
Clemastine (Compound) resembles Doxylamine (Compound) and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Tacrine
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Tacrine
Clemastine (Compound) resembles Mepenzolate (Compound) and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Tacrine
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Dicyclomine and Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine and Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Tacrine
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine and Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Dicyclomine and Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Tacrine
Clemastine (Compound) resembles Doxylamine (Compound) and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Dicyclomine and Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Tacrine
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Mechlorethamine and Mechlorethamine may cause a minor interaction that can limit clinical effects when taken with Tacrine
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Dicyclomine and Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Tacrine |
DB01229 | DB08827 | 973 | 990 | [
"DDInter1378",
"DDInter1085"
] | Paclitaxel (protein-bound) | Lomitapide | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R). | Moderate | 1 | [
[
[
973,
24,
990
]
],
[
[
973,
63,
1080
],
[
1080,
1,
990
]
],
[
[
973,
6,
8374
],
[
8374,
45,
990
]
],
[
[
973,
21,
28701
],
[
28701,
60,
990
]
],
[
[
973,
24,
1362
],
[
1362,
63,
990
]
],
[
[
973,
63,
752
],
[
752,
24,
990
]
],
[
[
973,
24,
1491
],
[
1491,
24,
990
]
],
[
[
973,
63,
79
],
[
79,
25,
990
]
],
[
[
973,
24,
1320
],
[
1320,
64,
990
]
],
[
[
973,
24,
980
],
[
980,
25,
990
]
]
] | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomitapide"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Conivaptan"
],
[
"Conivaptan",
"{u} (Compound) resembles {v} (Compound)",
"Lomitapide"
]
],
[
[
"Paclitaxel",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Lomitapide"
]
],
[
[
"Paclitaxel",
"{u} (Compound) causes {v} (Side Effect)",
"Discomfort"
],
[
"Discomfort",
"{u} (Side Effect) is caused by {v} (Compound)",
"Lomitapide"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomitapide"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomitapide"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
],
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomitapide"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
[
"Sorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
"Elagolix",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tocilizumab"
],
[
"Tocilizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
]
]
] | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Lomitapide
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Conivaptan and Conivaptan (Compound) resembles Lomitapide (Compound)
Paclitaxel (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lomitapide (Compound)
Paclitaxel (Compound) causes Discomfort (Side Effect) and Discomfort (Side Effect) is caused by Lomitapide (Compound)
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Lomitapide
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Lomitapide
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Lomitapide
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may lead to a major life threatening interaction when taken with Lomitapide
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may lead to a major life threatening interaction when taken with Lomitapide
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab and Tocilizumab may lead to a major life threatening interaction when taken with Lomitapide |
DB01075 | DB11160 | 1,376 | 337 | [
"DDInter569",
"DDInter1459"
] | Diphenhydramine | Phenyltoloxamine | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnotic, and antiparkinson properties [L5269, F3352]. As histamine receptors exist both peripherally and in the central nervous system, diphenhydramine has been shown to cause sedation due to its competitive antagonism of histamine H1 receptors within the central nervous system [L5263, L5266, L5269, F3379, A174541]. While its use in allergy therapy can sometimes fall out of favor due to its sedative effect, diphenhydramine has been repurposed | Phenyltoloxamine is an antihistamine drug with sedative and analgesic effects. It is a H1 receptor blocker and a member of the ethanolamine class of antihistaminergic drugs. It is available in combination products that also contain other analgesics and antitussives such as acetaminophen. Phenyltoloxamine citrate is the more common salt form that acts as an active ingredient in pharmaceutical products and promotes hay fever relief via reversing the effects of histamine. Phenyltoloxamine acts as an adjuvant analgesic, which augments the analgesic effect of acetaminophen. It also potentiates the effects of other drugs, such as codeine and codeine derivatives. Although phenyltoloxamine's ability to potentiate the effects of analgesics may be explained in part by its chemical nature as a first-generation H1 antihistamine that is capable of crossing the blood-brain barrier and causing tranquilizing effects at CNS histamine receptors, many of the drug's specific pharmacokinetics are not readily available - perhaps also because many early (phenyltoloxamine was involved in studies as early as the 1950s) first-generation antihistamines were not optimally investigated . Nevertheless, phenyltoloxamine is used to a fairly limited extent in contemporary medicine, with only very few products involving it as an active ingredient. | Moderate | 1 | [
[
[
1376,
24,
337
]
],
[
[
1376,
23,
771
],
[
771,
62,
337
]
],
[
[
1376,
35,
820
],
[
820,
24,
337
]
],
[
[
1376,
63,
999
],
[
999,
24,
337
]
],
[
[
1376,
24,
1511
],
[
1511,
24,
337
]
],
[
[
1376,
74,
100
],
[
100,
24,
337
]
],
[
[
1376,
24,
1609
],
[
1609,
63,
337
]
],
[
[
1376,
64,
1621
],
[
1621,
25,
337
]
],
[
[
1376,
23,
771
],
[
771,
62,
820
],
[
820,
24,
337
]
],
[
[
1376,
35,
820
],
[
820,
23,
771
],
[
771,
62,
337
]
]
] | [
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyltoloxamine"
]
],
[
[
"Diphenhydramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
],
[
"Hyaluronidase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Phenyltoloxamine"
]
],
[
[
"Diphenhydramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyltoloxamine"
]
],
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
],
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyltoloxamine"
]
],
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
[
"Mepenzolate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyltoloxamine"
]
],
[
[
"Diphenhydramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyltoloxamine"
]
],
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
],
[
"Pentoxyverine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyltoloxamine"
]
],
[
[
"Diphenhydramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium chloride"
],
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenyltoloxamine"
]
],
[
[
"Diphenhydramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
],
[
"Hyaluronidase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyltoloxamine"
]
],
[
[
"Diphenhydramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
],
[
"Hyaluronidase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Phenyltoloxamine"
]
]
] | Diphenhydramine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase and Hyaluronidase may cause a minor interaction that can limit clinical effects when taken with Phenyltoloxamine
Diphenhydramine (Compound) resembles Alimemazine (Compound) and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Phenyltoloxamine
Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Phenyltoloxamine
Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Phenyltoloxamine
Diphenhydramine (Compound) resembles Brompheniramine (Compound) and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Phenyltoloxamine
Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Phenyltoloxamine
Diphenhydramine may lead to a major life threatening interaction when taken with Potassium chloride and Potassium chloride may lead to a major life threatening interaction when taken with Phenyltoloxamine
Diphenhydramine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase and Hyaluronidase may cause a minor interaction that can limit clinical effects when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Phenyltoloxamine
Diphenhydramine (Compound) resembles Alimemazine (Compound) and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase and Hyaluronidase may cause a minor interaction that can limit clinical effects when taken with Phenyltoloxamine |
DB08890 | DB11228 | 16 | 721 | [
"DDInter1069",
"DDInter1184"
] | Linaclotide | Methylcellulose | Linaclotide is a synthetic 14-amino acid cyclic peptide and first-in-class guanylate cyclase-C (G-CC) agonist.[A260271, L47211] Linaclotide is structurally related to human guanylin and uroguanylin, paracrine peptide hormones that are endogenous activators of GC-C. It is also a homolog of a heat-stable enterotoxin derived from _Escherichia coli_, the first natural ligand that activates GC-C. Linaclotide is used for the treatment of various types of constipation, including irritable bowel syndrome with constipation. Linaclotide was first approved by the FDA on August 30, 2012. It gained EMA and Health Canada approval on November 26, 2012 and December 3, 2013, respectively. Linaclotide works to improve the symptoms of constipation and gastrointestinal symptoms of conditions involving constipation | Methyl cellulose polymer consisting of numerous linked glucose molecules used as a stabiliser, thickener and emulsifier for foodstuffs and cosmetics. The Degree of Substitution (DS) of a given form of methyl cellulose is defined as the average number of substituted hydroxyl groups per glucose with a theoretical maximum of 3, however more typical values are 1.3 2.6. Methyl cellulose is a hydrophilic white powder in pure form and dissolves in cold (but not in hot) water, forming a clear viscous solution or gel. It is available under a variety of trade names as a treatment for constipation. Like cellulose, it is not digestible, not toxic, and not allergenic | Minor | 0 | [
[
[
16,
23,
721
]
],
[
[
16,
23,
1662
],
[
1662,
23,
721
]
],
[
[
16,
62,
355
],
[
355,
24,
721
]
],
[
[
16,
23,
1662
],
[
1662,
63,
355
],
[
355,
24,
721
]
],
[
[
16,
62,
660
],
[
660,
23,
1411
],
[
1411,
23,
721
]
],
[
[
16,
62,
355
],
[
355,
40,
1647
],
[
1647,
23,
721
]
],
[
[
16,
62,
831
],
[
831,
24,
1411
],
[
1411,
23,
721
]
],
[
[
16,
62,
660
],
[
660,
62,
245
],
[
245,
23,
721
]
],
[
[
16,
62,
831
],
[
831,
63,
245
],
[
245,
23,
721
]
],
[
[
16,
23,
286
],
[
286,
63,
1411
],
[
1411,
23,
721
]
]
] | [
[
[
"Linaclotide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methylcellulose"
]
],
[
[
"Linaclotide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Picosulfuric acid"
],
[
"Picosulfuric acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methylcellulose"
]
],
[
[
"Linaclotide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lactulose"
],
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylcellulose"
]
],
[
[
"Linaclotide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Picosulfuric acid"
],
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
],
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylcellulose"
]
],
[
[
"Linaclotide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Esomeprazole"
],
[
"Esomeprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methylcellulose"
]
],
[
[
"Linaclotide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lactulose"
],
[
"Lactulose",
"{u} (Compound) resembles {v} (Compound)",
"Acarbose"
],
[
"Acarbose",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methylcellulose"
]
],
[
[
"Linaclotide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Indomethacin"
],
[
"Indomethacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methylcellulose"
]
],
[
[
"Linaclotide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Esomeprazole"
],
[
"Esomeprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methylcellulose"
]
],
[
[
"Linaclotide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Indomethacin"
],
[
"Indomethacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methylcellulose"
]
],
[
[
"Linaclotide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methylcellulose"
]
]
] | Linaclotide may cause a minor interaction that can limit clinical effects when taken with Picosulfuric acid and Picosulfuric acid may cause a minor interaction that can limit clinical effects when taken with Methylcellulose
Linaclotide may cause a minor interaction that can limit clinical effects when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Methylcellulose
Linaclotide may cause a minor interaction that can limit clinical effects when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Methylcellulose
Linaclotide may cause a minor interaction that can limit clinical effects when taken with Esomeprazole and Esomeprazole may cause a minor interaction that can limit clinical effects when taken with Tolbutamide and Tolbutamide may cause a minor interaction that can limit clinical effects when taken with Methylcellulose
Linaclotide may cause a minor interaction that can limit clinical effects when taken with Lactulose and Lactulose (Compound) resembles Acarbose (Compound) and Acarbose may cause a minor interaction that can limit clinical effects when taken with Methylcellulose
Linaclotide may cause a minor interaction that can limit clinical effects when taken with Indomethacin and Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a minor interaction that can limit clinical effects when taken with Methylcellulose
Linaclotide may cause a minor interaction that can limit clinical effects when taken with Esomeprazole and Esomeprazole may cause a minor interaction that can limit clinical effects when taken with Glimepiride and Glimepiride may cause a minor interaction that can limit clinical effects when taken with Methylcellulose
Linaclotide may cause a minor interaction that can limit clinical effects when taken with Indomethacin and Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a minor interaction that can limit clinical effects when taken with Methylcellulose
Linaclotide may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a minor interaction that can limit clinical effects when taken with Methylcellulose |
DB01254 | DB14444 | 1,213 | 151 | [
"DDInter484",
"DDInter924"
] | Dasatinib | Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein BCR-ABL. BCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the pathogenesis of CML and 15-30% of ALL cases.[A11377,A33432] Dasatinib also inhibits a spectrum of kinases involved in cancer, including several SRC-family kinases. Unlike [imatinib], another tyrosine kinase used for the treatment of CML and Ph-positive ALL, dasatinib inhibits the active and inactive conformations of the ABL | A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to. There are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability. | Moderate | 1 | [
[
[
1213,
24,
151
]
],
[
[
1213,
63,
66
],
[
66,
24,
151
]
],
[
[
1213,
24,
1619
],
[
1619,
24,
151
]
],
[
[
1213,
25,
1468
],
[
1468,
24,
151
]
],
[
[
1213,
64,
1172
],
[
1172,
24,
151
]
],
[
[
1213,
25,
676
],
[
676,
63,
151
]
],
[
[
1213,
63,
66
],
[
66,
24,
134
],
[
134,
24,
151
]
],
[
[
1213,
24,
1619
],
[
1619,
63,
66
],
[
66,
24,
151
]
],
[
[
1213,
63,
1573
],
[
1573,
63,
66
],
[
66,
24,
151
]
],
[
[
1213,
25,
1468
],
[
1468,
63,
66
],
[
66,
24,
151
]
]
] | [
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
],
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
],
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ibritumomab tiuxetan"
],
[
"Ibritumomab tiuxetan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
],
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
],
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
],
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
]
] | Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Dasatinib may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Dasatinib may lead to a major life threatening interaction when taken with Ibritumomab tiuxetan and Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Dasatinib may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Dasatinib may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) |
DB04855 | DB11718 | 540 | 927 | [
"DDInter602",
"DDInter640"
] | Dronedarone | Encorafenib | Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate control, rhythm control, prevention of thromboembolic events, and treatment of the underlying disease. Similar to [amiodarone], dronedarone is a multichannel blocker that works to control rhythm and rate in atrial fibrillation. It meets criteria of all four Vaughan Williams antiarrhythmic drug classes by blocking sodium, potassium, and calcium ion channels and inhibiting β-adrenergic receptors.[A34604,L8699] Dronedarone is a related benzofuran compound to amiodarone but its chemical structure lacks iodine moieties which are associated with amiodarone-induced thyroid problems.[A34604,T28] Additionally | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and secretion. Mutations in this gene, most frequently the V600E mutation, are the most commonly identified cancer-causing mutations in melanoma, and have been isolated in various other cancers as well, including non-Hodgkin lymphoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukemia and adenocarcinoma of the lung. On June 27, 2018, the Food and Drug Administration approved encorafenib and [binimetinib] (BRAFTOVI and MEKTOVI, Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. | Major | 2 | [
[
[
540,
25,
927
]
],
[
[
540,
62,
112
],
[
112,
23,
927
]
],
[
[
540,
24,
720
],
[
720,
24,
927
]
],
[
[
540,
63,
372
],
[
372,
24,
927
]
],
[
[
540,
25,
1491
],
[
1491,
24,
927
]
],
[
[
540,
64,
1520
],
[
1520,
24,
927
]
],
[
[
540,
25,
484
],
[
484,
63,
927
]
],
[
[
540,
24,
564
],
[
564,
63,
927
]
],
[
[
540,
63,
597
],
[
597,
25,
927
]
],
[
[
540,
24,
1017
],
[
1017,
64,
927
]
]
] | [
[
[
"Dronedarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
],
[
[
"Dronedarone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Encorafenib"
]
],
[
[
"Dronedarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
],
[
"Mineral oil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Dronedarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
],
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Dronedarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Midostaurin"
],
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Dronedarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Primaquine"
],
[
"Primaquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Dronedarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Dronedarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abemaciclib"
],
[
"Abemaciclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Dronedarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
],
[
[
"Dronedarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
]
] | Dronedarone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Dronedarone may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil and Mineral oil may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Dronedarone may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Dronedarone may lead to a major life threatening interaction when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Dronedarone may lead to a major life threatening interaction when taken with Primaquine and Primaquine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Dronedarone may lead to a major life threatening interaction when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Dronedarone may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib and Abemaciclib may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Dronedarone may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may lead to a major life threatening interaction when taken with Encorafenib
Dronedarone may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may lead to a major life threatening interaction when taken with Encorafenib |
DB00615 | DB00619 | 690 | 1,419 | [
"DDInter1589",
"DDInter909"
] | Rifabutin | Imatinib | A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients. | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy".. The discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient. Imatinib was approved on February 1st ,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751] | Major | 2 | [
[
[
690,
25,
1419
]
],
[
[
690,
6,
7950
],
[
7950,
45,
1419
]
],
[
[
690,
7,
3727
],
[
3727,
46,
1419
]
],
[
[
690,
21,
28847
],
[
28847,
60,
1419
]
],
[
[
690,
62,
1101
],
[
1101,
23,
1419
]
],
[
[
690,
24,
309
],
[
309,
63,
1419
]
],
[
[
690,
25,
283
],
[
283,
63,
1419
]
],
[
[
690,
63,
475
],
[
475,
24,
1419
]
],
[
[
690,
62,
608
],
[
608,
24,
1419
]
],
[
[
690,
23,
86
],
[
86,
63,
1419
]
]
] | [
[
[
"Rifabutin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Imatinib"
]
],
[
[
"Rifabutin",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Imatinib"
]
],
[
[
"Rifabutin",
"{u} (Compound) upregulates {v} (Gene)",
"MAL"
],
[
"MAL",
"{u} (Gene) is upregulated by {v} (Compound)",
"Imatinib"
]
],
[
[
"Rifabutin",
"{u} (Compound) causes {v} (Side Effect)",
"Eye disorder"
],
[
"Eye disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Imatinib"
]
],
[
[
"Rifabutin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Imatinib"
]
],
[
[
"Rifabutin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
],
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
]
],
[
[
"Rifabutin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
]
],
[
[
"Rifabutin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
]
],
[
[
"Rifabutin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
]
],
[
[
"Rifabutin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Miconazole"
],
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
]
]
] | Rifabutin (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Imatinib (Compound)
Rifabutin (Compound) upregulates MAL (Gene) and MAL (Gene) is upregulated by Imatinib (Compound)
Rifabutin (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Imatinib (Compound)
Rifabutin may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Imatinib
Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone and Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Imatinib
Rifabutin may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Imatinib
Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib
Rifabutin may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib
Rifabutin may cause a minor interaction that can limit clinical effects when taken with Miconazole and Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Imatinib |
DB00394 | DB09473 | 218 | 884 | [
"DDInter168",
"DDInter918"
] | Beclomethasone dipropionate | Indium In-111 oxyquinoline | Beclomethasone dipropionate is a second-generation synthetic corticosteroid and diester of beclomethasone, which is structurally similar to [dexamethasone]. It is a prodrug of an active metabolite beclomethasone 17-monopropionate (17-BMP) which acts on the glucocorticoid receptor to mediates its therapeutic action. Beclomethasone dipropionate itself posesses weak glucocorticoid receptor binding affinity and is rapidly converted into 17-BMP upon administration. Formulations for oral inhalation, intranasal, and topical use are available for beclomethasone dipropionate. Beclomethasone dipropionate became first available in a pressurized metered-dose inhaler in 1972 and later in a dry powder inhaler and an aqueous nasal spray. Due to its anti-inflammatory, antipruritic, and | Indium In 111 oxyquinoline (oxine) is a diagnostic radiopharmaceutical intended for radiolabeling of autologous leukocytes. It is composed of a 3:1 saturated complex of In-111 isotope and oxyquinoline. Indium-111 decays by isomeric transition and electron capture to cadmium-111, emitting a gamma ray that can be detected with a gamma ray camera. It is therefore useful in nuclear medicine, and is used in the labeling of leukocytes for localization of processes to which leukocytes migrate, such as those associated with abscesses or other infections. The degree of accuracy may vary with labeling techniques and with the size, location and nature of the inflammatory process. Following intravenous administration, the lipid-soluble complex is able to penetrate platelet cell membranes. Once inside, Indium detaches from the oxyquinoline complexes and becomes attached to cytoplasmic components. | Moderate | 1 | [
[
[
218,
24,
884
]
],
[
[
218,
1,
423
],
[
423,
24,
884
]
],
[
[
218,
1,
423
],
[
423,
40,
891
],
[
891,
24,
884
]
],
[
[
218,
1,
891
],
[
891,
1,
423
],
[
423,
24,
884
]
],
[
[
218,
24,
1680
],
[
1680,
62,
1572
],
[
1572,
24,
884
]
],
[
[
218,
24,
1680
],
[
1680,
63,
870
],
[
870,
24,
884
]
],
[
[
218,
1,
617
],
[
617,
63,
597
],
[
597,
24,
884
]
],
[
[
218,
63,
1028
],
[
1028,
23,
1572
],
[
1572,
24,
884
]
],
[
[
218,
24,
1680
],
[
1680,
25,
1448
],
[
1448,
24,
884
]
],
[
[
218,
63,
1028
],
[
1028,
24,
870
],
[
870,
24,
884
]
]
] | [
[
[
"Beclomethasone dipropionate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indium In-111 oxyquinoline"
]
],
[
[
"Beclomethasone dipropionate",
"{u} (Compound) resembles {v} (Compound)",
"Ciclesonide"
],
[
"Ciclesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indium In-111 oxyquinoline"
]
],
[
[
"Beclomethasone dipropionate",
"{u} (Compound) resembles {v} (Compound)",
"Ciclesonide"
],
[
"Ciclesonide",
"{u} (Compound) resembles {v} (Compound)",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indium In-111 oxyquinoline"
]
],
[
[
"Beclomethasone dipropionate",
"{u} (Compound) resembles {v} (Compound)",
"Prednisolone"
],
[
"Prednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Ciclesonide"
],
[
"Ciclesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indium In-111 oxyquinoline"
]
],
[
[
"Beclomethasone dipropionate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etacrynic acid"
],
[
"Etacrynic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Demeclocycline"
],
[
"Demeclocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indium In-111 oxyquinoline"
]
],
[
[
"Beclomethasone dipropionate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etacrynic acid"
],
[
"Etacrynic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indium In-111 oxyquinoline"
]
],
[
[
"Beclomethasone dipropionate",
"{u} (Compound) resembles {v} (Compound)",
"Budesonide"
],
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indium In-111 oxyquinoline"
]
],
[
[
"Beclomethasone dipropionate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Torasemide"
],
[
"Torasemide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Demeclocycline"
],
[
"Demeclocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indium In-111 oxyquinoline"
]
],
[
[
"Beclomethasone dipropionate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etacrynic acid"
],
[
"Etacrynic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Streptomycin"
],
[
"Streptomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indium In-111 oxyquinoline"
]
],
[
[
"Beclomethasone dipropionate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Torasemide"
],
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indium In-111 oxyquinoline"
]
]
] | Beclomethasone dipropionate (Compound) resembles Ciclesonide (Compound) and Ciclesonide may cause a moderate interaction that could exacerbate diseases when taken with Indium In-111 oxyquinoline
Beclomethasone dipropionate (Compound) resembles Ciclesonide (Compound) and Ciclesonide (Compound) resembles Prednisolone (Compound) and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Indium In-111 oxyquinoline
Beclomethasone dipropionate (Compound) resembles Prednisolone (Compound) and Prednisolone (Compound) resembles Ciclesonide (Compound) and Ciclesonide may cause a moderate interaction that could exacerbate diseases when taken with Indium In-111 oxyquinoline
Beclomethasone dipropionate may cause a moderate interaction that could exacerbate diseases when taken with Etacrynic acid and Etacrynic acid may cause a minor interaction that can limit clinical effects when taken with Demeclocycline and Demeclocycline may cause a moderate interaction that could exacerbate diseases when taken with Indium In-111 oxyquinoline
Beclomethasone dipropionate may cause a moderate interaction that could exacerbate diseases when taken with Etacrynic acid and Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Indium In-111 oxyquinoline
Beclomethasone dipropionate (Compound) resembles Budesonide (Compound) and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Indium In-111 oxyquinoline
Beclomethasone dipropionate may cause a moderate interaction that could exacerbate diseases when taken with Torasemide and Torasemide may cause a minor interaction that can limit clinical effects when taken with Demeclocycline and Demeclocycline may cause a moderate interaction that could exacerbate diseases when taken with Indium In-111 oxyquinoline
Beclomethasone dipropionate may cause a moderate interaction that could exacerbate diseases when taken with Etacrynic acid and Etacrynic acid may lead to a major life threatening interaction when taken with Streptomycin and Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Indium In-111 oxyquinoline
Beclomethasone dipropionate may cause a moderate interaction that could exacerbate diseases when taken with Torasemide and Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Indium In-111 oxyquinoline |
DB00563 | DB11936 | 663 | 1,030 | [
"DDInter1174",
"DDInter176"
] | Methotrexate | Bempedoic acid | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma.[A180322,L7144,L7147,L7150,L7180] Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients are intolerant of those treatments. Methotrexate was granted FDA approval on 7 December 1953. | High levels of LDL cholesterol (LDL-C) are a major risk factor for cardiovascular events. Caused by genetic mutations or lifestyle factors, hypercholesterolemia can significantly reduce quality of life and increase the risk of mortality from cardiovascular disease. About 1 in 4 patients, or 15 million Americans with elevated LDL-C, are insufficiently managed with maximally tolerated statin therapy alone, requiring additional treatment for hypercholesterolemia. Bempedoic acid is first-in-class adenosine triphosphate-citrate lyase (ACL) inhibitor used once a day for reducing LDL cholesterol levels in statin-refractory patients.[L12144,L12147] It was developed by Esperion Therapeutics Inc. and approved by the FDA on February 21, 2020. A combination product of bempedoic acid and [ezetimibe] was approved on February 26, 2020 for increased control of LDL cholesterol levels in patients experiencing refractory elevations despite previous statin treatment.[L12144,L12150] | Moderate | 1 | [
[
[
663,
24,
1030
]
],
[
[
663,
24,
14
],
[
14,
24,
1030
]
],
[
[
663,
24,
891
],
[
891,
25,
1030
]
],
[
[
663,
63,
251
],
[
251,
25,
1030
]
],
[
[
663,
24,
14
],
[
14,
63,
467
],
[
467,
25,
1030
]
],
[
[
663,
24,
891
],
[
891,
24,
473
],
[
473,
24,
1030
]
],
[
[
663,
24,
617
],
[
617,
40,
891
],
[
891,
25,
1030
]
],
[
[
663,
24,
1486
],
[
1486,
63,
473
],
[
473,
24,
1030
]
],
[
[
663,
63,
251
],
[
251,
24,
473
],
[
473,
24,
1030
]
],
[
[
663,
6,
6648
],
[
6648,
45,
1413
],
[
1413,
24,
1030
]
]
] | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bempedoic acid"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
],
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bempedoic acid"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
],
[
"Prednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bempedoic acid"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
],
[
"Betamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bempedoic acid"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
],
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
],
[
"Simvastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bempedoic acid"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
],
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bempedoic acid"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
],
[
"Budesonide",
"{u} (Compound) resembles {v} (Compound)",
"Prednisolone"
],
[
"Prednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bempedoic acid"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
],
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bempedoic acid"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
],
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
],
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bempedoic acid"
]
],
[
[
"Methotrexate",
"{u} (Compound) binds {v} (Gene)",
"SLCO1A2"
],
[
"SLCO1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Fexofenadine"
],
[
"Fexofenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bempedoic acid"
]
]
] | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Bempedoic acid
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may lead to a major life threatening interaction when taken with Bempedoic acid
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone may lead to a major life threatening interaction when taken with Bempedoic acid
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may lead to a major life threatening interaction when taken with Bempedoic acid
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Bempedoic acid
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide (Compound) resembles Prednisolone (Compound) and Prednisolone may lead to a major life threatening interaction when taken with Bempedoic acid
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Bempedoic acid
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Bempedoic acid
Methotrexate (Compound) binds SLCO1A2 (Gene) and SLCO1A2 (Gene) is bound by Fexofenadine (Compound) and Fexofenadine may cause a moderate interaction that could exacerbate diseases when taken with Bempedoic acid |
DB00295 | DB00980 | 475 | 969 | [
"DDInter1244",
"DDInter1564"
] | Morphine | Ramelteon | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [fentanyl], [methadone], [hydrocodone], [hydromorphone], [meperidine], and [oxycodone]. Morphine was granted FDA approval in 1941. | Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse. | Major | 2 | [
[
[
475,
25,
969
]
],
[
[
475,
6,
8374
],
[
8374,
45,
969
]
],
[
[
475,
21,
28714
],
[
28714,
60,
969
]
],
[
[
475,
24,
100
],
[
100,
24,
969
]
],
[
[
475,
24,
214
],
[
214,
63,
969
]
],
[
[
475,
63,
701
],
[
701,
24,
969
]
],
[
[
475,
6,
8374
],
[
8374,
45,
100
],
[
100,
24,
969
]
],
[
[
475,
21,
28714
],
[
28714,
60,
1242
],
[
1242,
24,
969
]
],
[
[
475,
21,
28876
],
[
28876,
60,
1220
],
[
1220,
63,
969
]
],
[
[
475,
24,
100
],
[
100,
6,
8374
],
[
8374,
45,
969
]
]
] | [
[
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ramelteon"
]
],
[
[
"Morphine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Ramelteon"
]
],
[
[
"Morphine",
"{u} (Compound) causes {v} (Side Effect)",
"Asthenia"
],
[
"Asthenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ramelteon"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ramelteon"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ramelteon"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ramelteon"
]
],
[
[
"Morphine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Brompheniramine"
],
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ramelteon"
]
],
[
[
"Morphine",
"{u} (Compound) causes {v} (Side Effect)",
"Asthenia"
],
[
"Asthenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Cetirizine"
],
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ramelteon"
]
],
[
[
"Morphine",
"{u} (Compound) causes {v} (Side Effect)",
"Anaphylactoid reaction"
],
[
"Anaphylactoid reaction",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ramelteon"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
[
"Brompheniramine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Ramelteon"
]
]
] | Morphine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ramelteon (Compound)
Morphine (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Ramelteon (Compound)
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Ramelteon
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Ramelteon
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Ramelteon
Morphine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Brompheniramine (Compound) and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Ramelteon
Morphine (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Cetirizine (Compound) and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Ramelteon
Morphine (Compound) causes Anaphylactoid reaction (Side Effect) and Anaphylactoid reaction (Side Effect) is caused by Dexamethasone (Compound) and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Ramelteon
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ramelteon (Compound) |
DB12364 | DB12500 | 1,421 | 283 | [
"DDInter200",
"DDInter714"
] | Betrixaban | Fedratinib | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa. It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity. Betrixaban, now developed by Portola Pharmaceuticals Inc., is prescribed as a venous thromboembolism (VTE) prophylactic for adult patients with moderate to severe restricted motility or with other risks for VTE. VTE can be manifested as deep vein thrombosis or pulmonary embolism and it is a leading cause of preventable death in hospitalized patients. | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Major | 2 | [
[
[
1421,
25,
283
]
],
[
[
1421,
63,
1593
],
[
1593,
23,
283
]
],
[
[
1421,
64,
122
],
[
122,
23,
283
]
],
[
[
1421,
24,
1339
],
[
1339,
62,
283
]
],
[
[
1421,
63,
336
],
[
336,
24,
283
]
],
[
[
1421,
64,
885
],
[
885,
24,
283
]
],
[
[
1421,
63,
888
],
[
888,
25,
283
]
],
[
[
1421,
64,
1564
],
[
1564,
25,
283
]
],
[
[
1421,
25,
503
],
[
503,
64,
283
]
],
[
[
1421,
63,
1593
],
[
1593,
23,
271
],
[
271,
23,
283
]
]
] | [
[
[
"Betrixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
],
[
[
"Betrixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fedratinib"
]
],
[
[
"Betrixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Verapamil"
],
[
"Verapamil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fedratinib"
]
],
[
[
"Betrixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Berotralstat"
],
[
"Berotralstat",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fedratinib"
]
],
[
[
"Betrixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nifedipine"
],
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Betrixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Betrixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
],
[
[
"Betrixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Defibrotide"
],
[
"Defibrotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
],
[
[
"Betrixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
],
[
"Zanubrutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
],
[
[
"Betrixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
],
[
"Mirabegron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fedratinib"
]
]
] | Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Betrixaban may lead to a major life threatening interaction when taken with Verapamil and Verapamil may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Berotralstat and Berotralstat may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Betrixaban may lead to a major life threatening interaction when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may lead to a major life threatening interaction when taken with Fedratinib
Betrixaban may lead to a major life threatening interaction when taken with Defibrotide and Defibrotide may lead to a major life threatening interaction when taken with Fedratinib
Betrixaban may lead to a major life threatening interaction when taken with Zanubrutinib and Zanubrutinib may lead to a major life threatening interaction when taken with Fedratinib
Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Fedratinib |
DB09101 | DB12130 | 70 | 1,017 | [
"DDInter633",
"DDInter1094"
] | Elvitegravir | Lorlatinib | Elvitegravir is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI) used for the treatment of HIV-1 infection in antiretroviral treatment-experienced adults. Because integrase is necessary for viral replication, inhibition prevents the integration of HIV-1 DNA into the host genome and thereby blocks the formation of the HIV-1 provirus and resulting propagation of the viral infection. Although available as a single dose tablet, elvitegravir must be used in combination with an HIV protease inhibitor coadministered with ritonavir and another antiretroviral drug. Elvitegravir was first licensed from Japan Tobacco in 2008 and developed by Gilead Sciences. It was FDA approved on August 27, 2012. On September 24, 2014, the FDA approved the single pill form of elvitegravir. | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC. | Moderate | 1 | [
[
[
70,
24,
1017
]
],
[
[
70,
63,
1512
],
[
1512,
24,
1017
]
],
[
[
70,
24,
1320
],
[
1320,
24,
1017
]
],
[
[
70,
63,
1220
],
[
1220,
25,
1017
]
],
[
[
70,
64,
129
],
[
129,
25,
1017
]
],
[
[
70,
25,
1604
],
[
1604,
25,
1017
]
],
[
[
70,
63,
1512
],
[
1512,
63,
590
],
[
590,
24,
1017
]
],
[
[
70,
24,
1320
],
[
1320,
62,
608
],
[
608,
23,
1017
]
],
[
[
70,
63,
303
],
[
303,
64,
1101
],
[
1101,
23,
1017
]
],
[
[
70,
63,
868
],
[
868,
62,
608
],
[
608,
23,
1017
]
]
] | [
[
[
"Elvitegravir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Elvitegravir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Elvitegravir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Elvitegravir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
]
],
[
[
"Elvitegravir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
]
],
[
[
"Elvitegravir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumacaftor"
],
[
"Lumacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
]
],
[
[
"Elvitegravir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetohexamide"
],
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Elvitegravir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
"Elagolix",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lorlatinib"
]
],
[
[
"Elvitegravir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Medroxyprogesterone acetate"
],
[
"Medroxyprogesterone acetate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lorlatinib"
]
],
[
[
"Elvitegravir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lorlatinib"
]
]
] | Elvitegravir may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Elvitegravir may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Elvitegravir may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may lead to a major life threatening interaction when taken with Lorlatinib
Elvitegravir may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Lorlatinib
Elvitegravir may lead to a major life threatening interaction when taken with Lumacaftor and Lumacaftor may lead to a major life threatening interaction when taken with Lorlatinib
Elvitegravir may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Elvitegravir may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Elvitegravir may cause a moderate interaction that could exacerbate diseases when taken with Medroxyprogesterone acetate and Medroxyprogesterone acetate may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Elvitegravir may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Lorlatinib |
DB00414 | DB01406 | 590 | 984 | [
"DDInter16",
"DDInter472"
] | Acetohexamide | Danazol | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders. | Moderate | 1 | [
[
[
590,
24,
984
]
],
[
[
590,
63,
989
],
[
989,
1,
984
]
],
[
[
590,
24,
1546
],
[
1546,
1,
984
]
],
[
[
590,
24,
1026
],
[
1026,
40,
984
]
],
[
[
590,
63,
1336
],
[
1336,
40,
984
]
],
[
[
590,
24,
222
],
[
222,
23,
984
]
],
[
[
590,
24,
127
],
[
127,
24,
984
]
],
[
[
590,
24,
1017
],
[
1017,
63,
984
]
],
[
[
590,
63,
254
],
[
254,
24,
984
]
],
[
[
590,
24,
1377
],
[
1377,
25,
984
]
]
] | [
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Danazol"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Progesterone"
],
[
"Progesterone",
"{u} (Compound) resembles {v} (Compound)",
"Danazol"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyltestosterone"
],
[
"Methyltestosterone",
"{u} (Compound) resembles {v} (Compound)",
"Danazol"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxandrolone"
],
[
"Oxandrolone",
"{u} (Compound) resembles {v} (Compound)",
"Danazol"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etonogestrel"
],
[
"Etonogestrel",
"{u} (Compound) resembles {v} (Compound)",
"Danazol"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Danazol"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miglitol"
],
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Danazol"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Danazol"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitisinone"
],
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Danazol"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Danazol"
]
]
] | Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Progesterone and Progesterone (Compound) resembles Danazol (Compound)
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Methyltestosterone and Methyltestosterone (Compound) resembles Danazol (Compound)
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Oxandrolone and Oxandrolone (Compound) resembles Danazol (Compound)
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Etonogestrel and Etonogestrel (Compound) resembles Danazol (Compound)
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Danazol
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Miglitol and Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Danazol
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Danazol
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Nitisinone and Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Danazol
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Danazol |
DB00635 | DB00800 | 1,573 | 572 | [
"DDInter1515",
"DDInter720"
] | Prednisone | Fenoldopam | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | A dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation. | Moderate | 1 | [
[
[
1573,
24,
572
]
],
[
[
1573,
21,
28931
],
[
28931,
60,
572
]
],
[
[
1573,
1,
1220
],
[
1220,
63,
572
]
],
[
[
1573,
63,
1648
],
[
1648,
24,
572
]
],
[
[
1573,
24,
549
],
[
549,
63,
572
]
],
[
[
1573,
25,
593
],
[
593,
63,
572
]
],
[
[
1573,
40,
167
],
[
167,
24,
572
]
],
[
[
1573,
1,
175
],
[
175,
24,
572
]
],
[
[
1573,
21,
28931
],
[
28931,
60,
1220
],
[
1220,
63,
572
]
],
[
[
1573,
21,
28658
],
[
28658,
60,
274
],
[
274,
24,
572
]
]
] | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenoldopam"
]
],
[
[
"Prednisone",
"{u} (Compound) causes {v} (Side Effect)",
"Haemorrhage"
],
[
"Haemorrhage",
"{u} (Side Effect) is caused by {v} (Compound)",
"Fenoldopam"
]
],
[
[
"Prednisone",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenoldopam"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenoldopam"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
[
"Dapagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenoldopam"
]
],
[
[
"Prednisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenoldopam"
]
],
[
[
"Prednisone",
"{u} (Compound) resembles {v} (Compound)",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenoldopam"
]
],
[
[
"Prednisone",
"{u} (Compound) resembles {v} (Compound)",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenoldopam"
]
],
[
[
"Prednisone",
"{u} (Compound) causes {v} (Side Effect)",
"Haemorrhage"
],
[
"Haemorrhage",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenoldopam"
]
],
[
[
"Prednisone",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caused by {v} (Compound)",
"Phentolamine"
],
[
"Phentolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenoldopam"
]
]
] | Prednisone (Compound) causes Haemorrhage (Side Effect) and Haemorrhage (Side Effect) is caused by Fenoldopam (Compound)
Prednisone (Compound) resembles Dexamethasone (Compound) and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Fenoldopam
Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Fenoldopam
Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Fenoldopam
Prednisone may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Fenoldopam
Prednisone (Compound) resembles Hydrocortisone (Compound) and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Fenoldopam
Prednisone (Compound) resembles Triamcinolone (Compound) and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Fenoldopam
Prednisone (Compound) causes Haemorrhage (Side Effect) and Haemorrhage (Side Effect) is caused by Dexamethasone (Compound) and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Fenoldopam
Prednisone (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Phentolamine (Compound) and Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Fenoldopam |
DB00349 | DB01006 | 902 | 300 | [
"DDInter401",
"DDInter1040"
] | Clobazam | Letrozole | Clobazam belongs to the 1,5-benzodiazepine class of drugs and is marketed under different names, Onfi, Frisium, Urbanyl, and others.. Clobazam was first synthesized in 1966 and first published in 1969, following the incidental synthesis and discovery of the first benzodiazepine chlordiazepoxide in the 1950s. Unlike older 1,4-benzodiazepines, clobazam has a better side-effects profile, particularly less sedative and amnesic effects.[A256963,A256868] This is likely because of clobazam's higher affinity to the α<sub>2</sub> subunit of the GABA<sub>A</sub> receptor, which mediates anxiolytic effects, than the α<sub>1</sub> subunit, which mediates sedative effect. Additionally, clobazam is believed | Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990.[A190543,A1559,L11623,L11626] It is a third generation aromatase inhibitor like [exemestane] and [anastrozole], meaning it does not significantly affect cortisol, aldosterone, and thyroxine. Letrozole was granted FDA approval on 25 July 1997. | Moderate | 1 | [
[
[
902,
24,
300
]
],
[
[
902,
6,
8374
],
[
8374,
45,
300
]
],
[
[
902,
21,
28646
],
[
28646,
60,
300
]
],
[
[
902,
24,
478
],
[
478,
63,
300
]
],
[
[
902,
40,
1335
],
[
1335,
24,
300
]
],
[
[
902,
24,
723
],
[
723,
24,
300
]
],
[
[
902,
24,
770
],
[
770,
64,
300
]
],
[
[
902,
6,
8374
],
[
8374,
45,
11229
],
[
11229,
40,
300
]
],
[
[
902,
21,
28646
],
[
28646,
60,
307
],
[
307,
23,
300
]
],
[
[
902,
21,
29429
],
[
29429,
60,
177
],
[
177,
63,
300
]
]
] | [
[
[
"Clobazam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Letrozole"
]
],
[
[
"Clobazam",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Letrozole"
]
],
[
[
"Clobazam",
"{u} (Compound) causes {v} (Side Effect)",
"Unspecified disorder of skin and subcutaneous tissue"
],
[
"Unspecified disorder of skin and subcutaneous tissue",
"{u} (Side Effect) is caused by {v} (Compound)",
"Letrozole"
]
],
[
[
"Clobazam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Letrozole"
]
],
[
[
"Clobazam",
"{u} (Compound) resembles {v} (Compound)",
"Oxcarbazepine"
],
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Letrozole"
]
],
[
[
"Clobazam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Letrozole"
]
],
[
[
"Clobazam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Letrozole"
]
],
[
[
"Clobazam",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Bifonazole"
],
[
"Bifonazole",
"{u} (Compound) resembles {v} (Compound)",
"Letrozole"
]
],
[
[
"Clobazam",
"{u} (Compound) causes {v} (Side Effect)",
"Unspecified disorder of skin and subcutaneous tissue"
],
[
"Unspecified disorder of skin and subcutaneous tissue",
"{u} (Side Effect) is caused by {v} (Compound)",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Letrozole"
]
],
[
[
"Clobazam",
"{u} (Compound) causes {v} (Side Effect)",
"Infestation NOS"
],
[
"Infestation NOS",
"{u} (Side Effect) is caused by {v} (Compound)",
"Estrone sulfate"
],
[
"Estrone sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Letrozole"
]
]
] | Clobazam (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Letrozole (Compound)
Clobazam (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Letrozole (Compound)
Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Letrozole
Clobazam (Compound) resembles Oxcarbazepine (Compound) and Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Letrozole
Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Letrozole
Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Letrozole
Clobazam (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bifonazole (Compound) and Bifonazole (Compound) resembles Letrozole (Compound)
Clobazam (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Letrozole
Clobazam (Compound) causes Infestation NOS (Side Effect) and Infestation NOS (Side Effect) is caused by Estrone sulfate (Compound) and Estrone sulfate may cause a moderate interaction that could exacerbate diseases when taken with Letrozole |
DB00359 | DB00445 | 161 | 322 | [
"DDInter1721",
"DDInter655"
] | Sulfadiazine | Epirubicin | One of the short-acting sulfonamides used in combination with pyrimethamine to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections. | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Moderate | 1 | [
[
[
161,
24,
322
]
],
[
[
161,
21,
29455
],
[
29455,
60,
322
]
],
[
[
161,
1,
1247
],
[
1247,
62,
322
]
],
[
[
161,
63,
482
],
[
482,
24,
322
]
],
[
[
161,
24,
384
],
[
384,
63,
322
]
],
[
[
161,
1,
698
],
[
698,
63,
322
]
],
[
[
161,
21,
29455
],
[
29455,
60,
1628
],
[
1628,
1,
322
]
],
[
[
161,
1,
1247
],
[
1247,
18,
1918
],
[
1918,
57,
322
]
],
[
[
161,
63,
482
],
[
482,
5,
11555
],
[
11555,
44,
322
]
],
[
[
161,
24,
384
],
[
384,
63,
1247
],
[
1247,
62,
322
]
]
] | [
[
[
"Sulfadiazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
]
],
[
[
"Sulfadiazine",
"{u} (Compound) causes {v} (Side Effect)",
"Agranulocytosis"
],
[
"Agranulocytosis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Epirubicin"
]
],
[
[
"Sulfadiazine",
"{u} (Compound) resembles {v} (Compound)",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Epirubicin"
]
],
[
[
"Sulfadiazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
],
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
]
],
[
[
"Sulfadiazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
]
],
[
[
"Sulfadiazine",
"{u} (Compound) resembles {v} (Compound)",
"Sulfadoxine"
],
[
"Sulfadoxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
]
],
[
[
"Sulfadiazine",
"{u} (Compound) causes {v} (Side Effect)",
"Agranulocytosis"
],
[
"Agranulocytosis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Doxorubicin"
],
[
"Doxorubicin",
"{u} (Compound) resembles {v} (Compound)",
"Epirubicin"
]
],
[
[
"Sulfadiazine",
"{u} (Compound) resembles {v} (Compound)",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} (Compound) downregulates {v} (Gene)",
"PCNA"
],
[
"PCNA",
"{u} (Gene) is downregulated by {v} (Compound)",
"Epirubicin"
]
],
[
[
"Sulfadiazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
],
[
"Tioguanine",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Disease) is treated by {v} (Compound)",
"Epirubicin"
]
],
[
[
"Sulfadiazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Epirubicin"
]
]
] | Sulfadiazine (Compound) causes Agranulocytosis (Side Effect) and Agranulocytosis (Side Effect) is caused by Epirubicin (Compound)
Sulfadiazine (Compound) resembles Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Epirubicin
Sulfadiazine may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin
Sulfadiazine may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin
Sulfadiazine (Compound) resembles Sulfadoxine (Compound) and Sulfadoxine may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin
Sulfadiazine (Compound) causes Agranulocytosis (Side Effect) and Agranulocytosis (Side Effect) is caused by Doxorubicin (Compound) and Doxorubicin (Compound) resembles Epirubicin (Compound)
Sulfadiazine (Compound) resembles Sulfamethoxazole (Compound) and Sulfamethoxazole (Compound) downregulates PCNA (Gene) and PCNA (Gene) is downregulated by Epirubicin (Compound)
Sulfadiazine may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Epirubicin (Compound)
Sulfadiazine may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Epirubicin |
DB06603 | DB08868 | 39 | 1,011 | [
"DDInter1387",
"DDInter737"
] | Panobinostat | Fingolimod | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat is marketed by Novartis under the brand name Farydak. Panobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market. | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially approved by the FDA in 2010. Fingolimod was also studied for the treatment of COVID-19, the disease caused by infection with the SARS-CoV-2 virus.[L12654,L12657] | Major | 2 | [
[
[
39,
25,
1011
]
],
[
[
39,
62,
1247
],
[
1247,
23,
1011
]
],
[
[
39,
24,
578
],
[
578,
23,
1011
]
],
[
[
39,
24,
144
],
[
144,
63,
1011
]
],
[
[
39,
63,
867
],
[
867,
24,
1011
]
],
[
[
39,
24,
1136
],
[
1136,
24,
1011
]
],
[
[
39,
64,
1052
],
[
1052,
24,
1011
]
],
[
[
39,
62,
479
],
[
479,
24,
1011
]
],
[
[
39,
25,
880
],
[
880,
63,
1011
]
],
[
[
39,
64,
876
],
[
876,
25,
1011
]
]
] | [
[
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Panobinostat",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fingolimod"
]
],
[
[
"Panobinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fingolimod"
]
],
[
[
"Panobinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
],
[
"Olodaterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fingolimod"
]
],
[
[
"Panobinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olanzapine"
],
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fingolimod"
]
],
[
[
"Panobinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
],
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fingolimod"
]
],
[
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ritodrine"
],
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fingolimod"
]
],
[
[
"Panobinostat",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fingolimod"
]
],
[
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivabradine"
],
[
"Ivabradine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fingolimod"
]
],
[
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tizanidine"
],
[
"Tizanidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
]
] | Panobinostat may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Fingolimod
Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Fingolimod
Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Olanzapine and Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Denosumab and Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Panobinostat may lead to a major life threatening interaction when taken with Ritodrine and Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Panobinostat may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Panobinostat may lead to a major life threatening interaction when taken with Ivabradine and Ivabradine may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Panobinostat may lead to a major life threatening interaction when taken with Tizanidine and Tizanidine may lead to a major life threatening interaction when taken with Fingolimod |
DB00700 | DB01246 | 312 | 820 | [
"DDInter656",
"DDInter45"
] | Eplerenone | Alimemazine | Eplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. The resulting increased plasma renin activity and aldosterone circulating levels do not overcome the effects of eplerenone. Eplerenone selectively binds to recombinant human mineralocorticoid receptors relative to its binding to recombinant human glucocorticoid, progesterone and androgen receptors. | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
312,
24,
820
]
],
[
[
312,
24,
104
],
[
104,
40,
820
]
],
[
[
312,
24,
401
],
[
401,
24,
820
]
],
[
[
312,
6,
8374
],
[
8374,
45,
820
]
],
[
[
312,
21,
28666
],
[
28666,
60,
820
]
],
[
[
312,
63,
1614
],
[
1614,
24,
820
]
],
[
[
312,
24,
433
],
[
433,
63,
820
]
],
[
[
312,
40,
443
],
[
443,
24,
820
]
],
[
[
312,
23,
129
],
[
129,
63,
820
]
],
[
[
312,
25,
609
],
[
609,
24,
820
]
]
] | [
[
[
"Eplerenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Eplerenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} (Compound) resembles {v} (Compound)",
"Alimemazine"
]
],
[
[
"Eplerenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Eplerenone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Alimemazine"
]
],
[
[
"Eplerenone",
"{u} (Compound) causes {v} (Side Effect)",
"Nervous system disorder"
],
[
"Nervous system disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Alimemazine"
]
],
[
[
"Eplerenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
],
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Eplerenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
],
[
"Ertugliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Eplerenone",
"{u} (Compound) resembles {v} (Compound)",
"Spironolactone"
],
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Eplerenone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Eplerenone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
]
] | Eplerenone may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Alimemazine (Compound)
Eplerenone may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine
Eplerenone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Alimemazine (Compound)
Eplerenone (Compound) causes Nervous system disorder (Side Effect) and Nervous system disorder (Side Effect) is caused by Alimemazine (Compound)
Eplerenone may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine
Eplerenone may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin and Ertugliflozin may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine
Eplerenone (Compound) resembles Spironolactone (Compound) and Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine
Eplerenone may cause a minor interaction that can limit clinical effects when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine
Eplerenone may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine |
DB00889 | DB08875 | 1,133 | 1,618 | [
"DDInter840",
"DDInter262"
] | Granisetron | Cabozantinib | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019 for the treatment of hepatocellular carcinoma in previously treated patients.[L15128,L15133] | Major | 2 | [
[
[
1133,
25,
1618
]
],
[
[
1133,
23,
112
],
[
112,
23,
1618
]
],
[
[
1133,
24,
384
],
[
384,
63,
1618
]
],
[
[
1133,
62,
307
],
[
307,
24,
1618
]
],
[
[
1133,
24,
805
],
[
805,
24,
1618
]
],
[
[
1133,
63,
355
],
[
355,
24,
1618
]
],
[
[
1133,
25,
41
],
[
41,
63,
1618
]
],
[
[
1133,
25,
222
],
[
222,
24,
1618
]
],
[
[
1133,
64,
529
],
[
529,
24,
1618
]
],
[
[
1133,
63,
322
],
[
322,
25,
1618
]
]
] | [
[
[
"Granisetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Granisetron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cabozantinib"
]
],
[
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Granisetron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dalfopristin"
],
[
"Dalfopristin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
],
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Granisetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levomilnacipran"
],
[
"Levomilnacipran",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Granisetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Granisetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluvoxamine"
],
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
]
] | Granisetron may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Granisetron may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Dalfopristin and Dalfopristin may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Granisetron may lead to a major life threatening interaction when taken with Levomilnacipran and Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Granisetron may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Granisetron may lead to a major life threatening interaction when taken with Fluvoxamine and Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may lead to a major life threatening interaction when taken with Cabozantinib |
DB00991 | DB06715 | 97 | 239 | [
"DDInter1358",
"DDInter1500"
] | Oxaprozin | Potassium Iodide | Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. | Saturated solution of Potassium Iodide (SSKI) is used pharmaceutically for emergency use in patients experiencing acute symptoms of severe hyperthyroidism (also known as thyroid storm or thyrotoxic crisis). SSKI can also be used for radioiodine-contamination emergencies or in preparation of thyrotoxic patients for thyroidectomy. | Moderate | 1 | [
[
[
97,
24,
239
]
],
[
[
97,
21,
29196
],
[
29196,
60,
239
]
],
[
[
97,
24,
877
],
[
877,
63,
239
]
],
[
[
97,
63,
1274
],
[
1274,
24,
239
]
],
[
[
97,
40,
998
],
[
998,
24,
239
]
],
[
[
97,
24,
848
],
[
848,
24,
239
]
],
[
[
97,
21,
29196
],
[
29196,
60,
1171
],
[
1171,
24,
239
]
],
[
[
97,
24,
877
],
[
877,
63,
116
],
[
116,
63,
239
]
],
[
[
97,
63,
1274
],
[
1274,
21,
29196
],
[
29196,
60,
239
]
],
[
[
97,
40,
998
],
[
998,
63,
1274
],
[
1274,
24,
239
]
]
] | [
[
[
"Oxaprozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Potassium Iodide"
]
],
[
[
"Oxaprozin",
"{u} (Compound) causes {v} (Side Effect)",
"Paraesthesia"
],
[
"Paraesthesia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Potassium Iodide"
]
],
[
[
"Oxaprozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Potassium Iodide"
]
],
[
[
"Oxaprozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Potassium Iodide"
]
],
[
[
"Oxaprozin",
"{u} (Compound) resembles {v} (Compound)",
"Phenylbutazone"
],
[
"Phenylbutazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Potassium Iodide"
]
],
[
[
"Oxaprozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Potassium Iodide"
]
],
[
[
"Oxaprozin",
"{u} (Compound) causes {v} (Side Effect)",
"Paraesthesia"
],
[
"Paraesthesia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Meloxicam"
],
[
"Meloxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Potassium Iodide"
]
],
[
[
"Oxaprozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-131"
],
[
"Iodide I-131",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Potassium Iodide"
]
],
[
[
"Oxaprozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} (Compound) causes {v} (Side Effect)",
"Paraesthesia"
],
[
"Paraesthesia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Potassium Iodide"
]
],
[
[
"Oxaprozin",
"{u} (Compound) resembles {v} (Compound)",
"Phenylbutazone"
],
[
"Phenylbutazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Potassium Iodide"
]
]
] | Oxaprozin (Compound) causes Paraesthesia (Side Effect) and Paraesthesia (Side Effect) is caused by Potassium Iodide (Compound)
Oxaprozin may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin and Macimorelin may cause a moderate interaction that could exacerbate diseases when taken with Potassium Iodide
Oxaprozin may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Potassium Iodide
Oxaprozin (Compound) resembles Phenylbutazone (Compound) and Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Potassium Iodide
Oxaprozin may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Potassium Iodide
Oxaprozin (Compound) causes Paraesthesia (Side Effect) and Paraesthesia (Side Effect) is caused by Meloxicam (Compound) and Meloxicam may cause a moderate interaction that could exacerbate diseases when taken with Potassium Iodide
Oxaprozin may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin and Macimorelin may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131 and Iodide I-131 may cause a moderate interaction that could exacerbate diseases when taken with Potassium Iodide
Oxaprozin may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen (Compound) causes Paraesthesia (Side Effect) and Paraesthesia (Side Effect) is caused by Potassium Iodide (Compound)
Oxaprozin (Compound) resembles Phenylbutazone (Compound) and Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Potassium Iodide |
DB00215 | DB12141 | 1,230 | 971 | [
"DDInter388",
"DDInter817"
] | Citalopram | Gilteritinib | Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] Citalopram enhances serotonergic transmission through the inhibition of serotonin reuptake, and among all the SSRIs, citalopram appears to be the most selective toward serotonin reuptake inhibition.[A261316,A14720] Specifically, it has a very minimal effect on dopamine and norepinephrine transportation and virtually no affinity for muscarinic, histaminergic, or GABAergic receptors. Citalopram was approved by the FDA in 1998 for the treatment of depression in adults 18 years or older. | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies. Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018. This drug was approved after being designed as an orphan drug with a fast track and priority review status. | Major | 2 | [
[
[
1230,
25,
971
]
],
[
[
1230,
23,
112
],
[
112,
23,
971
]
],
[
[
1230,
25,
485
],
[
485,
24,
971
]
],
[
[
1230,
25,
823
],
[
823,
63,
971
]
],
[
[
1230,
24,
1409
],
[
1409,
24,
971
]
],
[
[
1230,
23,
597
],
[
597,
24,
971
]
],
[
[
1230,
24,
1421
],
[
1421,
63,
971
]
],
[
[
1230,
64,
600
],
[
600,
24,
971
]
],
[
[
1230,
23,
159
],
[
159,
63,
971
]
],
[
[
1230,
25,
1425
],
[
1425,
25,
971
]
]
] | [
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gilteritinib"
]
],
[
[
"Citalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gilteritinib"
]
],
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pentamidine"
],
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triclabendazole"
],
[
"Triclabendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
],
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Citalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
],
[
"Betrixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Citalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisapride"
],
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gilteritinib"
]
]
] | Citalopram may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Citalopram may lead to a major life threatening interaction when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Citalopram may lead to a major life threatening interaction when taken with Triclabendazole and Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Apixaban and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Citalopram may cause a minor interaction that can limit clinical effects when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban and Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Citalopram may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Citalopram may cause a minor interaction that can limit clinical effects when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Citalopram may lead to a major life threatening interaction when taken with Cisapride and Cisapride may lead to a major life threatening interaction when taken with Gilteritinib |
DB00334 | DB12141 | 867 | 971 | [
"DDInter1326",
"DDInter817"
] | Olanzapine | Gilteritinib | Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug interactions. Olanzapine very closely resembles [clozapine] and only differs by two additional methyl groups and the absence of a chloride moiety. It was discovered by scientists at Eli Lilly and approved to be marketed in the US in 1996. | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies. Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018. This drug was approved after being designed as an orphan drug with a fast track and priority review status. | Moderate | 1 | [
[
[
867,
24,
971
]
],
[
[
867,
23,
112
],
[
112,
23,
971
]
],
[
[
867,
24,
485
],
[
485,
24,
971
]
],
[
[
867,
24,
823
],
[
823,
63,
971
]
],
[
[
867,
63,
1645
],
[
1645,
24,
971
]
],
[
[
867,
1,
623
],
[
623,
24,
971
]
],
[
[
867,
64,
475
],
[
475,
24,
971
]
],
[
[
867,
24,
1425
],
[
1425,
25,
971
]
],
[
[
867,
24,
982
],
[
982,
64,
971
]
],
[
[
867,
1,
695
],
[
695,
25,
971
]
]
] | [
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Olanzapine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gilteritinib"
]
],
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
],
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
],
[
"Triclabendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metformin"
],
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Olanzapine",
"{u} (Compound) resembles {v} (Compound)",
"Quetiapine"
],
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Olanzapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisapride"
],
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gilteritinib"
]
],
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gilteritinib"
]
],
[
[
"Olanzapine",
"{u} (Compound) resembles {v} (Compound)",
"Clozapine"
],
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gilteritinib"
]
]
] | Olanzapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole and Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Olanzapine (Compound) resembles Quetiapine (Compound) and Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Olanzapine may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Cisapride and Cisapride may lead to a major life threatening interaction when taken with Gilteritinib
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Gilteritinib
Olanzapine (Compound) resembles Clozapine (Compound) and Clozapine may lead to a major life threatening interaction when taken with Gilteritinib |
DB01124 | DB01175 | 1,411 | 318 | [
"DDInter1828",
"DDInter672"
] | Tolbutamide | Escitalopram | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer.[A39738,A185819] Amongst SSRIs, escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in this class. Escitalopram also differentiates itself from other SSRIs via allosteric action on its target - this may be the mechanism responsible for its observed superior efficacy and faster onset compared to other SSRIs.[A185825,A185726,A185822] | Moderate | 1 | [
[
[
1411,
24,
318
]
],
[
[
1411,
63,
1230
],
[
1230,
1,
318
]
],
[
[
1411,
6,
10215
],
[
10215,
45,
318
]
],
[
[
1411,
21,
28725
],
[
28725,
60,
318
]
],
[
[
1411,
64,
86
],
[
86,
23,
318
]
],
[
[
1411,
63,
168
],
[
168,
23,
318
]
],
[
[
1411,
24,
1478
],
[
1478,
62,
318
]
],
[
[
1411,
63,
999
],
[
999,
24,
318
]
],
[
[
1411,
1,
245
],
[
245,
24,
318
]
],
[
[
1411,
24,
98
],
[
98,
63,
318
]
]
] | [
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
],
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Citalopram"
],
[
"Citalopram",
"{u} (Compound) resembles {v} (Compound)",
"Escitalopram"
]
],
[
[
"Tolbutamide",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",
"Escitalopram"
]
],
[
[
"Tolbutamide",
"{u} (Compound) causes {v} (Side Effect)",
"Pancytopenia"
],
[
"Pancytopenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Escitalopram"
]
],
[
[
"Tolbutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Miconazole"
],
[
"Miconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Escitalopram"
]
],
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Escitalopram"
]
],
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Escitalopram"
]
],
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
],
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
],
[
[
"Tolbutamide",
"{u} (Compound) resembles {v} (Compound)",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
],
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
],
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
]
] | Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram (Compound) resembles Escitalopram (Compound)
Tolbutamide (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Escitalopram (Compound)
Tolbutamide (Compound) causes Pancytopenia (Side Effect) and Pancytopenia (Side Effect) is caused by Escitalopram (Compound)
Tolbutamide may lead to a major life threatening interaction when taken with Miconazole and Miconazole may cause a minor interaction that can limit clinical effects when taken with Escitalopram
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Escitalopram
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a minor interaction that can limit clinical effects when taken with Escitalopram
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram
Tolbutamide (Compound) resembles Glimepiride (Compound) and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram |
DB00705 | DB01390 | 441 | 1,117 | [
"DDInter496",
"DDInter1683"
] | Delavirdine | Sodium bicarbonate | A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. | Sodium bicarbonate is a white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions. | Moderate | 1 | [
[
[
441,
24,
1117
]
],
[
[
441,
21,
29093
],
[
29093,
60,
1117
]
],
[
[
441,
24,
1220
],
[
1220,
23,
1117
]
],
[
[
441,
63,
1127
],
[
1127,
23,
1117
]
],
[
[
441,
64,
175
],
[
175,
23,
1117
]
],
[
[
441,
25,
263
],
[
263,
62,
1117
]
],
[
[
441,
25,
1486
],
[
1486,
23,
1117
]
],
[
[
441,
25,
1213
],
[
1213,
24,
1117
]
],
[
[
441,
25,
594
],
[
594,
63,
1117
]
],
[
[
441,
24,
1040
],
[
1040,
63,
1117
]
]
] | [
[
[
"Delavirdine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium bicarbonate"
]
],
[
[
"Delavirdine",
"{u} (Compound) causes {v} (Side Effect)",
"Fatigue"
],
[
"Fatigue",
"{u} (Side Effect) is caused by {v} (Compound)",
"Sodium bicarbonate"
]
],
[
[
"Delavirdine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium bicarbonate"
]
],
[
[
"Delavirdine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nizatidine"
],
[
"Nizatidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium bicarbonate"
]
],
[
[
"Delavirdine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium bicarbonate"
]
],
[
[
"Delavirdine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Axitinib"
],
[
"Axitinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium bicarbonate"
]
],
[
[
"Delavirdine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium bicarbonate"
]
],
[
[
"Delavirdine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium bicarbonate"
]
],
[
[
"Delavirdine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bosutinib"
],
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium bicarbonate"
]
],
[
[
"Delavirdine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium bicarbonate"
]
]
] | Delavirdine (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Sodium bicarbonate (Compound)
Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Sodium bicarbonate
Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Nizatidine and Nizatidine may cause a minor interaction that can limit clinical effects when taken with Sodium bicarbonate
Delavirdine may lead to a major life threatening interaction when taken with Triamcinolone and Triamcinolone may cause a minor interaction that can limit clinical effects when taken with Sodium bicarbonate
Delavirdine may lead to a major life threatening interaction when taken with Axitinib and Axitinib may cause a minor interaction that can limit clinical effects when taken with Sodium bicarbonate
Delavirdine may lead to a major life threatening interaction when taken with Methylprednisolone and Methylprednisolone may cause a minor interaction that can limit clinical effects when taken with Sodium bicarbonate
Delavirdine may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Sodium bicarbonate
Delavirdine may lead to a major life threatening interaction when taken with Bosutinib and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Sodium bicarbonate
Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Sodium bicarbonate |
DB00358 | DB06448 | 1,010 | 171 | [
"DDInter1140",
"DDInter1087"
] | Mefloquine | Lonafarnib | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortality; 90% of deaths from malaria occur in Africa. Individuals at the highest risk for malaria are those in disease naïve populations, children under age 5, refugees in Central and Eastern Africa, nonimmune civilian and military travelers, pregnant women, and immigrants traveling to their place of origin. Mefloquine, commonly known as Lariam, is an antimalarial drug used for the prevention and treatment of malaria caused by infection with Plasmodium vivax and Plasmodium falciparum. The drug was initially discovered by the Walter Reed Army Institute of Research (WRAIR) during a malaria drug discovery program between 196 | Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cutaneous effects, lipoatrophy, alopecia, and a severe failure to thrive; HGPS is uniformly fatal.[A224379, A224384, A224389, A224394, A224399] Mechanistically, HGPS is underpinned by a single heterozygous C-to-T mutation at position 1824 of the _LMNA_ gene, which results in the accumulation of an aberrant farnesylated form of lamin A called progerin in the inner nuclear membrane.[A224379, A224394] Lonafarnib is a farnesyl transferase (FTase) inhibitor (FTI), which reduces the farnesylation of numerous cellular proteins, including progerin; as progerin farnesylation is important for localization to the nuclear membrane, lonafarnib inhibits progerin accumulation and improves symptoms in HGPS patients.[A224379, A224414, A224419, L23414] Merck originally developed Lonafarnib and subsequently licensed it to Eiger Biopharmaceuticals Inc., which currently markets it under the trademark ZOKINVY™.[L23414, L23544] Lonafarnib was granted FDA approval on November 20, 2020, and is the first FDA-approved treatment for HGPS and other related progeroid laminopathies.[L23414, L23549] | Moderate | 1 | [
[
[
1010,
24,
171
]
],
[
[
1010,
24,
888
],
[
888,
24,
171
]
],
[
[
1010,
23,
112
],
[
112,
24,
171
]
],
[
[
1010,
63,
1051
],
[
1051,
24,
171
]
],
[
[
1010,
24,
98
],
[
98,
63,
171
]
],
[
[
1010,
25,
868
],
[
868,
63,
171
]
],
[
[
1010,
25,
1487
],
[
1487,
24,
171
]
],
[
[
1010,
24,
129
],
[
129,
64,
171
]
],
[
[
1010,
25,
1493
],
[
1493,
25,
171
]
],
[
[
1010,
25,
1618
],
[
1618,
64,
171
]
]
] | [
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
]
],
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
]
],
[
[
"Mefloquine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
]
],
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aminoglutethimide"
],
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
]
],
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
],
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
]
],
[
[
"Mefloquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
]
],
[
[
"Mefloquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
]
],
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lonafarnib"
]
],
[
[
"Mefloquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Halofantrine"
],
[
"Halofantrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lonafarnib"
]
],
[
[
"Mefloquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
],
[
"Cabozantinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lonafarnib"
]
]
] | Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Mefloquine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide and Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Mefloquine may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Mefloquine may lead to a major life threatening interaction when taken with Hydroxychloroquine and Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Lonafarnib
Mefloquine may lead to a major life threatening interaction when taken with Halofantrine and Halofantrine may lead to a major life threatening interaction when taken with Lonafarnib
Mefloquine may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may lead to a major life threatening interaction when taken with Lonafarnib |
DB00238 | DB08816 | 188 | 578 | [
"DDInter1285",
"DDInter1802"
] | Nevirapine | Ticagrelor | A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class. | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagrelor was granted EMA approval on 3 December 2010. Ticagrelor was granted FDA approval on 20 July 2011. | Moderate | 1 | [
[
[
188,
24,
578
]
],
[
[
188,
6,
8374
],
[
8374,
45,
578
]
],
[
[
188,
21,
28646
],
[
28646,
60,
578
]
],
[
[
188,
24,
1135
],
[
1135,
62,
578
]
],
[
[
188,
24,
723
],
[
723,
24,
578
]
],
[
[
188,
24,
868
],
[
868,
63,
578
]
],
[
[
188,
23,
1101
],
[
1101,
24,
578
]
],
[
[
188,
25,
313
],
[
313,
63,
578
]
],
[
[
188,
25,
866
],
[
866,
24,
578
]
],
[
[
188,
63,
1324
],
[
1324,
24,
578
]
]
] | [
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Nevirapine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Ticagrelor"
]
],
[
[
"Nevirapine",
"{u} (Compound) causes {v} (Side Effect)",
"Unspecified disorder of skin and subcutaneous tissue"
],
[
"Unspecified disorder of skin and subcutaneous tissue",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ticagrelor"
]
],
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticagrelor"
]
],
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Nevirapine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Nevirapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sonidegib"
],
[
"Sonidegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Nevirapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobimetinib"
],
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
]
] | Nevirapine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ticagrelor (Compound)
Nevirapine (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Ticagrelor (Compound)
Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Nevirapine may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Nevirapine may lead to a major life threatening interaction when taken with Sonidegib and Sonidegib may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Nevirapine may lead to a major life threatening interaction when taken with Cobimetinib and Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor |
DB08816 | DB12674 | 578 | 975 | [
"DDInter1802",
"DDInter1105"
] | Ticagrelor | Lurbinectedin | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagrelor was granted EMA approval on 3 December 2010. Ticagrelor was granted FDA approval on 20 July 2011. | Lurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma, chronic lymphocytic leukemia (CLL), breast cancer, and small-cell lung cancer (SCLC). It is a derivative of the marine-derived agent ecteinascidin ([trabectedin]), an anticancer agent found in extracts of the tunicate _Ecteinascidia turbinata_, with the primary difference being the substitution of the tetrahydroisoquinoline with a tetrahydro β‐carboline that results in increased antitumour activity of lurbinectedin as compared to its predecessor. On June 15, 2020, the FDA granted accelerated approval and orphan drug designation to lurbinectedin for the treatment of adult patients with metastatic SCLC who have experienced disease progression despite therapy with platinum-based agents. This accelerated approval is based on the rate and duration of therapeutic response observed in ongoing clinical trials and is contingent on the verification of these results in confirmatory trials. | Moderate | 1 | [
[
[
578,
24,
975
]
],
[
[
578,
24,
159
],
[
159,
63,
975
]
],
[
[
578,
24,
98
],
[
98,
24,
975
]
],
[
[
578,
63,
147
],
[
147,
24,
975
]
],
[
[
578,
64,
1213
],
[
1213,
24,
975
]
],
[
[
578,
24,
351
],
[
351,
25,
975
]
],
[
[
578,
64,
609
],
[
609,
25,
975
]
],
[
[
578,
25,
1604
],
[
1604,
25,
975
]
],
[
[
578,
23,
1011
],
[
1011,
25,
975
]
],
[
[
578,
63,
1419
],
[
1419,
25,
975
]
]
] | [
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurbinectedin"
]
],
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurbinectedin"
]
],
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
],
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurbinectedin"
]
],
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
],
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurbinectedin"
]
],
[
[
"Ticagrelor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurbinectedin"
]
],
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lurbinectedin"
]
],
[
[
"Ticagrelor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lurbinectedin"
]
],
[
[
"Ticagrelor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumacaftor"
],
[
"Lumacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lurbinectedin"
]
],
[
[
"Ticagrelor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lurbinectedin"
]
],
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lurbinectedin"
]
]
] | Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Ticagrelor may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Lurbinectedin
Ticagrelor may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Lurbinectedin
Ticagrelor may lead to a major life threatening interaction when taken with Lumacaftor and Lumacaftor may lead to a major life threatening interaction when taken with Lurbinectedin
Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Lurbinectedin
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may lead to a major life threatening interaction when taken with Lurbinectedin |
DB00598 | DB08884 | 1,523 | 796 | [
"DDInter1013",
"DDInter800"
] | Labetalol | Gadoxetic acid | Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture. Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984. | Gadoxetic acid (gadoxetate) is a paramagnetic gadolinium-containing ionic linear contrast agent in which its salt form, gadoxetate disodium, is used for intravenous injection. Ethoxybenzyl diethylenetriaminepentaacetic acid is the moiety that chelates with a gadolinium ion and forms a stable complex with it to make up the drug. Gadoxetate is a unique gadolinium-based contrasting agent (GBCA) with both dynamic phase and hepatobiliary phase and thus has different pharmacokinetic and pharmacodynamic properties compared to other GBCAs. Since gadoxetate uptake is mediated by organic anion-transporting polypeptides (OATPs) and liver tumor cells lack OATPs, liver tumors show a lack of contrast of enhancement and therefore heightening the liver parenchyma-liver tumours contrast. Gadoxetic acid, under the form gadoxetate disodium, is marketed by Bayer HealthCare Pharmaceuticals under the brand name EOVIST and FDA approved in 2008. | Moderate | 1 | [
[
[
1523,
24,
796
]
],
[
[
1523,
63,
457
],
[
457,
1,
796
]
],
[
[
1523,
24,
1106
],
[
1106,
1,
796
]
],
[
[
1523,
21,
28841
],
[
28841,
60,
796
]
],
[
[
1523,
63,
457
],
[
457,
40,
1106
],
[
1106,
1,
796
]
],
[
[
1523,
24,
1106
],
[
1106,
1,
457
],
[
457,
1,
796
]
],
[
[
1523,
21,
28841
],
[
28841,
60,
457
],
[
457,
1,
796
]
],
[
[
1523,
21,
28886
],
[
28886,
60,
88
],
[
88,
24,
796
]
],
[
[
1523,
24,
1106
],
[
1106,
21,
28991
],
[
28991,
60,
796
]
],
[
[
1523,
24,
1431
],
[
1431,
40,
622
],
[
622,
1,
796
]
]
] | [
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadoxetic acid"
]
],
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadodiamide"
],
[
"Gadodiamide",
"{u} (Compound) resembles {v} (Compound)",
"Gadoxetic acid"
]
],
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadofosveset trisodium"
],
[
"Gadofosveset trisodium",
"{u} (Compound) resembles {v} (Compound)",
"Gadoxetic acid"
]
],
[
[
"Labetalol",
"{u} (Compound) causes {v} (Side Effect)",
"Bronchospasm"
],
[
"Bronchospasm",
"{u} (Side Effect) is caused by {v} (Compound)",
"Gadoxetic acid"
]
],
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadodiamide"
],
[
"Gadodiamide",
"{u} (Compound) resembles {v} (Compound)",
"Gadofosveset trisodium"
],
[
"Gadofosveset trisodium",
"{u} (Compound) resembles {v} (Compound)",
"Gadoxetic acid"
]
],
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadofosveset trisodium"
],
[
"Gadofosveset trisodium",
"{u} (Compound) resembles {v} (Compound)",
"Gadodiamide"
],
[
"Gadodiamide",
"{u} (Compound) resembles {v} (Compound)",
"Gadoxetic acid"
]
],
[
[
"Labetalol",
"{u} (Compound) causes {v} (Side Effect)",
"Bronchospasm"
],
[
"Bronchospasm",
"{u} (Side Effect) is caused by {v} (Compound)",
"Gadodiamide"
],
[
"Gadodiamide",
"{u} (Compound) resembles {v} (Compound)",
"Gadoxetic acid"
]
],
[
[
"Labetalol",
"{u} (Compound) causes {v} (Side Effect)",
"Respiratory distress"
],
[
"Respiratory distress",
"{u} (Side Effect) is caused by {v} (Compound)",
"Metoprolol"
],
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadoxetic acid"
]
],
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadofosveset trisodium"
],
[
"Gadofosveset trisodium",
"{u} (Compound) causes {v} (Side Effect)",
"Gastric irritation"
],
[
"Gastric irritation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Gadoxetic acid"
]
],
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadopentetic acid"
],
[
"Gadopentetic acid",
"{u} (Compound) resembles {v} (Compound)",
"Gadoversetamide"
],
[
"Gadoversetamide",
"{u} (Compound) resembles {v} (Compound)",
"Gadoxetic acid"
]
]
] | Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Gadodiamide and Gadodiamide (Compound) resembles Gadoxetic acid (Compound)
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Gadofosveset trisodium and Gadofosveset trisodium (Compound) resembles Gadoxetic acid (Compound)
Labetalol (Compound) causes Bronchospasm (Side Effect) and Bronchospasm (Side Effect) is caused by Gadoxetic acid (Compound)
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Gadodiamide and Gadodiamide (Compound) resembles Gadofosveset trisodium (Compound) and Gadofosveset trisodium (Compound) resembles Gadoxetic acid (Compound)
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Gadofosveset trisodium and Gadofosveset trisodium (Compound) resembles Gadodiamide (Compound) and Gadodiamide (Compound) resembles Gadoxetic acid (Compound)
Labetalol (Compound) causes Bronchospasm (Side Effect) and Bronchospasm (Side Effect) is caused by Gadodiamide (Compound) and Gadodiamide (Compound) resembles Gadoxetic acid (Compound)
Labetalol (Compound) causes Respiratory distress (Side Effect) and Respiratory distress (Side Effect) is caused by Metoprolol (Compound) and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Gadoxetic acid
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Gadofosveset trisodium and Gadofosveset trisodium (Compound) causes Gastric irritation (Side Effect) and Gastric irritation (Side Effect) is caused by Gadoxetic acid (Compound)
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Gadopentetic acid and Gadopentetic acid (Compound) resembles Gadoversetamide (Compound) and Gadoversetamide (Compound) resembles Gadoxetic acid (Compound) |
DB06723 | DB14491 | 115 | 428 | [
"DDInter58",
"DDInter725"
] | Aluminum hydroxide | Ferrous fumarate | Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects. | Used in treatment of iron deficiency anemia. | Moderate | 1 | [
[
[
115,
24,
428
]
],
[
[
115,
63,
1096
],
[
1096,
23,
428
]
],
[
[
115,
62,
752
],
[
752,
23,
428
]
],
[
[
115,
63,
1008
],
[
1008,
24,
428
]
],
[
[
115,
24,
133
],
[
133,
24,
428
]
],
[
[
115,
25,
1475
],
[
1475,
24,
428
]
],
[
[
115,
62,
1191
],
[
1191,
24,
428
]
],
[
[
115,
64,
1231
],
[
1231,
24,
428
]
],
[
[
115,
25,
1459
],
[
1459,
25,
428
]
],
[
[
115,
63,
1096
],
[
1096,
23,
1193
],
[
1193,
23,
428
]
]
] | [
[
[
"Aluminum hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous fumarate"
]
],
[
[
"Aluminum hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ferrous fumarate"
]
],
[
[
"Aluminum hydroxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ferrous fumarate"
]
],
[
[
"Aluminum hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risedronic acid"
],
[
"Risedronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous fumarate"
]
],
[
[
"Aluminum hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Baloxavir marboxil"
],
[
"Baloxavir marboxil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous fumarate"
]
],
[
[
"Aluminum hydroxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sodium citrate"
],
[
"Sodium citrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous fumarate"
]
],
[
[
"Aluminum hydroxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Levodopa"
],
[
"Levodopa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous fumarate"
]
],
[
[
"Aluminum hydroxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tolevamer"
],
[
"Tolevamer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous fumarate"
]
],
[
[
"Aluminum hydroxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolutegravir"
],
[
"Dolutegravir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ferrous fumarate"
]
],
[
[
"Aluminum hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ferrous fumarate"
]
]
] | Aluminum hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Ferrous fumarate
Aluminum hydroxide may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Ferrous fumarate
Aluminum hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Risedronic acid and Risedronic acid may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate
Aluminum hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Baloxavir marboxil and Baloxavir marboxil may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate
Aluminum hydroxide may lead to a major life threatening interaction when taken with Sodium citrate and Sodium citrate may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate
Aluminum hydroxide may cause a minor interaction that can limit clinical effects when taken with Levodopa and Levodopa may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate
Aluminum hydroxide may lead to a major life threatening interaction when taken with Tolevamer and Tolevamer may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate
Aluminum hydroxide may lead to a major life threatening interaction when taken with Dolutegravir and Dolutegravir may lead to a major life threatening interaction when taken with Ferrous fumarate
Aluminum hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Ferrous fumarate |
DB00295 | DB01159 | 475 | 419 | [
"DDInter1244",
"DDInter854"
] | Morphine | Halothane | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [fentanyl], [methadone], [hydrocodone], [hydromorphone], [meperidine], and [oxycodone]. Morphine was granted FDA approval in 1941. | A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required. (From AMA Drug Evaluations Annual, 1994, p178) | Moderate | 1 | [
[
[
475,
24,
419
]
],
[
[
475,
24,
1280
],
[
1280,
1,
419
]
],
[
[
475,
6,
8374
],
[
8374,
45,
419
]
],
[
[
475,
24,
256
],
[
256,
62,
419
]
],
[
[
475,
24,
971
],
[
971,
63,
419
]
],
[
[
475,
24,
1264
],
[
1264,
24,
419
]
],
[
[
475,
23,
1425
],
[
1425,
25,
419
]
],
[
[
475,
24,
1166
],
[
1166,
25,
419
]
],
[
[
475,
24,
1280
],
[
1280,
6,
1829
],
[
1829,
45,
419
]
],
[
[
475,
6,
8374
],
[
8374,
45,
256
],
[
256,
62,
419
]
]
] | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Halothane"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoflurane"
],
[
"Isoflurane",
"{u} (Compound) resembles {v} (Compound)",
"Halothane"
]
],
[
[
"Morphine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Halothane"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prasugrel"
],
[
"Prasugrel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Halothane"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Halothane"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Halothane"
]
],
[
[
"Morphine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cisapride"
],
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Halothane"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dolasetron"
],
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Halothane"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoflurane"
],
[
"Isoflurane",
"{u} (Compound) binds {v} (Gene)",
"ALB"
],
[
"ALB",
"{u} (Gene) is bound by {v} (Compound)",
"Halothane"
]
],
[
[
"Morphine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Prasugrel"
],
[
"Prasugrel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Halothane"
]
]
] | Morphine may cause a moderate interaction that could exacerbate diseases when taken with Isoflurane and Isoflurane (Compound) resembles Halothane (Compound)
Morphine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Halothane (Compound)
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel and Prasugrel may cause a minor interaction that can limit clinical effects when taken with Halothane
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Halothane
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Halothane
Morphine may cause a minor interaction that can limit clinical effects when taken with Cisapride and Cisapride may lead to a major life threatening interaction when taken with Halothane
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Dolasetron and Dolasetron may lead to a major life threatening interaction when taken with Halothane
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Isoflurane and Isoflurane (Compound) binds ALB (Gene) and ALB (Gene) is bound by Halothane (Compound)
Morphine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Prasugrel (Compound) and Prasugrel may cause a minor interaction that can limit clinical effects when taken with Halothane |
DB00865 | DB09241 | 939 | 1,629 | [
"DDInter187",
"DDInter1186"
] | Benzphetamine | Methylene blue | A sympathomimetic agent with properties similar to dextroamphetamine. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222) | Methylene blue is an oxidation-reduction agent. The intravenous form of methylene blue is approved by the FDA for the treatment of pediatric and adult patients with acquired methemoglobinemia. Historically, it has been widely used in Africa to treat malaria, but now it disappeared when chloroquine (CQ) and other drugs entered the market. Its use as an urinary tract antiseptic has also been investigated. Methylthioninium chloride (INN, or methylene blue, proposed trade name Rember) is an investigational drug being developed by the University of Aberdeen and TauRx Therapeutics that has been shown in early clinical trials to be an inhibitor of Tau protein aggregation. The drug is of potential interest for the treatment of patients with Alzheimer's disease. | Major | 2 | [
[
[
939,
25,
1629
]
],
[
[
939,
24,
1148
],
[
1148,
24,
1629
]
],
[
[
939,
63,
1674
],
[
1674,
24,
1629
]
],
[
[
939,
64,
73
],
[
73,
25,
1629
]
],
[
[
939,
40,
93
],
[
93,
25,
1629
]
],
[
[
939,
63,
1445
],
[
1445,
25,
1629
]
],
[
[
939,
1,
1405
],
[
1405,
25,
1629
]
],
[
[
939,
24,
468
],
[
468,
25,
1629
]
],
[
[
939,
25,
593
],
[
593,
25,
1629
]
],
[
[
939,
37,
247
],
[
247,
25,
1629
]
]
] | [
[
[
"Benzphetamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
]
],
[
[
"Benzphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylene blue"
]
],
[
[
"Benzphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orciprenaline"
],
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylene blue"
]
],
[
[
"Benzphetamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phentermine"
],
[
"Phentermine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
]
],
[
[
"Benzphetamine",
"{u} (Compound) resembles {v} (Compound)",
"Dextroamphetamine"
],
[
"Dextroamphetamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
]
],
[
[
"Benzphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pseudoephedrine"
],
[
"Pseudoephedrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
]
],
[
[
"Benzphetamine",
"{u} (Compound) resembles {v} (Compound)",
"Cyclobenzaprine"
],
[
"Cyclobenzaprine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
]
],
[
[
"Benzphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isometheptene"
],
[
"Isometheptene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
]
],
[
[
"Benzphetamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
]
],
[
[
"Benzphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Iobenguane"
],
[
"Iobenguane",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
]
]
] | Benzphetamine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue
Benzphetamine may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline and Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue
Benzphetamine may lead to a major life threatening interaction when taken with Phentermine and Phentermine may lead to a major life threatening interaction when taken with Methylene blue
Benzphetamine (Compound) resembles Dextroamphetamine (Compound) and Dextroamphetamine may lead to a major life threatening interaction when taken with Methylene blue
Benzphetamine may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine may lead to a major life threatening interaction when taken with Methylene blue
Benzphetamine (Compound) resembles Cyclobenzaprine (Compound) and Cyclobenzaprine may lead to a major life threatening interaction when taken with Methylene blue
Benzphetamine may cause a moderate interaction that could exacerbate diseases when taken with Isometheptene and Isometheptene may lead to a major life threatening interaction when taken with Methylene blue
Benzphetamine may lead to a major life threatening interaction when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Methylene blue
Benzphetamine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Benzphetamine may lead to a major life threatening interaction when taken with Iobenguane and Iobenguane may lead to a major life threatening interaction when taken with Methylene blue |
DB01097 | DB11760 | 1,377 | 119 | [
"DDInter1033",
"DDInter1742"
] | Leflunomide | Talazoparib | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair. Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 and by the EMA in June 2019. It was approved by Health Canada in September 2020. Talazoparib is currently used in the treatment of BRCA-mutated breast cancer and HRR-mutated prostate cancer.[L47236, L47301, L47306] | Major | 2 | [
[
[
1377,
25,
119
]
],
[
[
1377,
64,
66
],
[
66,
24,
119
]
],
[
[
1377,
24,
1129
],
[
1129,
63,
119
]
],
[
[
1377,
25,
713
],
[
713,
24,
119
]
],
[
[
1377,
24,
1367
],
[
1367,
24,
119
]
],
[
[
1377,
25,
287
],
[
287,
63,
119
]
],
[
[
1377,
63,
597
],
[
597,
24,
119
]
],
[
[
1377,
25,
1137
],
[
1137,
25,
119
]
],
[
[
1377,
25,
779
],
[
779,
64,
119
]
],
[
[
1377,
64,
1066
],
[
1066,
25,
119
]
]
] | [
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Talazoparib"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
],
[
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
],
[
"Human adenovirus e serotype 4 strain cl-68578 antigen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dimethyl fumarate"
],
[
"Dimethyl fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
],
[
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
],
[
"Hepatitis B Vaccine (Recombinant)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diroximel fumarate"
],
[
"Diroximel fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
],
[
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Measles virus vaccine live attenuated"
],
[
"Measles virus vaccine live attenuated",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Talazoparib"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
],
[
"Smallpox (Vaccinia) Vaccine, Live",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Talazoparib"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Talazoparib"
]
]
] | Leflunomide may lead to a major life threatening interaction when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen and Human adenovirus e serotype 4 strain cl-68578 antigen may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Leflunomide may lead to a major life threatening interaction when taken with Dimethyl fumarate and Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant) and Hepatitis B Vaccine (Recombinant) may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Leflunomide may lead to a major life threatening interaction when taken with Diroximel fumarate and Diroximel fumarate may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Leflunomide may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated and Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken with Talazoparib
Leflunomide may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live and Smallpox (Vaccinia) Vaccine, Live may lead to a major life threatening interaction when taken with Talazoparib
Leflunomide may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Talazoparib |
DB00047 | DB06718 | 176 | 1,687 | [
"DDInter932",
"DDInter1709"
] | Insulin glargine | Stanozolol | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis. Insulin is an important treatment in the management of Type 1 Diabetes (T1D), which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to produce or | Stanozolol is a synthetic anabolic steroid with therapeutic uses in treating hereditary angioedema. Stanozolol is derived from testosterone, and has been abused by several high profile professional athletes. | Moderate | 1 | [
[
[
176,
24,
1687
]
],
[
[
176,
24,
1197
],
[
1197,
1,
1687
]
],
[
[
176,
24,
1561
],
[
1561,
40,
1687
]
],
[
[
176,
24,
1573
],
[
1573,
24,
1687
]
],
[
[
176,
24,
637
],
[
637,
63,
1687
]
],
[
[
176,
63,
305
],
[
305,
24,
1687
]
],
[
[
176,
24,
1197
],
[
1197,
40,
11219
],
[
11219,
1,
1687
]
],
[
[
176,
24,
989
],
[
989,
1,
11219
],
[
11219,
1,
1687
]
],
[
[
176,
24,
1573
],
[
1573,
35,
1546
],
[
1546,
1,
1687
]
],
[
[
176,
24,
1220
],
[
1220,
24,
1546
],
[
1546,
1,
1687
]
]
] | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stanozolol"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norethisterone"
],
[
"Norethisterone",
"{u} (Compound) resembles {v} (Compound)",
"Stanozolol"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Testosterone"
],
[
"Testosterone",
"{u} (Compound) resembles {v} (Compound)",
"Stanozolol"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
],
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stanozolol"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
],
[
"Asparaginase Erwinia chrysanthemi",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stanozolol"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stanozolol"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norethisterone"
],
[
"Norethisterone",
"{u} (Compound) resembles {v} (Compound)",
"Testosterone Propionate"
],
[
"Testosterone Propionate",
"{u} (Compound) resembles {v} (Compound)",
"Stanozolol"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Progesterone"
],
[
"Progesterone",
"{u} (Compound) resembles {v} (Compound)",
"Testosterone Propionate"
],
[
"Testosterone Propionate",
"{u} (Compound) resembles {v} (Compound)",
"Stanozolol"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
],
[
"Prednisone",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyltestosterone"
],
[
"Methyltestosterone",
"{u} (Compound) resembles {v} (Compound)",
"Stanozolol"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyltestosterone"
],
[
"Methyltestosterone",
"{u} (Compound) resembles {v} (Compound)",
"Stanozolol"
]
]
] | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Norethisterone and Norethisterone (Compound) resembles Stanozolol (Compound)
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Testosterone and Testosterone (Compound) resembles Stanozolol (Compound)
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Stanozolol
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi and Asparaginase Erwinia chrysanthemi may cause a moderate interaction that could exacerbate diseases when taken with Stanozolol
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Stanozolol
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Norethisterone and Norethisterone (Compound) resembles Testosterone Propionate (Compound) and Testosterone Propionate (Compound) resembles Stanozolol (Compound)
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Progesterone and Progesterone (Compound) resembles Testosterone Propionate (Compound) and Testosterone Propionate (Compound) resembles Stanozolol (Compound)
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone (Compound) resembles Methyltestosterone (Compound) and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Methyltestosterone and Methyltestosterone (Compound) resembles Stanozolol (Compound)
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Methyltestosterone and Methyltestosterone (Compound) resembles Stanozolol (Compound) |
DB00959 | DB06414 | 1,486 | 655 | [
"DDInter1191",
"DDInter703"
] | Methylprednisolone | Etravirine | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was successful in treating COVID-19-associated pneumonia in one patient with long-term immunosuppression. The efficacy of methylprednisolone in novel coronavirus pneumonia is being investigated further in clinical trials. | Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 100mg tablets in the treatment of adult HIV-1 infection documented to be resistant to therapy with other NNRTIs and antiretroviral agents. On March 26, 2012, approval was extended for use in treatment-experienced pediatric patients 6 to 18 years of age, weighing at least 16 kg. Etravarine must always be used in combination with other antiretroviral drugs. Etravirine exerts its effects via direct inhibition of the reverse transcriptase enzyme of human immunodeficiency virus type 1 (HIV-1), and consequently blocks DNA-dependent and RNA-dependent polymerase activity. Etravirine does not inhibit human DNA polymerase alpha, beta or gamma. Common side effects of use include mild to moderate rash within the first 6 weeks of therapy, nausea, diarrhea and peripheral neuropathy. Patients are advised to immediately contact their healthcare provider if a rash develops. In 2009, postmarketing case reports of Stevens-Johnson Syndrome, toxic epidermal necrolysis, erythema multiforme, and other hypersensitivity reactions lead to a revision of etravirine's "Warnings and Precautions," as well as notification of health care providers. In 2013, reports of Autoimmune disorders (such as Graves’ disease, polymyositis, and Guillain-Barré syndrome) in the setting of immune reconstitution, as well as more in depth information about the development of rashes in patients taking etravirine, lead to a modification of etravirine's monograph. | Moderate | 1 | [
[
[
1486,
24,
655
]
],
[
[
1486,
6,
4973
],
[
4973,
45,
655
]
],
[
[
1486,
21,
28723
],
[
28723,
60,
655
]
],
[
[
1486,
63,
1101
],
[
1101,
23,
655
]
],
[
[
1486,
1,
175
],
[
175,
24,
655
]
],
[
[
1486,
64,
1057
],
[
1057,
24,
655
]
],
[
[
1486,
63,
245
],
[
245,
24,
655
]
],
[
[
1486,
40,
1220
],
[
1220,
24,
655
]
],
[
[
1486,
25,
976
],
[
976,
63,
655
]
],
[
[
1486,
24,
478
],
[
478,
24,
655
]
]
] | [
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
]
],
[
[
"Methylprednisolone",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Etravirine"
]
],
[
[
"Methylprednisolone",
"{u} (Compound) causes {v} (Side Effect)",
"Malnutrition"
],
[
"Malnutrition",
"{u} (Side Effect) is caused by {v} (Compound)",
"Etravirine"
]
],
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Etravirine"
]
],
[
[
"Methylprednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
]
],
[
[
"Methylprednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
]
],
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
]
],
[
[
"Methylprednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
]
],
[
[
"Methylprednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
]
],
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
]
]
] | Methylprednisolone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Etravirine (Compound)
Methylprednisolone (Compound) causes Malnutrition (Side Effect) and Malnutrition (Side Effect) is caused by Etravirine (Compound)
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Etravirine
Methylprednisolone (Compound) resembles Triamcinolone (Compound) and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Etravirine
Methylprednisolone may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Etravirine
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Etravirine
Methylprednisolone (Compound) resembles Dexamethasone (Compound) and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Etravirine
Methylprednisolone may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Etravirine
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Etravirine |
DB00443 | DB12010 | 251 | 214 | [
"DDInter195",
"DDInter785"
] | Betamethasone | Fostamatinib | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and negligible mineralocorticoid activity. | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK kinase.[A235008, A235013, A235018] | Moderate | 1 | [
[
[
251,
24,
214
]
],
[
[
251,
25,
976
],
[
976,
24,
214
]
],
[
[
251,
63,
1428
],
[
1428,
24,
214
]
],
[
[
251,
24,
723
],
[
723,
24,
214
]
],
[
[
251,
1,
1573
],
[
1573,
24,
214
]
],
[
[
251,
23,
307
],
[
307,
24,
214
]
],
[
[
251,
40,
167
],
[
167,
24,
214
]
],
[
[
251,
24,
179
],
[
179,
63,
214
]
],
[
[
251,
25,
676
],
[
676,
63,
214
]
],
[
[
251,
62,
523
],
[
523,
24,
214
]
]
] | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Betamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isradipine"
],
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisone"
],
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Betamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telotristat ethyl"
],
[
"Telotristat ethyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Betamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Betamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Alprazolam"
],
[
"Alprazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
]
] | Betamethasone may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Isradipine and Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Betamethasone (Compound) resembles Prednisone (Compound) and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Betamethasone may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Betamethasone (Compound) resembles Hydrocortisone (Compound) and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl and Telotristat ethyl may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Betamethasone may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Betamethasone may cause a minor interaction that can limit clinical effects when taken with Alprazolam and Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib |
DB00877 | DB00991 | 629 | 97 | [
"DDInter1678",
"DDInter1358"
] | Sirolimus | Oxaprozin | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive activities were later discovered, it was extensively investigated as an immunosuppressive and antitumour agent. Its primary mechanism of action is the inhibition of the mammalian target of rapamycin (mTOR), which is a serine/threonine-specific protein kinase that regulates cell growth, proliferation, and survival. mTOR is an important therapeutic target for various diseases, as it was shown to regulate longevity and maintain normal glucose homeostasis. Targeting mTOR received more attention especially in cancer, as mTOR signalling pathways are constitutively activated in | Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. | Major | 2 | [
[
[
629,
25,
97
]
],
[
[
629,
63,
939
],
[
939,
40,
97
]
],
[
[
629,
64,
362
],
[
362,
1,
97
]
],
[
[
629,
64,
1274
],
[
1274,
24,
97
]
],
[
[
629,
63,
307
],
[
307,
1,
97
]
],
[
[
629,
64,
1236
],
[
1236,
40,
97
]
],
[
[
629,
21,
28744
],
[
28744,
60,
97
]
],
[
[
629,
63,
752
],
[
752,
23,
97
]
],
[
[
629,
63,
1555
],
[
1555,
24,
97
]
],
[
[
629,
24,
1486
],
[
1486,
24,
97
]
]
] | [
[
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxaprozin"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzphetamine"
],
[
"Benzphetamine",
"{u} (Compound) resembles {v} (Compound)",
"Oxaprozin"
]
],
[
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} (Compound) resembles {v} (Compound)",
"Oxaprozin"
]
],
[
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaprozin"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} (Compound) resembles {v} (Compound)",
"Oxaprozin"
]
],
[
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} (Compound) resembles {v} (Compound)",
"Oxaprozin"
]
],
[
[
"Sirolimus",
"{u} (Compound) causes {v} (Side Effect)",
"Deafness"
],
[
"Deafness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Oxaprozin"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Oxaprozin"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaprozin"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaprozin"
]
]
] | Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Benzphetamine and Benzphetamine (Compound) resembles Oxaprozin (Compound)
Sirolimus may lead to a major life threatening interaction when taken with Phenytoin and Phenytoin (Compound) resembles Oxaprozin (Compound)
Sirolimus may lead to a major life threatening interaction when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Oxaprozin
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil (Compound) resembles Oxaprozin (Compound)
Sirolimus may lead to a major life threatening interaction when taken with Carbamazepine and Carbamazepine (Compound) resembles Oxaprozin (Compound)
Sirolimus (Compound) causes Deafness (Side Effect) and Deafness (Side Effect) is caused by Oxaprozin (Compound)
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Oxaprozin
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Oxaprozin
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Oxaprozin |
DB00022 | DB08860 | 268 | 788 | [
"DDInter1408",
"DDInter1479"
] | Peginterferon alfa-2b | Pitavastatin | Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) resulting in less use of Peginterferon alfa-2b. Peginterferon alfa-2b is derived from the alfa-2b moeity of recombinant human interferon and acts by binding to human type 1 interferon receptors. Activation and dimerization of this receptor induces the body's innate antiviral response by activating the janus kinase | Pitavastatin, also known as the brand name product Livalo, is a lipid-lowering drug belonging to the statin class of medications. By inhibiting the endogenous production of cholesterol within the liver, statins lower abnormal cholesterol and lipid levels and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid. This is the third step in a sequence of metabolic reactions involved in the production of several compounds involved in lipid metabolism and transport including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very low-density lipoprotein (VLDL). Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD, such as those with Type 2 Diabetes. The clear evidence of the benefit of statin use coupled with very minimal side effects or long term effects has resulted in this class becoming one of the most widely prescribed medications in North America.[A181087, A181406] Pitavastatin and other drugs from the statin class of medications including [atorvastatin], [pravastatin], [rosuvastatin], [fluvastatin], and [lovastatin] are considered first-line options for the treatment of dyslipidemia.[A181087, A181406] Increasing use of the statin class of drugs is largely due to the fact that cardiovascular disease (CVD), which includes heart attack, atherosclerosis, angina, peripheral artery disease, and stroke, has become a leading cause of death in high-income countries and a major cause of morbidity around the world. Elevated cholesterol levels, and in particular, elevated low-density lipoprotein (LDL) levels, are an important risk factor for the development of CVD.[A181087,A181553] Use of statins to target and reduce LDL levels has been shown in a number of landmark studies to significantly reduce the risk of development of CVD and all-cause mortality.[A181090,A181093,A181096,A181427,A181475,A181538] Statins are considered a cost-effective treatment option for CVD due to their evidence of reducing all-cause mortality including fatal and non-fatal CVD as well as the need for surgical revascularization or angioplasty following a heart attack.[A181087, A181406] Evidence has shown that even for low-risk individuals (with <10% risk of a major vascular event occurring within 5 years) statins cause a 20%-22% relative reduction in major cardiovascular events (heart attack, stroke, coronary revascularization, and coronary death) for every 1 mmol/L reduction in LDL without any significant side effects or risks.[A181397, A181403] While all statin medications are considered equally effective from a clinical standpoint, [rosuvastatin] is considered the most potent; doses of 10 to 40mg [rosuvastatin] per day were found in clinical studies to result in a 45.8% to 54.6% decrease in LDL cholesterol levels.[A181409,A181535,A181538,A1793] Study data has confirmed that pitavastatin's potency in lowering LDL-C is comparable to that of other statins but also has increased efficacy in increasing HDL-C (also known as "good cholesterol").[A182000,A182003,A182006] Despite these differences in potency, several trials have demonstrated only minimal differences in terms of clinical outcomes between statins.[A181538, A181427] | Moderate | 1 | [
[
[
268,
24,
788
]
],
[
[
268,
24,
671
],
[
671,
1,
788
]
],
[
[
268,
24,
700
],
[
700,
40,
788
]
],
[
[
268,
24,
126
],
[
126,
23,
788
]
],
[
[
268,
24,
850
],
[
850,
63,
788
]
],
[
[
268,
24,
663
],
[
663,
24,
788
]
],
[
[
268,
63,
1057
],
[
1057,
24,
788
]
],
[
[
268,
25,
72
],
[
72,
24,
788
]
],
[
[
268,
25,
1510
],
[
1510,
64,
788
]
],
[
[
268,
25,
1377
],
[
1377,
25,
788
]
]
] | [
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
],
[
"Fluvastatin",
"{u} (Compound) resembles {v} (Compound)",
"Pitavastatin"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atorvastatin"
],
[
"Atorvastatin",
"{u} (Compound) resembles {v} (Compound)",
"Pitavastatin"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pitavastatin"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eltrombopag"
],
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pitavastatin"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pitavastatin"
]
]
] | Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin (Compound) resembles Pitavastatin (Compound)
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Atorvastatin and Atorvastatin (Compound) resembles Pitavastatin (Compound)
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Pitavastatin
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin
Peginterferon alfa-2b may lead to a major life threatening interaction when taken with Eltrombopag and Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin
Peginterferon alfa-2b may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Pitavastatin
Peginterferon alfa-2b may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Pitavastatin |
DB12364 | DB14276 | 1,421 | 1,631 | [
"DDInter200",
"DDInter1892"
] | Betrixaban | Turmeric | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa. It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity. Betrixaban, now developed by Portola Pharmaceuticals Inc., is prescribed as a venous thromboembolism (VTE) prophylactic for adult patients with moderate to severe restricted motility or with other risks for VTE. VTE can be manifested as deep vein thrombosis or pulmonary embolism and it is a leading cause of preventable death in hospitalized patients. | Turmeric is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug. | Minor | 0 | [
[
[
1421,
23,
1631
]
],
[
[
1421,
64,
20
],
[
20,
23,
1631
]
],
[
[
1421,
64,
20
],
[
20,
24,
1018
],
[
1018,
23,
1631
]
],
[
[
1421,
64,
1018
],
[
1018,
63,
20
],
[
20,
23,
1631
]
],
[
[
1421,
64,
1578
],
[
1578,
25,
20
],
[
20,
23,
1631
]
],
[
[
1421,
64,
500
],
[
500,
64,
20
],
[
20,
23,
1631
]
],
[
[
1421,
62,
297
],
[
297,
62,
20
],
[
20,
23,
1631
]
],
[
[
1421,
23,
944
],
[
944,
62,
20
],
[
20,
23,
1631
]
],
[
[
1421,
63,
758
],
[
758,
63,
20
],
[
20,
23,
1631
]
],
[
[
1421,
63,
529
],
[
529,
24,
1018
],
[
1018,
23,
1631
]
]
] | [
[
[
"Betrixaban",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
]
],
[
[
"Betrixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tenecteplase"
],
[
"Tenecteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
]
],
[
[
"Betrixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tenecteplase"
],
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
]
],
[
[
"Betrixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tenecteplase"
],
[
"Tenecteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
]
],
[
[
"Betrixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tenecteplase"
],
[
"Tenecteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
]
],
[
[
"Betrixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enoxaparin"
],
[
"Enoxaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tenecteplase"
],
[
"Tenecteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
]
],
[
[
"Betrixaban",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
],
[
"Clove",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tenecteplase"
],
[
"Tenecteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
]
],
[
[
"Betrixaban",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tenecteplase"
],
[
"Tenecteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
]
],
[
[
"Betrixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluoxetine"
],
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tenecteplase"
],
[
"Tenecteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
]
],
[
[
"Betrixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvoxamine"
],
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
]
]
] | Betrixaban may lead to a major life threatening interaction when taken with Tenecteplase and Tenecteplase may cause a minor interaction that can limit clinical effects when taken with Turmeric
Betrixaban may lead to a major life threatening interaction when taken with Tenecteplase and Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Turmeric
Betrixaban may lead to a major life threatening interaction when taken with Ticlopidine and Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Tenecteplase and Tenecteplase may cause a minor interaction that can limit clinical effects when taken with Turmeric
Betrixaban may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may lead to a major life threatening interaction when taken with Tenecteplase and Tenecteplase may cause a minor interaction that can limit clinical effects when taken with Turmeric
Betrixaban may lead to a major life threatening interaction when taken with Enoxaparin and Enoxaparin may lead to a major life threatening interaction when taken with Tenecteplase and Tenecteplase may cause a minor interaction that can limit clinical effects when taken with Turmeric
Betrixaban may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Tenecteplase and Tenecteplase may cause a minor interaction that can limit clinical effects when taken with Turmeric
Betrixaban may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Tenecteplase and Tenecteplase may cause a minor interaction that can limit clinical effects when taken with Turmeric
Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Fluoxetine and Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Tenecteplase and Tenecteplase may cause a minor interaction that can limit clinical effects when taken with Turmeric
Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine and Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Turmeric |
DB00477 | DB09082 | 216 | 659 | [
"DDInter363",
"DDInter1934"
] | Chlorpromazine | Vilanterol | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug administration). Vilanterol was designed based on the salmeterol molecular scaffold, particularly as a antedrug analog of salmeterol modification by modifying the salmeterol molecule to create homochiral compounds with the (R)-configuration. Vilanterol is 1000 and 400 fold more selective for β2 than β1 and β3 adrenoceptors, respectively, with a faster onset of action than salmeterol. Additionally, vilanterol demonstrated a significantly longer duration of action than salmeterol, with the bronchodilator effect still apparent at 22h. Vilanterol's pharmacological effect is attributable to stimulation of intracellular adenylyl cyclase which catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). Increases in cyclic AMP are associated with the relaxation of bronchial smooth muscle and inhibition of the release of hypersensitivity mediators from mast cells in the lungs.[A7738,A259961] Vilanterol is approved for use in several combination products such as with [fluticasone furoate] under the tradename BREO ELLIPTA, with [umeclidinium bromide] as ANORO ELLIPTA, and with both [fluticasone furoate] and [umeclidinium bromide] under the trade name TRELEGY ELLIPTA.[L46481,L44461,L44456] BREO ELLIPTA is the first vilanterol-containing product to be approved by the FDA in May 2013, followed by ANORO ELLIPTA in December 2013 and TRELEGY ELLIPTA in September 2020.[L46876,L46881,L46886] Although all 3 products are approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD), only TRELEGY ELLIPTA and BREO ELLIPTA are approved for maintenance treatments of asthma in patients aged 18 years and older and 5 years and older respectively.[L46481,L44461,L44456] | Moderate | 1 | [
[
[
216,
24,
659
]
],
[
[
216,
24,
870
],
[
870,
23,
659
]
],
[
[
216,
24,
1296
],
[
1296,
63,
659
]
],
[
[
216,
25,
1069
],
[
1069,
24,
659
]
],
[
[
216,
24,
1450
],
[
1450,
24,
659
]
],
[
[
216,
63,
1181
],
[
1181,
24,
659
]
],
[
[
216,
64,
702
],
[
702,
24,
659
]
],
[
[
216,
40,
1178
],
[
1178,
24,
659
]
],
[
[
216,
25,
982
],
[
982,
63,
659
]
],
[
[
216,
35,
820
],
[
820,
24,
659
]
]
] | [
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vilanterol"
]
],
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Chlorpromazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
],
[
"Vandetanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
],
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terfenadine"
],
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Chlorpromazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Chlorpromazine",
"{u} (Compound) resembles {v} (Compound)",
"Trifluoperazine"
],
[
"Trifluoperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Chlorpromazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Chlorpromazine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
]
] | Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Chlorpromazine may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Chlorpromazine may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Chlorpromazine (Compound) resembles Trifluoperazine (Compound) and Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Chlorpromazine may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Chlorpromazine (Compound) resembles Alimemazine (Compound) and Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol |
DB00081 | DB01030 | 273 | 869 | [
"DDInter1838",
"DDInter1835"
] | Tositumomab | Topotecan | Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine). | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. | Moderate | 1 | [
[
[
273,
24,
869
]
],
[
[
273,
24,
1270
],
[
1270,
63,
869
]
],
[
[
273,
63,
1184
],
[
1184,
24,
869
]
],
[
[
273,
24,
599
],
[
599,
24,
869
]
],
[
[
273,
25,
1064
],
[
1064,
24,
869
]
],
[
[
273,
25,
1213
],
[
1213,
63,
869
]
],
[
[
273,
64,
1172
],
[
1172,
24,
869
]
],
[
[
273,
64,
1057
],
[
1057,
25,
869
]
],
[
[
273,
25,
676
],
[
676,
64,
869
]
],
[
[
273,
25,
695
],
[
695,
25,
869
]
]
] | [
[
[
"Tositumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
]
],
[
[
"Tositumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
],
[
"Tuberculin purified protein derivative",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
]
],
[
[
"Tositumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anakinra"
],
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
]
],
[
[
"Tositumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
]
],
[
[
"Tositumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
]
],
[
[
"Tositumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
]
],
[
[
"Tositumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ibritumomab tiuxetan"
],
[
"Ibritumomab tiuxetan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
]
],
[
[
"Tositumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Topotecan"
]
],
[
[
"Tositumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Topotecan"
]
],
[
[
"Tositumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clozapine"
],
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Topotecan"
]
]
] | Tositumomab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative and Tuberculin purified protein derivative may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Tositumomab may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Tositumomab may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Tositumomab may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Tositumomab may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Tositumomab may lead to a major life threatening interaction when taken with Ibritumomab tiuxetan and Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Tositumomab may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Topotecan
Tositumomab may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Topotecan
Tositumomab may lead to a major life threatening interaction when taken with Clozapine and Clozapine may lead to a major life threatening interaction when taken with Topotecan |
DB00023 | DB08903 | 305 | 996 | [
"DDInter127",
"DDInter170"
] | Asparaginase Escherichia coli | Bedaquiline | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginase from _E. coli_ has clinically shown to exhibit antitumor actions in models of leukaemias [A31996, A31997]. L-asparaginase of _E. coli_ is marketed under several different trade names, including Elspar, for the treatment of acute lymphoblastic leukemia (ALL) as part of a multi-agent chemotherapeutic regimen. It is available as intramuscular or intravenous injections. Therapeutic L-asparaginase from _E. coli_ works by depleting the levels | Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affect DNA gyrase; instead, bedaquiline inhibits the c subunit of ATP synthase responsible for synthesizing ATP. Consequently, bedaquiline can be used to treat mycobacterial infection, particularly tuberculosis (TB). Although the current standard of TB treatment of anti-TB drugs for 2 months, including 2 key drugs [isoniazid] and [rifampin], is highly effective, the emergence of multidrug-resistant TB (MDR-TB) to [isoniazid] and [rifampin] has substantially worsened patients outcome. Bedaquiline was approved by the FDA on December 28, 2012, to treat pulmonary MDR-TB, following favorable results in multiple pre-clinical and clinical studies.[A261856,A261861] It is the first drug that was approved in the last 40 years by the FDA for TB unresponsive to current treatments on the market. Currently, bedaquiline is the last-line anti-TB drug and must only be used in an appropriate combination regimen.[L48506,A261866] | Moderate | 1 | [
[
[
305,
24,
996
]
],
[
[
305,
24,
713
],
[
713,
63,
996
]
],
[
[
305,
24,
848
],
[
848,
24,
996
]
],
[
[
305,
63,
491
],
[
491,
24,
996
]
],
[
[
305,
25,
770
],
[
770,
24,
996
]
],
[
[
305,
24,
609
],
[
609,
25,
996
]
],
[
[
305,
25,
1377
],
[
1377,
25,
996
]
],
[
[
305,
24,
484
],
[
484,
64,
996
]
],
[
[
305,
24,
888
],
[
888,
36,
996
]
],
[
[
305,
24,
713
],
[
713,
63,
350
],
[
350,
24,
996
]
]
] | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
],
[
"Dimethyl fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon alfa-2a"
],
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bedaquiline"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bedaquiline"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bedaquiline"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Bedaquiline"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
],
[
"Dimethyl fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
],
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
]
] | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2a and Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Asparaginase Escherichia coli may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Bedaquiline
Asparaginase Escherichia coli may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Bedaquiline
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may lead to a major life threatening interaction when taken with Bedaquiline
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen (Compound) resembles Bedaquiline (Compound) and Tamoxifen may lead to a major life threatening interaction when taken with Bedaquiline
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline |
DB00876 | DB06822 | 1,414 | 802 | [
"DDInter658",
"DDInter1812"
] | Eprosartan | Tinzaparin | Eprosartan is an angiotensin II receptor antagonist used to treat hypertension. It performs 2 actions on the renin angiotensin system. By preventing the binding of angiotensin II to AT1, vascular smooth muscle relaxes and vasodilation occurs. By inhibiting norepinephrine production, blood pressure is further reduced. | Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. Tinzaparin is composed of molecules with and without a special site for high affinity binding to antithrombin III (ATIII). This complex greatly accelerates the inhibition of factor Xa. It is an anticoagulant and considered an antithrombotic. Tinzaparin must be given either subcutaneously or parenterally. LMWHs are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin. | Moderate | 1 | [
[
[
1414,
24,
802
]
],
[
[
1414,
1,
240
],
[
240,
24,
802
]
],
[
[
1414,
24,
1479
],
[
1479,
25,
802
]
],
[
[
1414,
63,
1512
],
[
1512,
25,
802
]
],
[
[
1414,
1,
240
],
[
240,
1,
911
],
[
911,
63,
802
]
],
[
[
1414,
24,
1479
],
[
1479,
23,
944
],
[
944,
62,
802
]
],
[
[
1414,
63,
1512
],
[
1512,
23,
297
],
[
297,
62,
802
]
],
[
[
1414,
63,
1685
],
[
1685,
24,
1631
],
[
1631,
62,
802
]
],
[
[
1414,
1,
240
],
[
240,
40,
217
],
[
217,
24,
802
]
],
[
[
1414,
63,
1512
],
[
1512,
24,
222
],
[
222,
24,
802
]
]
] | [
[
[
"Eprosartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tinzaparin"
]
],
[
[
"Eprosartan",
"{u} (Compound) resembles {v} (Compound)",
"Losartan"
],
[
"Losartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tinzaparin"
]
],
[
[
"Eprosartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tinzaparin"
]
],
[
[
"Eprosartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tinzaparin"
]
],
[
[
"Eprosartan",
"{u} (Compound) resembles {v} (Compound)",
"Losartan"
],
[
"Losartan",
"{u} (Compound) resembles {v} (Compound)",
"Azilsartan medoxomil"
],
[
"Azilsartan medoxomil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tinzaparin"
]
],
[
[
"Eprosartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tinzaparin"
]
],
[
[
"Eprosartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
],
[
"Clove",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tinzaparin"
]
],
[
[
"Eprosartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin human"
],
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Turmeric"
],
[
"Turmeric",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tinzaparin"
]
],
[
[
"Eprosartan",
"{u} (Compound) resembles {v} (Compound)",
"Losartan"
],
[
"Losartan",
"{u} (Compound) resembles {v} (Compound)",
"Olmesartan"
],
[
"Olmesartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tinzaparin"
]
],
[
[
"Eprosartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tinzaparin"
]
]
] | Eprosartan (Compound) resembles Losartan (Compound) and Losartan may cause a moderate interaction that could exacerbate diseases when taken with Tinzaparin
Eprosartan may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may lead to a major life threatening interaction when taken with Tinzaparin
Eprosartan may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may lead to a major life threatening interaction when taken with Tinzaparin
Eprosartan (Compound) resembles Losartan (Compound) and Losartan (Compound) resembles Azilsartan medoxomil (Compound) and Azilsartan medoxomil may cause a moderate interaction that could exacerbate diseases when taken with Tinzaparin
Eprosartan may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Tinzaparin
Eprosartan may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Tinzaparin
Eprosartan may cause a moderate interaction that could exacerbate diseases when taken with Insulin human and Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Turmeric and Turmeric may cause a minor interaction that can limit clinical effects when taken with Tinzaparin
Eprosartan (Compound) resembles Losartan (Compound) and Losartan (Compound) resembles Olmesartan (Compound) and Olmesartan may cause a moderate interaction that could exacerbate diseases when taken with Tinzaparin
Eprosartan may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Tinzaparin |
DB00374 | DB00968 | 1,061 | 1,551 | [
"DDInter1852",
"DDInter1185"
] | Treprostinil | Methyldopa | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease.[L41855,L41860] The first agent approved for the treatment of PAH was [epoprostenol], a synthetic prostacyclin that significantly increases patients' quality of life. However, the use of epoprostenol is limited due to its short half-life (3-5 min) and instability at room temperature.[A248770,A248775] The use of more stable alternatives such as treprostinil provides patients with PAH with more treatment options. Treprostinil was approved by the FDA in 2002 for the treatment of pulmonary arterial hypertension. It is available in the following routes of administration: subcut | Methyldopa, or α-methyldopa, is a centrally acting sympatholytic agent and an antihypertensive agent. It is an analog of DOPA (3,4‐hydroxyphenylanine), and it is a prodrug, meaning that the drug requires biotransformation to an active metabolite for therapeutic effects. Methyldopa works by binding to alpha(α)-2 adrenergic receptors as an agonist, leading to the inhibition of adrenergic neuronal outflow and reduction of vasoconstrictor adrenergic signals. Methyldopa exists in two isomers D-α-methyldopa and L-α-methyldopa, which is the active form. First introduced in 1960 as an antihypertensive agent, methyldopa was considered to be useful in certain patient populations, such as pregnant women and patients with renal insufficiency. Since then, methyldopa was largely replaced by newer, better-tolerated antihypertensive agents; however, it is still used as monotherapy or in combination with [hydrochlorothiazide]. Methyldopa is also available as intravenous injection, which is used to manage hypertension when oral therapy is unfeasible and to treat hypertensive crisis. | Moderate | 1 | [
[
[
1061,
24,
1551
]
],
[
[
1061,
24,
874
],
[
874,
24,
1551
]
],
[
[
1061,
7,
2592
],
[
2592,
46,
1551
]
],
[
[
1061,
18,
6983
],
[
6983,
46,
1551
]
],
[
[
1061,
7,
12821
],
[
12821,
57,
1551
]
],
[
[
1061,
18,
10656
],
[
10656,
57,
1551
]
],
[
[
1061,
21,
28680
],
[
28680,
60,
1551
]
],
[
[
1061,
63,
1648
],
[
1648,
24,
1551
]
],
[
[
1061,
24,
1450
],
[
1450,
63,
1551
]
],
[
[
1061,
1,
885
],
[
885,
63,
1551
]
]
] | [
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyldopa"
]
],
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epinephrine"
],
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyldopa"
]
],
[
[
"Treprostinil",
"{u} (Compound) upregulates {v} (Gene)",
"CEBPD"
],
[
"CEBPD",
"{u} (Gene) is upregulated by {v} (Compound)",
"Methyldopa"
]
],
[
[
"Treprostinil",
"{u} (Compound) downregulates {v} (Gene)",
"GLOD4"
],
[
"GLOD4",
"{u} (Gene) is upregulated by {v} (Compound)",
"Methyldopa"
]
],
[
[
"Treprostinil",
"{u} (Compound) upregulates {v} (Gene)",
"TRIB1"
],
[
"TRIB1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Methyldopa"
]
],
[
[
"Treprostinil",
"{u} (Compound) downregulates {v} (Gene)",
"PSMG1"
],
[
"PSMG1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Methyldopa"
]
],
[
[
"Treprostinil",
"{u} (Compound) causes {v} (Side Effect)",
"Rash"
],
[
"Rash",
"{u} (Side Effect) is caused by {v} (Compound)",
"Methyldopa"
]
],
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyldopa"
]
],
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
],
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyldopa"
]
],
[
[
"Treprostinil",
"{u} (Compound) resembles {v} (Compound)",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyldopa"
]
]
] | Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Methyldopa
Treprostinil (Compound) upregulates CEBPD (Gene) and CEBPD (Gene) is upregulated by Methyldopa (Compound)
Treprostinil (Compound) downregulates GLOD4 (Gene) and GLOD4 (Gene) is upregulated by Methyldopa (Compound)
Treprostinil (Compound) upregulates TRIB1 (Gene) and TRIB1 (Gene) is downregulated by Methyldopa (Compound)
Treprostinil (Compound) downregulates PSMG1 (Gene) and PSMG1 (Gene) is downregulated by Methyldopa (Compound)
Treprostinil (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Methyldopa (Compound)
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Methyldopa
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Methyldopa
Treprostinil (Compound) resembles Epoprostenol (Compound) and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Methyldopa |
DB01224 | DB09564 | 623 | 1,296 | [
"DDInter1553",
"DDInter930"
] | Quetiapine | Insulin degludec | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable option for some patients with high sensitivity to other drugs, such as [clozapine] and [olanzapine]. | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism.[A18561,A18562,A18563,A18564,A174934] Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle.[A18561,A18562,A18563,A18564,A174934] Absorption of glucose into cells allows for its transformation into glycogen or fat for storage.[A18561,A18562,A18563,A18564,A174934] Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions.[A18561,A18562,A18563,A18564,A174934] Insulin is an essential treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to produce or synthesize the insulin needed to manage circulating blood sugar levels.[A18561,A18562,A18563,A18564,A174934] As a result, people with T1D rely primarily on exogenous forms of insulin, such as insulin degludec, to lower glucose levels in the blood.[A18561,A18562,A18563,A18564,A174934] Insulin is also used in the treatment of Type 2 Diabetes (T2D), another form of diabetes mellitus that is a slowly progressing metabolic disorder caused by a combination of genetic and lifestyle factors that promote chronically elevated blood sugar levels.[A18561,A18562,A18563,A18564,A174934] Without treatment or improvement in non-pharmacological measures such as diet and exercise to lower blood glucose, high blood sugar eventually causes cellular resistance to endogenous insulin, and in the long term, damage to pancreatic islet cells.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed later in the course of T2D, after several oral medications such as , , or have been tried, when sufficient damage has been caused to pancreatic cells that the body is no longer able to produce insulin on its own.[A18561,A18562,A18563,A18564,A174934] Marketed as the brand name product Tresiba, insulin degludec has a duration of action up to 42 hours allowing for once-daily dosing, typically at bedtime.[A18561,A18562,A18563,A18564,A174934] Due to its duration of action, Tresiba is considered "basal insulin" as it provides low concentrations of background insulin that can keep blood sugar stable between meals or overnight.[A18561,A18562,A18563,A18564,A174934] Basal insulin is often combined with short-acting "bolus insulin" such as , , or to provide higher doses of insulin required following meals. Use of basal and bolus insulin together is intended to mimic the pancreas' production of endogenous insulin, with the goal of avoiding any periods of hypoglycemia.[A18561,A18562,A18563,A18564,A174934] Compared to endogenous insulin, insulin degludec has an added hexadecanedioic acid on lysine at the B29 position, allowing for the formation of multi-hexamers.[A18561,A18562,A18563,A18564,A174934] When injected subcutaneously, these multi-hexamers form a drug depot store from which monomers are slowly and continuously absorbed into circulation.[A18561,A18562,A18563,A18564,A174934] As a result, Insulin Degludec has a protracted time action profile due to the delayed absorption from subcutaneous tissue depots into the systemic circulation.[A18561,A18562,A18563,A18564,A174934] Compared to available long-acting analogs such as and , which have a duration of action of 20-24 hours, insulin degludec provides a consistent level of basal insulin over 42 hours with a low peak: trough ratio.[A18561,A18562,A18563,A18564,A174934] Limitations of shorter-acting analogs include more frequent dosing and less stable pharmacokinetics, which may negatively impact patient adherence and glucose control, particularly nocturnal control.[A18561,A18562,A18563,A18564,A174934] Without an adequate supply of insulin to promote absorption of glucose from the bloodstream, blood sugar levels can climb to dangerously high levels and can result in symptoms such as fatigue, headache, blurred vision, and increased thirst.[A18561,A18562,A18563,A18564,A174934] If left untreated, the body starts to break down fat, instead of glucose, for energy which results in a build-up of ketone acids in the blood and a syndrome called ketoacidosis, which is a life-threatening medical emergency. In the long term, elevated blood sugar levels increase the risk of heart attack, stroke, and diabetic neuropathy.[A18561,A18562,A18563,A18564,A174934] Insulin Degludec was approved by the FDA in September 2015 as the product Tresiba, for use in providing glycemic control to adults with diabetes mellitus. | Moderate | 1 | [
[
[
623,
24,
1296
]
],
[
[
623,
63,
274
],
[
274,
23,
1296
]
],
[
[
623,
63,
1411
],
[
1411,
24,
1296
]
],
[
[
623,
24,
659
],
[
659,
24,
1296
]
],
[
[
623,
74,
104
],
[
104,
24,
1296
]
],
[
[
623,
40,
508
],
[
508,
24,
1296
]
],
[
[
623,
24,
1385
],
[
1385,
63,
1296
]
],
[
[
623,
25,
1487
],
[
1487,
24,
1296
]
],
[
[
623,
25,
877
],
[
877,
63,
1296
]
],
[
[
623,
64,
609
],
[
609,
24,
1296
]
]
] | [
[
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentolamine"
],
[
"Phentolamine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Insulin degludec"
]
],
[
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Quetiapine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Quetiapine",
"{u} (Compound) resembles {v} (Compound)",
"Promazine"
],
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
],
[
"Semaglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Quetiapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Quetiapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Quetiapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
]
] | Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Phentolamine and Phentolamine may cause a minor interaction that can limit clinical effects when taken with Insulin degludec
Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Quetiapine (Compound) resembles Methdilazine (Compound) and Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Quetiapine (Compound) resembles Promazine (Compound) and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide and Semaglutide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Quetiapine may lead to a major life threatening interaction when taken with Hydroxychloroquine and Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Quetiapine may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Quetiapine may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec |
DB00307 | DB10429 | 1,101 | 200 | [
"DDInter202",
"DDInter282"
] | Bexarotene | Candida albicans | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Candida albicans is a fungus which can provoke allergic reactions. Candida albicans is used in allergenic testing. | Moderate | 1 | [
[
[
1101,
24,
200
]
],
[
[
1101,
24,
1683
],
[
1683,
24,
200
]
],
[
[
1101,
25,
976
],
[
976,
24,
200
]
],
[
[
1101,
62,
168
],
[
168,
24,
200
]
],
[
[
1101,
24,
564
],
[
564,
63,
200
]
],
[
[
1101,
63,
1184
],
[
1184,
24,
200
]
],
[
[
1101,
64,
1064
],
[
1064,
24,
200
]
],
[
[
1101,
25,
1476
],
[
1476,
63,
200
]
],
[
[
1101,
23,
1419
],
[
1419,
24,
200
]
],
[
[
1101,
24,
1683
],
[
1683,
63,
1096
],
[
1096,
24,
200
]
]
] | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abemaciclib"
],
[
"Abemaciclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anakinra"
],
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
]
] | Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Bexarotene may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Bexarotene may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib and Abemaciclib may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Bexarotene may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Bexarotene may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Bexarotene may cause a minor interaction that can limit clinical effects when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans |
DB00065 | DB00072 | 581 | 550 | [
"DDInter923",
"DDInter1846"
] | Infliximab | Trastuzumab | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory cytokine involved in chronic inflammatory diseases. Its hyperactivity and enhanced signalling pathways can be observed in inflammatory diseases where it activates further pro-inflammatory cascades. By binding to both the soluble subunit and the membrane-bound precursor of TNF-α, infliximab disrupts the interaction of TNF-α with its receptors and may also cause lysis of cells that produce TNF-α. Infliximab was first approved by the FDA in 1998 under the market name Remicade as an intravenous injection. It is indicated for the treatment | Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). It is used as a treatment of human epidermal growth factor receptor (HER)-2+ metastatic breast cancer, where there is a proven amplification of the HER-2 oncogene or over-expression of the HER-2 protein in tumours. It is suggested that the overexpression or gene amplification of HER2 has been found in about 20–30% of breast cancers and elevated activation of HER2 triggers multiple downstream pathways leading to abnormal proliferation of cancer cells . Trastuzumab binds to HER2 and suppresses cancer cell growth, proliferation, and survival directly and indirectly . In December 2017, FDA approved OGIVRI (trastuzumab-dkst) as a biosimilar to Herceptin (trastuzumab) for the treatment of patients with breast or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) whose tumors overexpress the HER2 gene (HER2+). It displays biosimilar properties as Herceptin according to clinical data. While Ogivri is the first biosimilar approved in the U.S. for the treatment of breast cancer or stomach cancer, it is the second biosimilar approved in the U.S. for the treatment of cancer. Herzuma (trastuzumab-pkrb) is a biosimilar drug approved in December 2018 for the treatment of HER2-overexpressing breast cancer. KANJINTI (trastuzumab-anns) is another biosimilar approved by the FDA in June 2019. ONTRUZANT, another biosimilar of Herceptin, was approved by Health Canada in February 2022.[L40303, L40308] In November 2023, trastuzumab was also approved by the EMA under the brand name Herwenda. | Major | 2 | [
[
[
581,
25,
550
]
],
[
[
581,
24,
949
],
[
949,
63,
550
]
],
[
[
581,
25,
869
],
[
869,
63,
550
]
],
[
[
581,
64,
1184
],
[
1184,
24,
550
]
],
[
[
581,
25,
1292
],
[
1292,
64,
550
]
],
[
[
581,
64,
1057
],
[
1057,
25,
550
]
],
[
[
581,
24,
949
],
[
949,
63,
869
],
[
869,
63,
550
]
],
[
[
581,
25,
869
],
[
869,
24,
949
],
[
949,
63,
550
]
],
[
[
581,
64,
1184
],
[
1184,
24,
949
],
[
949,
63,
550
]
],
[
[
581,
24,
599
],
[
599,
24,
949
],
[
949,
63,
550
]
]
] | [
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trastuzumab"
]
],
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
],
[
"Clostridium tetani toxoid antigen (formaldehyde inactivated)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anakinra"
],
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
],
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trastuzumab"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trastuzumab"
]
],
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
],
[
"Clostridium tetani toxoid antigen (formaldehyde inactivated)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
],
[
"Clostridium tetani toxoid antigen (formaldehyde inactivated)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anakinra"
],
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
],
[
"Clostridium tetani toxoid antigen (formaldehyde inactivated)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab"
]
],
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
],
[
"Clostridium tetani toxoid antigen (formaldehyde inactivated)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab"
]
]
] | Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab
Infliximab may lead to a major life threatening interaction when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab
Infliximab may lead to a major life threatening interaction when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab
Infliximab may lead to a major life threatening interaction when taken with Deferiprone and Deferiprone may lead to a major life threatening interaction when taken with Trastuzumab
Infliximab may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Trastuzumab
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab
Infliximab may lead to a major life threatening interaction when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab
Infliximab may lead to a major life threatening interaction when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab |
DB00307 | DB00704 | 1,101 | 267 | [
"DDInter202",
"DDInter1263"
] | Bexarotene | Naltrexone | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Moderate | 1 | [
[
[
1101,
24,
267
]
],
[
[
1101,
24,
828
],
[
828,
25,
267
]
],
[
[
1101,
21,
28695
],
[
28695,
60,
267
]
],
[
[
1101,
25,
556
],
[
556,
24,
267
]
],
[
[
1101,
23,
68
],
[
68,
63,
267
]
],
[
[
1101,
24,
850
],
[
850,
63,
267
]
],
[
[
1101,
24,
1358
],
[
1358,
24,
267
]
],
[
[
1101,
62,
188
],
[
188,
24,
267
]
],
[
[
1101,
25,
1468
],
[
1468,
63,
267
]
],
[
[
1101,
23,
1236
],
[
1236,
24,
267
]
]
] | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxycodone"
],
[
"Oxycodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naltrexone"
]
],
[
[
"Bexarotene",
"{u} (Compound) causes {v} (Side Effect)",
"Dyspnoea"
],
[
"Dyspnoea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Naltrexone"
]
],
[
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Valproic acid"
],
[
"Valproic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
]
],
[
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Troleandomycin"
],
[
"Troleandomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Caspofungin"
],
[
"Caspofungin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
]
],
[
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
]
],
[
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
]
],
[
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
]
]
] | Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone and Oxycodone may lead to a major life threatening interaction when taken with Naltrexone
Bexarotene (Compound) causes Dyspnoea (Side Effect) and Dyspnoea (Side Effect) is caused by Naltrexone (Compound)
Bexarotene may lead to a major life threatening interaction when taken with Valproic acid and Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone
Bexarotene may cause a minor interaction that can limit clinical effects when taken with Troleandomycin and Troleandomycin may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Caspofungin and Caspofungin may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone
Bexarotene may cause a minor interaction that can limit clinical effects when taken with Nevirapine and Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone
Bexarotene may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone
Bexarotene may cause a minor interaction that can limit clinical effects when taken with Carbamazepine and Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone |
DB00197 | DB12332 | 1,324 | 1,619 | [
"DDInter1881",
"DDInter1626"
] | Troglitazone | Rucaparib | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the genetically-mutated cancer cells that lack a DNA repair mechanism, rucaparib causes cancer cell death and reduces tumour growth.[A18745,A31354] Rucaparib was granted FDA Breakthrough Therapy designation in April 2015 and accelerated approval in December 2016. The drug was later approved by the European Commission in May 2018. It is currently used to treat recurrent ovarian and prostate cancer in adults.[L42155,L42185] | Moderate | 1 | [
[
[
1324,
24,
1619
]
],
[
[
1324,
24,
222
],
[
222,
23,
1619
]
],
[
[
1324,
23,
271
],
[
271,
23,
1619
]
],
[
[
1324,
24,
1407
],
[
1407,
24,
1619
]
],
[
[
1324,
24,
159
],
[
159,
63,
1619
]
],
[
[
1324,
25,
879
],
[
879,
24,
1619
]
],
[
[
1324,
23,
1612
],
[
1612,
24,
1619
]
],
[
[
1324,
63,
521
],
[
521,
24,
1619
]
],
[
[
1324,
24,
1593
],
[
1593,
25,
1619
]
],
[
[
1324,
25,
246
],
[
246,
25,
1619
]
]
] | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rucaparib"
]
],
[
[
"Troglitazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
],
[
"Mirabegron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rucaparib"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eszopiclone"
],
[
"Eszopiclone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Troglitazone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumateperone"
],
[
"Lumateperone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Troglitazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fostemsavir"
],
[
"Fostemsavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
]
],
[
[
"Troglitazone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gatifloxacin"
],
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
]
]
] | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Eszopiclone and Eszopiclone may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Troglitazone may lead to a major life threatening interaction when taken with Lumateperone and Lumateperone may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Fostemsavir and Fostemsavir may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may lead to a major life threatening interaction when taken with Rucaparib
Troglitazone may lead to a major life threatening interaction when taken with Gatifloxacin and Gatifloxacin may lead to a major life threatening interaction when taken with Rucaparib |
DB00346 | DB01611 | 472 | 1,487 | [
"DDInter44",
"DDInter893"
] | Alfuzosin | Hydroxychloroquine | Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over 70. Alfuzosin is an alpha-1 adrenergic blocker used in the symptomatic treatment of BPH that works by relaxing the muscles in the prostate and bladder neck. It was initially approved by the FDA in 2003 and is marketed by several pharmaceutical companies. | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxychloroquine is also used for the prophylaxis of malaria in regions where chloroquine resistance is unlikely. It was developed during World War II as a derivative of [quinacrine] with less severe side effects. Chloroquine and hydroxychloroquine are both being investigated for the treatment of SARS-CoV-2. **The FDA emergency use authorization for hydroxychloroquine and [chloroquine] in the treatment of COVID-19 was revoked on 15 June 2020.** Hydroxychloroquine was granted FDA approval on 18 April 1955. A recent study reported a fatality in the group being treated with hydroxychloroquine for COVID-19. | Major | 2 | [
[
[
472,
25,
1487
]
],
[
[
472,
24,
1520
],
[
1520,
25,
1487
]
],
[
[
472,
7,
2216
],
[
2216,
46,
1487
]
],
[
[
472,
21,
28658
],
[
28658,
60,
1487
]
],
[
[
472,
24,
723
],
[
723,
24,
1487
]
],
[
[
472,
24,
286
],
[
286,
63,
1487
]
],
[
[
472,
63,
521
],
[
521,
24,
1487
]
],
[
[
472,
23,
752
],
[
752,
24,
1487
]
],
[
[
472,
25,
760
],
[
760,
63,
1487
]
],
[
[
472,
25,
868
],
[
868,
64,
1487
]
]
] | [
[
[
"Alfuzosin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primaquine"
],
[
"Primaquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Alfuzosin",
"{u} (Compound) upregulates {v} (Gene)",
"PAK1"
],
[
"PAK1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Hydroxychloroquine"
]
],
[
[
"Alfuzosin",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caused by {v} (Compound)",
"Hydroxychloroquine"
]
],
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Alfuzosin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Alfuzosin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Alfuzosin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
]
]
] | Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Primaquine and Primaquine may lead to a major life threatening interaction when taken with Hydroxychloroquine
Alfuzosin (Compound) upregulates PAK1 (Gene) and PAK1 (Gene) is upregulated by Hydroxychloroquine (Compound)
Alfuzosin (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Hydroxychloroquine (Compound)
Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine
Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine
Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine
Alfuzosin may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine
Alfuzosin may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine
Alfuzosin may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may lead to a major life threatening interaction when taken with Hydroxychloroquine |
DB09048 | DB15091 | 555 | 676 | [
"DDInter1284",
"DDInter1901"
] | Netupitant | Upadacitinib | Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy including highly emetogenic chemotherapy. Netupitant is a neurokinin 1 receptor antagonist. The combination drug is marketed by Eisai Inc. and Helsinn Therapeutics (U.S.) Inc. under the brand Akynzeo. | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage damage and bone destruction, leading to co-morbidities. Despite a variety of therapeutic agents available for treatment, up to 40% of the patients do not respond to current therapies, including biological therapies. The etiology of the disease is mostly unknown; however, the role of JAK as a driver of immune-mediated conditions was discovered, leading to the use of JAK as therapeutic targets for rheumatoid arthritis. To reduce dose-related toxicity (as seen with some pan-JAK inhibitors) without significantly affecting efficacy, more selective JAK1 inhibitors, upadacitinib and [filgotinib], were developed. The FDA approved upadacitinib in August 2019 and it is used for the treatment of active rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and ankylosing spondylitis. In December 2019, it was additionally approved by the European Commission and Health Canada.[L10899,L42540] Upadacitinib is marketed under the brand name RINVOQ for oral administration. | Moderate | 1 | [
[
[
555,
24,
676
]
],
[
[
555,
23,
283
],
[
283,
24,
676
]
],
[
[
555,
24,
214
],
[
214,
24,
676
]
],
[
[
555,
63,
723
],
[
723,
24,
676
]
],
[
[
555,
63,
891
],
[
891,
25,
676
]
],
[
[
555,
25,
1476
],
[
1476,
25,
676
]
],
[
[
555,
24,
951
],
[
951,
25,
676
]
],
[
[
555,
64,
594
],
[
594,
25,
676
]
],
[
[
555,
23,
384
],
[
384,
25,
676
]
],
[
[
555,
62,
1101
],
[
1101,
25,
676
]
]
] | [
[
[
"Netupitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
],
[
[
"Netupitant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
],
[
[
"Netupitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
],
[
[
"Netupitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
],
[
[
"Netupitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
],
[
"Prednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Netupitant",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Netupitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
],
[
"Palbociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Netupitant",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bosutinib"
],
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Netupitant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Netupitant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
]
] | Netupitant may cause a minor interaction that can limit clinical effects when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Netupitant may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Netupitant may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Netupitant may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may lead to a major life threatening interaction when taken with Upadacitinib
Netupitant may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may lead to a major life threatening interaction when taken with Upadacitinib
Netupitant may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib and Palbociclib may lead to a major life threatening interaction when taken with Upadacitinib
Netupitant may lead to a major life threatening interaction when taken with Bosutinib and Bosutinib may lead to a major life threatening interaction when taken with Upadacitinib
Netupitant may cause a minor interaction that can limit clinical effects when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Upadacitinib
Netupitant may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Upadacitinib |
DB01156 | DB01267 | 593 | 519 | [
"DDInter252",
"DDInter1381"
] | Bupropion | Paliperidone | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inhibiting the enzymes involved in the uptake of the neurotransmitters norepinephrine and dopamine from the synaptic cleft, therefore prolonging their duration of action within the neuronal synapse and the downstream effects of these neurotransmitters. More specifically, bupropion binds to the norepinephrine transporter (NET) and the dopamine transporter (DAT).[A6399,A178810] Bupropion was originally classified as an "atypical" antidepressant because it does not exert the same effects as the classical antidepressants such as Monoamine Oxidase Inhibitors (MA | Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism. Paliperidone is also active as an antagonist at alpha 1 and alpha 2 adrenergic receptors and H1 histaminergic receptors, which may explain some of the other effects of the drug. Paliperidone was approved by the FDA for treatment of schizophrenia on December 20, 2006. It is available as an extended-release tablet, a once-monthly intramuscular injection, an every-three-month intramuscular injection, and a twice-yearly gluteal injection.[L16168,L37744,L4137,L37749] | Major | 2 | [
[
[
593,
25,
519
]
],
[
[
593,
64,
1664
],
[
1664,
1,
519
]
],
[
[
593,
25,
924
],
[
924,
1,
519
]
],
[
[
593,
6,
12523
],
[
12523,
45,
519
]
],
[
[
593,
21,
28898
],
[
28898,
60,
519
]
],
[
[
593,
63,
1376
],
[
1376,
24,
519
]
],
[
[
593,
64,
1648
],
[
1648,
24,
519
]
],
[
[
593,
25,
129
],
[
129,
63,
519
]
],
[
[
593,
24,
591
],
[
591,
63,
519
]
],
[
[
593,
25,
820
],
[
820,
24,
519
]
]
] | [
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Paliperidone"
]
],
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Risperidone"
],
[
"Risperidone",
"{u} (Compound) resembles {v} (Compound)",
"Paliperidone"
]
],
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iloperidone"
],
[
"Iloperidone",
"{u} (Compound) resembles {v} (Compound)",
"Paliperidone"
]
],
[
[
"Bupropion",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Paliperidone"
]
],
[
[
"Bupropion",
"{u} (Compound) causes {v} (Side Effect)",
"Constipation"
],
[
"Constipation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Paliperidone"
]
],
[
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paliperidone"
]
],
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paliperidone"
]
],
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paliperidone"
]
],
[
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioflupane I-123"
],
[
"Ioflupane I-123",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paliperidone"
]
],
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paliperidone"
]
]
] | Bupropion may lead to a major life threatening interaction when taken with Risperidone and Risperidone (Compound) resembles Paliperidone (Compound)
Bupropion may lead to a major life threatening interaction when taken with Iloperidone and Iloperidone (Compound) resembles Paliperidone (Compound)
Bupropion (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Paliperidone (Compound)
Bupropion (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Paliperidone (Compound)
Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone
Bupropion may lead to a major life threatening interaction when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone
Bupropion may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone
Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Ioflupane I-123 and Ioflupane I-123 may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone
Bupropion may lead to a major life threatening interaction when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone |
DB00626 | DB00631 | 1,441 | 372 | [
"DDInter161",
"DDInter405"
] | Bacitracin | Clofarabine | Bacitracin is a combination of at least 9 bacitracins.[A955,A181952] 60-80% of commercially prepared bacitracin is bacitracin A. The bacillus that produces bacitracin was first isolated from a knee scrape in 1945 from the knee wound of a child named Margaret Tracy. Bacitracin was granted FDA approval on 29 July 1948.[A181997,L7748] | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaemia (ALL), only after at least two other types of treatment have failed. It is not known if the drug extends life expectancy. Its potential use in acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML) has been investigated. | Moderate | 1 | [
[
[
1441,
24,
372
]
],
[
[
1441,
7,
7720
],
[
7720,
46,
372
]
],
[
[
1441,
21,
28787
],
[
28787,
60,
372
]
],
[
[
1441,
25,
361
],
[
361,
63,
372
]
],
[
[
1441,
40,
1481
],
[
1481,
63,
372
]
],
[
[
1441,
63,
894
],
[
894,
24,
372
]
],
[
[
1441,
24,
1199
],
[
1199,
63,
372
]
],
[
[
1441,
25,
777
],
[
777,
64,
372
]
],
[
[
1441,
7,
7720
],
[
7720,
46,
1426
],
[
1426,
40,
372
]
],
[
[
1441,
21,
28787
],
[
28787,
60,
1426
],
[
1426,
40,
372
]
]
] | [
[
[
"Bacitracin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
]
],
[
[
"Bacitracin",
"{u} (Compound) upregulates {v} (Gene)",
"PTGS2"
],
[
"PTGS2",
"{u} (Gene) is upregulated by {v} (Compound)",
"Clofarabine"
]
],
[
[
"Bacitracin",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Clofarabine"
]
],
[
[
"Bacitracin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neomycin"
],
[
"Neomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
]
],
[
[
"Bacitracin",
"{u} (Compound) resembles {v} (Compound)",
"Polymyxin B"
],
[
"Polymyxin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
]
],
[
[
"Bacitracin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capreomycin"
],
[
"Capreomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
]
],
[
[
"Bacitracin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibandronate"
],
[
"Ibandronate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
]
],
[
[
"Bacitracin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iopromide"
],
[
"Iopromide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clofarabine"
]
],
[
[
"Bacitracin",
"{u} (Compound) upregulates {v} (Gene)",
"PTGS2"
],
[
"PTGS2",
"{u} (Gene) is upregulated by {v} (Compound)",
"Azacitidine"
],
[
"Azacitidine",
"{u} (Compound) resembles {v} (Compound)",
"Clofarabine"
]
],
[
[
"Bacitracin",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Azacitidine"
],
[
"Azacitidine",
"{u} (Compound) resembles {v} (Compound)",
"Clofarabine"
]
]
] | Bacitracin (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Clofarabine (Compound)
Bacitracin (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Clofarabine (Compound)
Bacitracin may lead to a major life threatening interaction when taken with Neomycin and Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine
Bacitracin (Compound) resembles Polymyxin B (Compound) and Polymyxin B may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine
Bacitracin may cause a moderate interaction that could exacerbate diseases when taken with Capreomycin and Capreomycin may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine
Bacitracin may cause a moderate interaction that could exacerbate diseases when taken with Ibandronate and Ibandronate may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine
Bacitracin may lead to a major life threatening interaction when taken with Iopromide and Iopromide may lead to a major life threatening interaction when taken with Clofarabine
Bacitracin (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Azacitidine (Compound) and Azacitidine (Compound) resembles Clofarabine (Compound)
Bacitracin (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Azacitidine (Compound) and Azacitidine (Compound) resembles Clofarabine (Compound) |
DB08880 | DB14761 | 1,510 | 242 | [
"DDInter1771",
"DDInter1578"
] | Teriflunomide | Remdesivir | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of hepatoxicity and teratogenicity for patients using teriflunomide. | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress syndrome (ARDS); COVID-19 can be fatal. Like other RNA viruses, SARS-CoV-2 depends on an RNA-dependent RNA polymerase (RdRp) enzyme complex for genomic replication, which can be inhibited by a class of drugs known as nucleoside analogues. Remdesivir (GS-5734) is an adenosine triphosphate analogue first described in the literature in 2016 as a potential treatment for Ebola.[A191379, A222393] Broad antiviral activity of remdesivir is suggested by its mechanism of action, and to date, it has demonstrated _in vitro_ activity against the _Arenaviridae_, _Flaviviridae_, _Filoviridae_, _Paramyxoviridae_, _Pneumoviridae_, and _Coronaviridae_ viral families. Remdesivir activity against the _Coronaviridae_ family was first demonstrated in 2017, leading to considerable interest in remdesivir as a possible treatment for COVID-19.[A191427, A198810] Remdesivir was confirmed as a non-obligate chain terminator of RdRp from SARS-CoV-2 and the related SARS-CoV and MERS-CoV, and has been investigated in multiple COVID-19 clinical trials.[L12174, L12177] After initially being granted an FDA Emergency Use Authorization (EUA) on May 1st, 2020, remdesivir was fully approved by the FDA for the treatment of COVID-19 on October 22, 2020. Remdesivir is currently marketed under the trademark name VEKLURY by Gilead Sciences Inc. Remdesivir was also approved by the European Commission on July 3, 2020. Remdesivir in combination with [baricitinib] for the treatment of COVID-19, was granted an FDA Emergency Use Authorization on November 19, 2020. | Moderate | 1 | [
[
[
1510,
24,
242
]
],
[
[
1510,
64,
1130
],
[
1130,
24,
242
]
],
[
[
1510,
24,
129
],
[
129,
24,
242
]
],
[
[
1510,
25,
384
],
[
384,
24,
242
]
],
[
[
1510,
64,
1487
],
[
1487,
25,
242
]
],
[
[
1510,
64,
1130
],
[
1130,
64,
1377
],
[
1377,
24,
242
]
],
[
[
1510,
64,
467
],
[
467,
25,
1377
],
[
1377,
24,
242
]
],
[
[
1510,
24,
129
],
[
129,
63,
467
],
[
467,
24,
242
]
],
[
[
1510,
25,
384
],
[
384,
63,
1130
],
[
1130,
24,
242
]
],
[
[
1510,
64,
482
],
[
482,
24,
1130
],
[
1130,
24,
242
]
]
] | [
[
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
]
],
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pioglitazone"
],
[
"Pioglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
]
],
[
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
]
],
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
]
],
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydroxychloroquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Remdesivir"
]
],
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pioglitazone"
],
[
"Pioglitazone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
]
],
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Simvastatin"
],
[
"Simvastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
]
],
[
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
],
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
]
],
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pioglitazone"
],
[
"Pioglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
]
],
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tioguanine"
],
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pioglitazone"
],
[
"Pioglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
]
]
] | Teriflunomide may lead to a major life threatening interaction when taken with Pioglitazone and Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Teriflunomide may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Teriflunomide may lead to a major life threatening interaction when taken with Hydroxychloroquine and Hydroxychloroquine may lead to a major life threatening interaction when taken with Remdesivir
Teriflunomide may lead to a major life threatening interaction when taken with Pioglitazone and Pioglitazone may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Teriflunomide may lead to a major life threatening interaction when taken with Simvastatin and Simvastatin may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Teriflunomide may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone and Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Teriflunomide may lead to a major life threatening interaction when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone and Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir |
DB00470 | DB01149 | 530 | 851 | [
"DDInter601",
"DDInter1274"
] | Dronabinol | Nefazodone | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effects of smoking cannabis such as increased appetite, reduced pain, and changes in emotional and cognitive processes. Due to its evidence as an appetite stimulant and an anti-nauseant, Dronabinol is approved for use in anorexia associated with weight loss in patients with AIDS and for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments [FDA Label]. Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most abundant cannabinoids found naturally in | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or even death, with the incidence of severe liver damage was shown to be approximately 1 in 250,000 to 300,000 patient-years. On May 20, 2004, Bristol-Myers Squibb discontinued the sale of Serzone in the United States. | Moderate | 1 | [
[
[
530,
24,
851
]
],
[
[
530,
24,
252
],
[
252,
40,
851
]
],
[
[
530,
24,
1178
],
[
1178,
1,
851
]
],
[
[
530,
63,
1242
],
[
1242,
24,
851
]
],
[
[
530,
6,
8374
],
[
8374,
45,
851
]
],
[
[
530,
21,
28762
],
[
28762,
60,
851
]
],
[
[
530,
24,
717
],
[
717,
24,
851
]
],
[
[
530,
24,
820
],
[
820,
63,
851
]
],
[
[
530,
1,
1614
],
[
1614,
24,
851
]
],
[
[
530,
25,
593
],
[
593,
64,
851
]
]
] | [
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nefazodone"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyzine"
],
[
"Hydroxyzine",
"{u} (Compound) resembles {v} (Compound)",
"Nefazodone"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
],
[
"Trifluoperazine",
"{u} (Compound) resembles {v} (Compound)",
"Nefazodone"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
],
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nefazodone"
]
],
[
[
"Dronabinol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Nefazodone"
]
],
[
[
"Dronabinol",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Compound)",
"Nefazodone"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethobenzamide"
],
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nefazodone"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nefazodone"
]
],
[
[
"Dronabinol",
"{u} (Compound) resembles {v} (Compound)",
"Nabilone"
],
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nefazodone"
]
],
[
[
"Dronabinol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nefazodone"
]
]
] | Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyzine and Hydroxyzine (Compound) resembles Nefazodone (Compound)
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Nefazodone (Compound)
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Nefazodone
Dronabinol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Nefazodone (Compound)
Dronabinol (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Nefazodone (Compound)
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Trimethobenzamide and Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Nefazodone
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Nefazodone
Dronabinol (Compound) resembles Nabilone (Compound) and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Nefazodone
Dronabinol may lead to a major life threatening interaction when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Nefazodone |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.